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Abstract
Background
Early accurate detection of all skin cancer types is essential to guide appropriate management and to improve morbidity and
survival. Melanoma and cutaneous squamous cell carcinoma (cSCC) are high risk skin cancers which have the potential to
metastasise and ultimately lead to death, whereas basal cell carcinoma (BCC) is usually localised with potential to infiltrate
and damage surrounding tissue. Anxiety around missing early curable cases needs to be balanced against inappropriate
referral and unnecessary excision of benign lesions. Computer assisted diagnosis (CAD) systems use artificial intelligence to
analyse lesion data and arrive at a diagnosis of skin cancer. When used in unreferred settings ('primary care'), CAD may
assist GPs or other clinicians to more appropriately triage high risk lesions to secondary care. Used alongside clinical and
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dermoscopic suspicion of malignancy, CAD may reduce unnecessary excisions without missing melanoma cases.
Objectives
To determine the accuracy of CAD systems for diagnosing cutaneous invasive melanoma and atypical intraepidermal
melanocytic variants, BCC or cSCC in adults, and to compare its accuracy with that of dermoscopy when dermoscopy is also
evaluated in CAD studies.
Search methods
We undertook a comprehensive search of the following databases from inception up to August 2016: Cochrane Central
Register of Controlled Trials; MEDLINE; EMBASE; CINAHL; CPCI; Zetoc; Science Citation Index; US National Institutes of
Health Ongoing Trials Register; NIHR Clinical Research Network Portfolio Database; and the World Health Organization
International Clinical Trials Registry Platform. We studied reference lists and published systematic review articles.
Selection criteria
Studies of any design that evaluated CAD alone, or in comparison with dermoscopy, in adults with lesions suspicious for
melanoma or BCC or cSCC, and compared with a reference standard of either histological confirmation or clinical follow-up.
Data collection and analysis
Two review authors independently extracted all data using a standardised data extraction and quality assessment form
(based on QUADAS-2). We contacted authors of included studies where information related to the target condition or
diagnostic threshold were missing. We estimated summary sensitivities and specificities separately by type of CAD system
using the bivariate hierarchical model. Comparisons of CAD with dermoscopy were made using a) all available CAD data
(indirect comparisons), and b) studies providing paired data for both tests (direct comparisons). The contribution of human
decision making to the accuracy of CAD diagnoses was examined in a sensitivity analysis by removing studies that gave
CAD results to clinicians to guide diagnostic decision-making.
Main results
In total 42 studies were included, 24 evaluating digital dermoscopy based CAD systems (Derm–CAD) in 23 study cohorts
with 9602 lesions (1220 melanomas, at least 83 BCCs, 9 cSCCs), providing 32 datasets for Derm–CAD and 7 for
dermoscopy. Eighteen studies evaluated spectroscopy based CAD (Spectro–CAD) in 16 study cohorts with 6336 lesions
(934 melanomas, 163 BCC, 49 cSCCs), providing 32 datasets for Spectro–CAD and 6 for dermoscopy. These consisted of
15 studies using multispectral imaging (MSI), 2 studies using electrical impedance spectroscopy (EIS) and 1 study using
diffuse reflectance spectroscopy. Studies were incompletely reported and of unclear to high risk of bias across all domains.
Included studies inadequately address the review question due to an abundance of low quality studies, poor reporting, and
recruitment of highly selected groups of participants.
Across all CAD systems, considerable variation was encountered in the hardware and software technologies used, the types
of classification algorithm employed, methods used to train the algorithms, and which lesion morphological features were
extracted and analysed across all CAD systems, and even between studies evaluating CAD systems. Meta–analysis found
CAD systems had high sensitivity for correct identification of cutaneous invasive melanoma and atypical intraepidermal
melanocytic variants in highly selected populations, but with low and very variable specificity, particularly for Spectro–CAD
systems. Pooled data from 22 studies estimated the sensitivity of Derm–CAD for the detection of melanoma as 90.1% (95%
CI: 84.0% to 94.0%) and specificity as 74.3% (95% CI: 63.6% to 82.7%). Pooled data from 8 studies estimated the sensitivity
of multispectral imaging CAD (MSI–CAD) as 92.9% (95% CI: 83.7% to 97.1%) and specificity as 43.6% (95% CI: 24.8% to
64.5%). When applied to a hypothetical population of 1000 lesions at the mean observed melanoma prevalence of 20%,
Derm–CAD would miss 20 melanomas and would lead to 206 false positive results for melanoma. MSI–CAD would miss 14
melanomas and would lead to 451 false diagnoses for melanoma. Preliminary findings suggest CAD systems are at least as
sensitive as assessment of dermoscopic images for the diagnosis of invasive melanoma and atypical intraepidermal
melanocytic variants. It is not possible to make summary statements regarding the use of CAD in unreferred populations, or
its accuracy in detecting keratinocyte cancers, or its use in any setting as a diagnostic aid, because of the paucity of studies.
Authors' conclusions
In highly selected patient populations all CAD types demonstrate high sensitivity, and could prove useful as a back-up for
specialist diagnosis to assist in minimising the risk of missing melanomas. However, the evidence–base is currently too poor
to understand whether CAD system outputs translate to different clinical decision–making in practice. Insufficient data are
available on the use of CAD in community settings, or for the detection of keratinocyte cancers. The evidence–base for
individual systems is too limited to draw conclusions on which might be preferred for practice. Prospective comparative
studies are required that evaluate the use of already evaluated CAD systems as diagnostic aids, by comparison to
face–to–face dermoscopy, and in participant populations that are representative of those in which the test would be used in
practice.
Plain language summary
What is the diagnostic accuracy of computer–assisted diagnosis techniques for the detection of skin cancer in
adults?
Why is improving the diagnosis of skin cancer important?
There are a number of different types of skin cancer including melanoma, squamous cell carcinoma (SCC) and basal cell
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carcinoma (BCC). Melanoma is one of the most dangerous forms. If it is not recognised early treatment can be delayed and
this risks the melanoma spreading to other organs in the body and may lead to eventual death. Cutaneous squamous cell
carcinoma (cSCC) and basal cell carcinoma (BCC) are considered less dangerous as they are localised (less likely to spread
to other parts of the body compared to melanoma). However, cSCC can spread to other parts of the body and BCC can
cause disfigurement if not recognised early. Diagnosing a skin cancer when it is not actually present (a false positive result)
might result in unnecessary surgery and other investigations and can cause stress and anxiety to the patient. Missing a
diagnosis of skin cancer may result in the wrong treatment being used or lead to a delay in effective treatment.
What is the aim of the review?
The aim of this Cochrane Review was to find out how accurate computer–assisted diagnosis (CAD) is for diagnosing
melanoma, BCC or cSCC. The review also compared the accuracy of two different types of CAD and compared the accuracy
of CAD with diagnosis by a doctor using a handheld illuminated microscope (a dermatoscope or ‘dermoscopy’). Researchers
in Cochrane included 42 studies to answer these questions.
What was studied in the review?
A number of tools are available to skin cancer specialists which allow a more detailed examination of the skin compared to
examination by the naked eye alone. Currently a dermatoscope which magnifies the skin lesion using a bright light source is
used by most skin cancer specialists. CAD tests are computer systems that analyse information about skin lesions obtained
from a dermatoscope or other techniques that use light to describe the features of a skin lesion (spectroscopy) to produce a
result indicating whether skin cancer is likely to be present. CAD systems that get their information from dermoscopic images
of lesions (Derm–CAD), or that use data from spectroscopy, were included in this review. Most of the spectroscopy studies
used data from multispectral imaging (MSI–CAD) and are the main focus here. Results from CAD systems can be used
alone to make a diagnosis of skin cancer (CAD–based diagnosis), or can be used by doctors in addition to their visual
inspection examination of a skin lesion to help them reach a diagnosis (CAD–aided diagnosis). Researchers examined how
useful CAD systems are to help diagnose skin cancers in addition to visual inspection and dermoscopy.
What are the main results of the review?
The review included 42 studies looking at CAD systems for the diagnosis of melanoma. There was not enough evidence to
determine the accuracy of CAD systems for the diagnosis of BCC (3 studies) or cSCC (1 study).
Derm–CAD results for diagnosis of melanoma
The main results for Derm-CAD are based on 22 studies including 8992 lesions.
Applied to a group of 1000 skin lesions, of whom 200 (20%) actually do have melanoma, the results suggest that:
- An estimated 386 people will have a Derm–CAD result suggesting that a melanoma is present and of these 206 (53%) will
not actually have a melanoma (false positive result)
- Of the 614 people with a Derm–CAD result indicating that no melanoma is present, 20 (3%) will in fact actually have a
melanoma (false negative result)
There was no evidence to suggest that dermoscopy or Derm–CAD was different in its ability to detect or rule out melanoma.
MSI–CAD results for diagnosis of melanoma
The main results for MSI–CAD are based on 8 studies including 2401 lesions. In a group of 1000 people, of whom 200 (20%)
actually do have melanoma, then:
- An estimated 637 people will have an MSI–CAD result suggesting that a melanoma is present and of these 451 (71%) will
not actually have a melanoma (false positive result)
- Of the 363 people with an MSI–CAD result indicating that no melanoma is present, 14 (4%) will in fact actually have a
melanoma (false negative result)
MSI–CAD detects more melanomas, but possibly produces more false positive results (an increase in unnecessary surgery).
How reliable are the results of the studies of this review?
Incomplete reporting of studies made it difficult for us to judge how reliable they were. Many studies had important limitations.
Some studies only included particular types of skin lesions or excluded lesions that were considered difficult to diagnose.
Importantly most of the studies only included skin lesions with a biopsy result which means that only a sample of lesions that
would be seen by a doctor in practice were included. These characteristics may result in CAD systems appearing more or
less accurate than they actually are.
Who do the results of this review apply to?
Studies were largely conducted in Europe (29, 69%) and North America (8, 19%). Mean age (reported in 6/42 studies)
ranged from 32–49 years for melanoma. The percentage of people with a final diagnosis of melanoma ranged from 1% to
52%. It was not always possible to tell whether suspicion of skin cancer in study participants was based on clinical
examination alone, or both clinical and dermoscopic examination. Almost all studies were done in people with skin lesions
who were seen at specialist clinics rather than by doctors in primary care.
What are the implications of this review?
CAD systems appear accurate for identification of melanomas in skin lesions that have been already selected for excision on
the basis of clinical examination (visual inspection and dermoscopy). It is possible that some CAD systems identify more
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melanomas than doctors using dermoscopy images. However, CAD systems also produced far more false positive
diagnoses than dermoscopy and could lead to considerable increases in unnecessary surgery. The performance of CAD
systems for detecting BCC and cSCC skin cancers is unclear. More studies are needed to evaluate the use of CAD by
doctors for the diagnosis of skin cancer in comparison to face-to-face diagnosis using dermoscopy, in both primary care and
in specialist skin cancer clinics.
How up-to-date is this review?
The review authors searched for and used studies published up to August 2016.
*In these studies, biopsy, clinical follow up, or specialist clinician diagnosis were the reference standards.
Background 
This review is one of a series of Cochrane Diagnostic Test Accuracy (DTA) reviews on the diagnosis and staging of
melanoma and keratinocyte skin cancers conducted for the National Institute for Health Research (NIHR) Cochrane
Systematic Reviews Programme. Appendix 1 shows the content and structure of the programme. Table 1 provides a
glossary of terms used and a table of acronyms used is provided in Appendix 2.
Target condition being diagnosed
There are three main forms of skin cancer. Melanoma is the most widely known amongst the general population, yet
the commonest skin cancers in Caucasian populations are those arising from keratinocytes: basal cell carcinoma
(BCC) and cutaneous squamous cell carcinoma (cSCC) (Gordon 2013; Madan 2010). In 2003, the World Health
Organization estimated that between two and three million ‘non-melanoma’ skin cancers (of which BCC and cSCC are
estimated to account for around 80% and 16% of cases, respectively) and 132,000 melanoma skin cancers occur
globally each year (WHO 2003).
In this diagnostic test accuracy review there are three target conditions of interest (a) melanoma, (b) basal cell carcinoma
(BCC), and (c) cutaneous squamous cell carcinoma (cSCC).
Melanoma
Melanoma arises from uncontrolled proliferation of melanocytes - the epidermal cells that produce pigment or melanin.
Cutaneous melanoma refers to any skin lesion with malignant melanocytes present in the dermis, and includes superficial
spreading, nodular, acral lentiginous, and lentigo maligna melanoma variants (see Figure 1). Melanoma in situ refers to
malignant melanocytes that are contained within the epidermis and have not invaded the dermis, but are at risk of
progression to melanoma if left untreated. Lentigo maligna, a subtype of melanoma in situ in chronically sun-damaged skin,
denotes another form of proliferation of abnormal melanocytes. Lentigo maligna can progress to invasive melanoma if its
growth breaches the dermo-epidermal junction during a vertical growth phase (when it is a 'lentigo maligna melanoma').
However its malignant transformation is both lower and slower than for melanoma in situ (Kasprzak 2015). Melanoma in situ
and lentigo maligna are both atypical intraepidermal melanocytic variants. Melanoma is one of the most serious forms
of skin cancer, with the potential to metastasise to other parts of the body via the lymphatic system and bloodstream. It
accounts for only a small proportion of skin cancer cases but is responsible for up to 75% deaths (Boring 1994; Cancer
Research UK 2017).
The incidence of melanoma rose to over 200,000 newly diagnosed cases worldwide in 2012 (Erdmann 2013; Ferlay 2015
), with an estimated 55,000 deaths (Ferlay 2015). In the UK, melanoma has one of the fastest rising incidence rates of
any cancer, and has the biggest projected increase in incidence between 2007 and 2030 (Mistry 2011). In the decade
leading up to 2013, age standardised incidence increased by 46%, with 14,500 new cases in 2013 and 2,459 deaths
in 2014 (Cancer Research UK 2017). Rates are higher in women than in men; however, the rate of incidence in men is
increasing faster than in women (Arnold 2014).The rising incidence in melanoma is thought to be primarily related to
an increase in recreational sun exposure and tanning bed use and an increasingly ageing population with higher
lifetime recreational ultraviolet (UV) exposure, in conjunction with possible earlier detection (Belbasis 2016; Linos 2009
). Putative risk factors are reviewed in detail elsewhere (Belbasis 2016).
A database of over 40,000 US patients from 1998 onwards which assisted the development of the 8th American
Joint Committee on Cancer (AJCC) Staging System indicated a five-year survival of 97% to 99% for stage I
melanoma, dropping to between 32% and 93% in stage III disease depending on tumour thickness, the
presence of ulceration and number of involved nodes (Gershenwald 2017). While these are substantial increases relative
to survival in 1975 (Cho 2014), mortality rates have remained static during the same period. This observation coupled
with increasing incidence of localised disease, suggests that improvements in survival may be due to earlier detection
and heightened vigilance (Cho 2014). Targeted therapies for stage IV melanoma (e.g. BRAF inhibitors) have
improved survival expectation and immunotherapies are evolving such that long term survival is being documented
(e.g. using BRAF-inhibitors (Chapman 2012; Villanueva 2010) and MEK inhibitors (Dummer 2014; Larkin 2014),
and immunomodulation (Chapman 2011; Hamid 2013; Hodi 2010).
Basal cell carcinoma
BCC can arise from multiple stem cell populations, including from the bulge and interfollicular epidermis (Grachtchouk 2011
). BCC growth is usually localised, but it can infiltrate and damage surrounding tissue, sometimes causing
considerable destruction and disfigurement, particularly when located on the face (Figure 2). The four main
subtypes of BCC are superficial, nodular, morphoeic (infiltrative) and pigmented. Lesions typically present as slow-
growing, asymptomatic papules, plaques, or nodules which bleed or form ulcers that do not heal (Firnhaber 2012).
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The diagnosis is often made incidentally rather than by people presenting with symptoms (Gordon 2013).
BCC most commonly occurs on sun-exposed sites on the head and neck (McCormack 1997) and are more common in
men and in people over the age of 40. A rising incidence of BCC in younger people has been attributed to increased
recreational sun exposure (Bath-Hextall 2007a; Gordon 2013; Musah 2013). Other risk factors include Fitzpatrick
skin types I and II (Fitzpatrick 1975; Lear 1997; Maia 1995), previous skin cancer history, immunosuppression, arsenic
exposure, and genetic predisposition such as in basal cell naevus (Gorlin) syndrome (Gorlin 2004; Zak-Prelich 2004).
Annual incidence is increasing worldwide; Europe has experienced an average increase of 5.5% per year over the last
four decades, the USA 2% per year, while estimates for the UK show incidence appears to be increasing more steeply
at a rate of an additional 6 / 100,000 persons per year (Lomas 2012). The rising incidence has been attributed to
an ageing population, changes in the distribution of known risk factors, particularly ultraviolet radiation, and
improved detection due to the increased awareness amongst both practitioners and the general population (Verkouteren
2017). Hoorens 2016 points to evidence for a gradual increase in the size of BCCs over time, with delays in diagnosis
ranging from 19 to 25 months.
According to National Institute for Health and Care Excellence (NICE) guidance (NICE 2010), low risk BCCs that may
be considered for excision are nodular lesions occurring in patients older than 24 years old who are not
immunosuppressed and do not have Gorlin syndrome. Furthermore, low risk lesions should be located below the
clavicle, should be small (< 1 cm) with well-defined margins, not recurrent following incomplete excision and are not
difficult to reach surgically or in highly visible locations (NICE 2010). Superficial BCCs are also typically low risk
and may be amenable to medical treatments such as photodynamic therapy or topical chemotherapy (Kelleners-Smeets
2017). Assigning BCCs as low or high risk influences the management options (Batra 2002; Randle 1996).
Advanced locally destructive BCC can arise from long-standing untreated lesions or from a recurrence of aggressive
basal cell carcinoma after primary treatment (Lear 2012). Very rarely, BCC metastasises to regional and distant
sites resulting in death, especially cases of large neglected lesions in those who are immunosuppressed or those
with Gorlin syndrome (McCusker 2014). Rates of metastasis are reported at 0.0028% to 0.55% (Lo 1991), with very
poor survival rates. It is recognised that basosquamous carcinoma (more like a high risk cSCC in behaviour and not
considered a true BCC) is likely to have accounted for many cases of apparent metastases of BCC hence teh
spuriously high reported incidence in some studies of up to 0.55% which is not seen in clinical practice (Garcia 2009).
Squamous cell carcinoma of the skin
Primary cSCC arises from the keratinocytes in the epidermis or its appendages. People with cSCC often present with
an ulcer or firm (indurated) papule, plaque, or nodule (Griffin 2016) often with an adherent crust (Madan 2010). cSCC can
arise in the absence of a precursor lesion or it can develop from pre-existing actinic keratosis (dysplastic epidermis) or
Bowen's disease (considered by some to be cSCC in situ). The estimated annual risk of progression is <1% to 20% (Alam
2001) and 5% for lesions developing from pre–existing dysplasia (Kao 1986). It remains locally invasive for a
variable length of time, but has the potential to spread to the regional lymph nodes or via the bloodstream to distant
sites, especially in immunosuppressed individuals (Lansbury 2010). High risk lesions are those arising on the lip or
ear, recurrent cSCC, lesions arising on non-exposed sites, scars or chronic ulcers, tumours larger than 20mm in
diameter or which have a histological depth of invasion greater than 4mm or poor differentiation status on
histopathological examination (Motley 2009).
Chronic ultraviolet light exposure through recreation or occupation is strongly linked to cSCC occurrence (Alam 2001). It
is particularly common in people with fair skin and in less common genetic disorders of pigmentation, such as albinism,
xeroderma pigmentosum, and recessive dystrophic epidermolysis bullosa (RDEB) (Alam 2001). Other recognised
risk factors include immunosuppression; chronic wounds; arsenic or radiation exposure; certain drug treatments,
such as voriconazole and BRAF mutation inhibitors; and previous skin cancer history (Baldursson 1993; Chowdri 1996; 
Dabski 1986; Fasching 1989; Lister 1997; Maloney 1996; O'Gorman 2014). In solid organ transplant recipients,
cSCC is the most common form of skin cancer; the risk of developing cSCC has been estimated at 65 to 253 times
that of the general population (Hartevelt 1990; Jensen 1999; Lansbury 2010). Overall, local and metastatic
recurrence of cSCC at five years is estimated at 8% and 5% respectively. The five-year survival rate of
metastatic cSCC of the head and neck is around 60% (Moeckelmann 2018).
Treatment
For primary melanoma, the mainstay of definitive treatment is wide local surgical excision of the lesion, to remove
both the tumour and any malignant cells that might have spread into the surrounding skin (Sladden 2009; Marsden 2010; 
NICE 2015; Garbe 2016; SIGN 2017). Recommended lateral surgical margins vary according to tumour thickness (Garbe
2016) and stage of disease at presentation (NICE 2015).
Treatment options for BCC and cSCC include surgery, other destructive techniques such as cryotherapy or
electrodesiccation and topical chemotherapy. A Cochrane systematic review of 27 randomised controlled trials (RCTs)
of interventions for BCC found very little good quality evidence for any of the interventions used (Bath-Hextall 2007b).
Complete surgical excision of primary BCC has a reported five-year recurrence rate of < 2% (Griffiths 2005; Walker 2006
), leading to significantly fewer recurrences than treatment with radiotherapy (Bath-Hextall 2007b). After apparent
clear histopathological margins (serial vertical sections) after standard excision biopsy with 4mm surgical peripheral
margins taken there is a 5-year reported recurrence rate of around 4% (Drucker 2017). Mohs micrographic surgery,
whereby horizontal sections of the tumour are microscopically examined intraoperatively and re-excision is undertaken
until the margins are tumour-free, can be considered for high risk lesions where standard wider excision margins of
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surrounding healthy skin might lead to considerable functional impairment (Bath-Hextall 2007b; Motley 2009; Lansbury 2010;
Stratigos 2015). Bath-Hextall and colleagues (Bath-Hextall 2007b) found a single trial comparing Mohs micrographic
surgery with standard excision in BCC (Smeets 2004); the update at 10 years follow-up showed no statistically significant
difference in recurrence with Mohs micrographic surgery (4.4% compared to 12.2% after surgical excision, P = 0.10) (van
Loo 2014).
The main treatments for high risk BCC are wide local excision, Mohs micrographic surgery and radiotherapy. For
low risk or superficial subtypes of BCC, or for small and or multiple BCCs at low risk sites (Marsden 2010), destructive
techniques other than excisional surgery may be used (e.g. electrodesiccation and curettage or cryotherapy (Alam 2001; 
Bath-Hextall 2007b)). Alternatively non-surgical (or non-destructive) treatments may be considered (Bath-Hextall 2007a; 
Drew 2017; Kim 2014), including topical chemotherapy such as imiquimod (Williams 2017), 5-fluorouracil (Arits 2013),
ingenol mebutate (Nart 2015) and photodynamic therapy (Bath-Hextall 2007b; Roozeboom 2016). Although non-
surgical techniques are increasingly used, they do not allow histological confirmation of tumour clearance, and their use
is dependent on accurate characterisation of the histological subtype and depth of tumour. The 2007 systematic review
of BCC interventions found limited evidence from very small RCTs for these approaches (Bath-Hextall 2007b), which
have only partially been addressed by subsequent studies (Bath-Hextall 2014; Kim 2014; Roozeboom 2012). Most BCC
trials have compared interventions within the same treatment class, and few have compared medical versus surgical
treatments (Kim 2014).
Vismodegib, a first-in-class Hedgehog signalling pathway inhibitor is now available for the treatment of metastatic or
locally advanced BCC based on the pivotal study ERIVANCE BCC (Sekulic 2012). It is licensed for use in these
patients where surgery or radiotherapy is inappropriate, e.g. for treating locally advanced periocular and orbital BCCs
with orbital salvage of patients who otherwise would have required exenteration (Wong 2017). However, NICE has
recently recommended against the use of vismodegib based on cost effectiveness and uncertainty of evidence (NICE 2017).
A systematic review of interventions for primary cSCC found only one RCT eligible for inclusion (Lansbury 2010). Current
practice therefore relies on evidence from observational studies, as reviewed in Lansbury 2013, for example. Surgical
excision with pre-determined margins is usually the first-line treatment (Motley 2009; Stratigos 2015). Estimates of
recurrence after Mohs micrographic surgery, surgical excision, or radiotherapy, which are likely to have been
evaluated in higher risk populations, have shown pooled recurrence rates of 3%, 5.4% and 6.4%, respectively with
overlapping confidence intervals; the review authors advise caution when comparing results across treatments (Lansbury
2013).
Index test(s)
Computer–aided diagnosis (CAD) describes a range of artificial intelligence-based techniques that automate the diagnosis of
skin cancer by using a computer to analyse lesion images, and determine the likelihood of malignancy, or need for excision.
Each CAD system has a data collection component, which collects imaging or non-visual data (e.g. electrical impedance
measurements) from the suspicious lesion and feeds it to the data processing component, which then performs a series of
analyses to arrive at a diagnostic classification.
Images are acquired using a number of different techniques, though most commonly by digital dermoscopy
(Derm–CAD) which creates digital subsurface images of the skin using a computer coupled with a dermatoscope,
videocamera and digital television (Rajpara 2009; Esteva 2017). Commercially available systems include the DB–MIPS®
(DB–Dermo MIPS) (Biomips Engineering SRL, Sienna Italy), MicroDERM (Visiomed AG, Germany), SolarScan
(Polartechnics Ltd, Australia) and MoleExpert (DermoScan GmbH, Germany), all of which are hand–held digital or video
dermatoscopes that communicate with CAD analysis software (see Figure 3).
Other systems use spectroscopy (Spectro-CAD), whereby information on cell characteristics (such as cell shape or size) is
gathered by measuring how electromagnetic waves pass through skin lesions. This information is most commonly acquired
using multispectral imaging (MSI–CAD) that enable computer–generated graphic representations of lesion morphology to be
produced from detecting light reflected at several wavelengths across the lesion. By far the most common of these is diffuse
reflectance spectrophotometry imaging (DRSi), which uses light that diffusely penetrates the skin to a depth of 2–2.5mm
beneath the surface to produce light reflectance images at a number of specific wavelengths across the visible – near
infrared light spectrum (approximately 400–1000nm) to capture variations in light attenuation and scattering from melanin,
collagen and blood vessel structures.
DRSi developed from diffuse reflectance spectroscopy, a non-visual spectroscopic technique which uses optical reflectance
to distinguish between lesion types based on spectral shape and calibrated level of reflected light for wavelengths
continuously varying from the ultraviolet (320 nm) to the near infrared (1100 nm) with a high spectral resolution (4 nm) (e.g.
Marchesini 1992; Wallace 2000b). Commercially available DRSi computer aided diagnosis (CAD) systems include the
SIAscope™ (MedX Health Corp, Canada), a hand–held unit that communicates with CAD analysis software (Figure 3). The
MelaFind® system (Strata Skin Sciences (formerly Mela Sciences Inc), Horsham, PA, USA) was FDA approved; however, it
no longer appears to be commercially available.
The Nevisense™ system (SciBase III, Sweden; Figure 3) is also commercially available, but is based on electrical
impedance spectroscopy (EIS), a non-optical method which seeks to provide information on cellular features by measuring
the feedback from an electrical current once it has passed through the intended tissue. With Nevisense™, an alternating
applied voltage (electrical current) is passed by a probe through a skin lesion and the current that is bounced back is
measured by the same probe, which measures a combination of tissue resistance and capacitance. At high frequencies,
conduction occurs easily through all tissue components, including cells, but at low frequencies current tends to flow only
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through the extracellular space. The spectral shape is therefore sensitive to cellular components and dimensions, internal
structure and cellular arrangements. The Nevisense™ EIS system measures at 4 multiple depths and at 35 frequencies
logarithmically distributed from 1.0 kHz to 2.5 MHz using a 5 x 5 mm area electrode covered in tiny pins that penetrate into
the stratum corneum.
Other non-visual sources of lesion data include Raman spectroscopy, in which a laser is used to excite
vibrations in molecules which then impart wavelength shifts to some of the scattered light waves, creating
spectral patterns that are related to the molecular structure of lesions (Maglogiannis 2009), and fluorescence
spectroscopy which uses a laser to excite electrons, causing molecules to absorb and then re-emit light in spectral
patterns that are also related to the molecular structure of lesions (Rallan 2004).
All CAD systems use machine learning, where a classification algorithm learns features of groups of lesions
(i.e. diagnostic types) by exposure to a ‘training set’ of lesions of known histological diagnosis. This process
creates a model which is designed to distinguish between these lesion types in future observations. Examples
of machine learning algorithms include discriminant analysis, decision trees, neural networks, fuzzy logic,
nearest k-neighbours, logistic regression and support vector machines (SVMs), and all use different
mathematical equations to set out how observed features relate to a given diagnosis (Maglogiannis 2009; Masood 2013).
Model outputs also vary, in part according to the type of data used to acquire lesion information, and can take the form of
binary outputs indicating the presence of malignancy versus benignity (e.g. the Melafind® system), risk scores which can be
used at varying thresholds (e.g. the DANAOS system used by MicroDerm), or graphical representations of the CAD pattern
analysis which highlight areas of concern within a lesion (e.g. the SIAgraphs produced by SIAscope™). Artificial intelligence
systems using continuous learning algorithms, where computer systems continuously develop their classification algorithm
as each new case is examined, and do not stop learning at the end of a training period, are not addressed in this review.
Clinical Pathway 
The diagnosis of skin lesions occurs in primary, secondary, and tertiary care settings by both generalist and specialist
healthcare providers. In the UK, people with concerns about a new or changing lesion will present to their general
practitioner rather than directly to a specialist in secondary care. A general practitioner with clinical concerns usually
refers a patient to a specialist in secondary care – usually a dermatologist but sometimes to a surgical specialist such
as a plastic surgeon or an ophthalmic surgeon. Suspicious skin lesions may also be identified in a referral setting, for
example by a general surgeon, and referred for a consultation with a skin cancer specialist (Figure 4). Skin cancers identified
by other specialist surgeons (such as an ear, nose, and throat (ENT) specialist or maxillofacial surgeon will usually be
diagnosed and treated without further referral.
Current UK guidelines recommend that all suspicious pigmented lesions presenting in primary care should be
assessed by taking a clinical history and visual inspection using the seven-point checklist (MacKie 1990); lesions
suspected to be melanoma or cSCC should be referred for appropriate specialist assessment within two weeks (Chao 2013; 
Marsden 2010; NICE 2015). Evidence is emerging, however, to suggest that excision of melanoma by GPs is not
associated with increased risk compared with outcomes in secondary care (Murchie 2017). In the UK, low risk BCC are
usually recommended for routine referral, with urgent referral for those in whom a delay could have a significant impact
on outcomes, for example due to large lesion size or critical site (NICE 2015). Appropriately qualified generalist care
providers increasingly undertake management of low risk BCC in the UK, such as by excision of low risk lesions (NICE
2010). Similar guidance is in place in Australia (CCAAC Network 2008).
For referred lesions, the specialist clinician will use history-taking, visual inspection of the lesion (in conjunction
with other skin lesions), palpation of the lesion and associated lymph nodes in conjunction with dermoscopic
examination to inform a clinical decision. If melanoma is suspected, then urgent 2mm excision biopsy is
recommended (Lederman 1985; Lees 1991); for cSCC predetermined surgical margin excision or a diagnostic biopsy may
be considered. BCC and pre-malignant lesions potentially eligible for nonsurgical treatment may undergo a diagnostic biopsy
before initiation of therapy if there is diagnostic uncertainty. Equivocal melanocytic lesions for which a definitive clinical
diagnosis cannot be reached may undergo surveillance to identify any lesion changes that would indicate excision biopsy or
reassurance and discharge for those lesions that remain stable over a period of time.
Theoretically, teledermatology consultations may aid appropriate triage of lesions into urgent referral; non-urgent secondary
care referral (e.g. for suspected basal cell carcinoma); or where available, referral to an intermediate care setting, e.g. clinics
run by GPs with a special interest in dermatology. The distinction between setting and examiner qualifications and
experience is important as specialist clinicians might work in primary care settings (for example, in the UK, general
practitioners (GPs) with a special interest in dermatology and skin surgery who have undergone appropriate training), and
generalists might practice in secondary care settings (for example, plastic surgeons who do not specialise in skin cancer).
The level of skill and experience in skin cancer diagnosis will vary for both generalist and specialist care providers and will
also impact on test accuracy.
Prior test(s)
Although smartphone applications and community-based teledermatology services can increasingly be directly
accessed by people who have concerns about a skin lesion (Chuchu 2018b), visual inspection of a suspicious lesion by a
clinician is usually the first in a series of tests to diagnose skin cancer. In the UK this usually takes place in primary care,
however in many countries people with suspicious lesions can present directly to a specialist setting.
A range of technologies have emerged to aid skin cancer diagnosis, both to ensure that malignancies (especially
melanoma) are not missed, and at the same time minimising unnecessary surgical procedures. Dermoscopy
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using a hand-held microscope has become the most widely used tool for clinicians to improve diagnostic
accuracy of pigmented lesions, in particular for melanoma (Argenziano 1998; Argenziano 2012; Haenssle 2010; Kittler
2002), although it is less well established for the diagnosis of BCC or cSCC. Dermoscopy is frequently combined with
visual inspection of a lesion in secondary care settings, and is also increasingly used in primary care, particularly in
countries such as Australia (Youl 2007).The diagnostic accuracy, and comparative accuracy, of visual inspection and
dermoscopy have been evaluated in a further three reviews in this series (Dinnes 2018a; Dinnes 2018b; Dinnes 2018c).
Consideration of the degree of prior testing that study participants have undergone is key to interpretation of test
accuracy indices, as these are known to vary according to the disease spectrum (or case-mix) of included participants
(Lachs 1992; Moons 1997; Leeflang 2013; Usher-Smith 2016). Spectrum effects are often observed when tests that
are developed further down the referral pathway have lower sensitivity and higher specificity when applied in settings
with participants with limited prior testing (Usher-Smith 2016). Studies of individuals with suspicious lesions at the
initial clinical presentation stage ('test naïve') are likely to have a wider range of differential diagnoses and include a
higher proportion of people with benign diagnoses compared with studies of participants who have been referred for
a specialist opinion on the basis of visual inspection (with or without dermoscopy) by a generalist practitioner.
Furthermore, studies in more specialist settings may focus on equivocal or difficult to diagnose lesions rather than
lesions with a more general level of clinical suspicion. However this direction of effect is not consistent across tests
and diseases, the mechanisms in action often being more complex than prevalence alone and can be difficult to
identify (Leeflang 2013). A simple categorisation of studies according to primary, secondary or specialist setting therefore
may not always adequately reflect these key differences in disease spectrum that can affect test performance.
Role of index test(s)
Skin cancer diagnosis, whether by visual inspection alone or with the use of dermoscopy is undertaken iteratively,
using both implicit pattern recognition (non-analytical reasoning) and more explicit ‘rules’ based on conscious
analytical reasoning (Norman 2009), the balance of which will vary according to experience and familiarity with the
diagnostic question. In the hands of experienced dermatologists, dermoscopy has been shown to enhance the
accuracy of skin cancer detection (especially melanoma) when compared to unaided visual examination (Dinnes 2018b; 
Dinnes 2018c). The subjectivity involved in interpreting lesion morphology is thought to underlie the decrease in
accuracy that occurs when the dermatoscope is used by less experienced clinicians (Binder 1995).
The addition of computer–based diagnosis to these investigations has potential to increase the detection of melanomas
by reducing the clinicians’ reliance on subjective information, which is necessarily interpreted using their experience of
past cases. The additive value of CAD systems is also likely to vary with differences in setting, prior testing and
selection of participants, as previously discussed (Prior test(s)). CAD systems could therefore fulfil three different roles in
clinical practice: 1) to help GPs, or other clinicians working in unreferred settings, to appropriately triage lesions for referral;
2) as part of a remote diagnostic service; or 3) as an expert–level second–opinion to specialists in referral settings. All three
roles would rely on CAD being as sensitive for the diagnosis of melanoma as experienced dermatologists. On the other
hand, the specificity required for CAD to add value differs for each of these three situations, as discussed below.
If sensitive enough, use of CAD in primary care could allow more appropriate triage of higher risk lesions to secondary care
by increasing the early detection of potentially malignant lesions. However, although a relatively lower specificity (higher false
positive rate) may be acceptable in a primary care setting, limiting false–positive diagnoses would create health service
benefits by avoiding unnecessary referral, and alleviating patient anxiety more promptly. Similarly, the remote use of CAD
could inform the need for referral, by sending images or other diagnostic data to specialist clinics, or even to commercial
organisations, for remote interpretation, much as teledermatology is already used. In this circumstance, a relatively high
specificity would be required in order to avoid unacceptable increases in rates of referral to specialist centres.
Finally, when used in referral settings as a complement to in-person diagnosis by a specialist, even if CAD could be shown
pick up difficult to diagnose melanomas that might be missed on VI or dermoscopy, the specificity of the system would be
need to be very high so as not to inordinately increase the burden of skin surgery. False-positive diagnoses not only cause
unnecessary scarring from a biopsy or excision procedure, but also increase patient anxiety whilst they await the definitive
histological results and increase healthcare costs as the number needed to remove to yield one melanoma diagnosis
increases. Pigmented lesions are common, so the resource implication for even a small increase in the threshold to excise
lesions in populations where melanoma rates are increasing, will avoid a considerable healthcare burden to both patient and
healthcare provider, as long as lesions that are not excised turn out to be benign. The use of CAD to detect melanoma in
specialist clinics would only be advantageous if it could be shown to detect skin cancers that would otherwise be missed, or
to decrease unnecessary surgical intervention (i.e. removal of false–positive lesions) with no loss of sensitivity.
Delay in diagnosis of a BCC as a result of a false-negative test is not as serious as for melanoma because BCCs are usually
slow-growing and very unlikely to metastasise, nevertheless delayed diagnosis can result in larger and more complex
surgical procedures with consequent greater morbidity. Very sensitive diagnostic tests for BCC, however may compromise
on lower specificity leading to a higher false positive rate and an increased burden of skin surgery such that a balance
between sensitivity and specificity is needed. The greatest potential advantage of CAD in the management of BCC is likely to
lie in its ability to perform rapid, non–invasive assessments of multiple lesions (common in BCC patients, Lear 1997).
The situation for cSCC is more similar to melanoma, in that the consequences of falsely reassuring a person that they do not
have skin cancer can be serious and potentially fatal given that removal of an early cSCC is usually curative. Thus, a good
diagnostic test for cSCC should demonstrate high sensitivity and a corresponding high negative predictive value. A test that
can also reduce false positive clinical diagnoses without missing true cases of cSCC has patient and resource benefits.
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Alternative test(s)
A number of other tests which may have a role in the diagnosis of skin cancer in a specialist setting have been
reviewed as part of our series of systematic reviews, including reflectance confocal microscopy (Dinnes 2018d Dinnes
2018e), optical coherence tomography (Ferrante di Ruffano 2018a), high frequency ultrasound (Dinnes 2018f) and
exfoliative cytology (Ferrante di Ruffano 2018b). Other tests with a role in earlier settings include teledermatology (Chuchu
2018a) and smart–phone applications (Chuchu 2018b). Reviews on the accuracy of gene expression testing and volatile
organic compounds could not be performed as planned due to an absence of relevant studies. Evidence permitting, the
accuracy of available tests will be compared in an overview review, exploiting within-study comparisons of tests and allowing
the analysis and comparison of commonly used diagnostic strategies where tests may be used singly or in combination.
We also considered and excluded a number of tests from this review such as tests used for screening (e.g. total body
photography of those with large numbers of typical or atypical naevi) or monitoring (e.g. CAD systems used to monitor the
progression of suspicious skin lesions).
Lastly, we did not assess the accuracy of histopathological confirmation following lesion excision because it is the
established reference standard for melanoma diagnosis and will be one of the standards against which the index tests are
evaluated in these reviews.
Rationale
Our series of reviews of diagnostic tests used to assist clinical diagnosis of skin cancer aims to identify the most accurate
approaches to diagnosis and provide clinical and policy decision-makers with the highest possible standard of evidence
on which to base diagnostic and treatment decisions. With increasing rates of melanoma and basal cell carcinoma and a
trend to adopt dermoscopy and other high resolution image analysis in primary care, the anxiety around missing early
malignant lesions needs to be balanced against the risk of too many unnecessary referrals, and to avoid sending too
many people with benign lesions for a specialist opinion. It is questionable whether all skin cancers identified by
sophisticated techniques, even in specialist settings, help to reduce morbidity and mortality. It is also a concern that
newer technologies incur the risk of increasing false-positive diagnoses. It is also possible that use of some technologies,
e.g., widespread use of dermoscopy in primary care with little or no training, could actually result in harm by missing
melanomas if they are used as replacement technologies for traditional history-taking and clinical examination of the
entire skin. Many branches of medicine have noted the danger of such "gizmo idolatry" amongst doctors (Leff 2008).
The central premise underlying CAD is that it uses quantitative, objective and expert–level assessments of lesion features,
which lessens the need for specialist training and lengthy experience in test use. Given the reliance on specialist training and
experience to make accurate skin cancer diagnosis using dermoscopy, CAD diagnosis has the potential to improve the
health of patients by widening access to specialist diagnostic capabilities in primary and secondary care. If sensitive enough,
introducing CAD could increase the early detection of skin cancers, which for melanoma and cSCC in particular, is critical to
improving outcomes. As with any technology requiring significant investment, a full understanding of the benefits including
patient acceptability and cost-effectiveness compared with usual practice should be obtained before such an approach can
be recommended; establishing the accuracy of diagnosis and referral accuracy is one of the key components.
We identified four published systematic reviews focussing on the accuracy of CAD, two synthesising the performance of
Derm–CAD systems (Ali 2012; Rajpara 2009), and two reviewing both Derm–CAD and Spectro–CAD systems (Rosado 2003;
Vestergaard 2008). All are limited by out–of–date search periods (Ali 2012 up to 2011, Rajpara 2009 and Vestergaard 2008
up to 2007, Rosado 2003 up to 2002), which is a key concern in the rapidly advancing field of machine learning. Another
concern for Ali 2012, Rajpara 2009 and Rosado 2003 is their inclusion of studies which are ineligible for the current
Cochrane review due to the absence of an independent validation set, a methodological feature likely to inflate the
apparent accuracy of predictive models (Altman 2009). Rosado 2003 also selected datasets on the basis of highest
performance, and pooled accuracy estimates for Derm–CAD with Spectro–CAD which we consider to be two different
diagnostic tests. There is therefore a need for an up-to-date and rigorous review of the accuracy of dermoscopy–based CAD
and of spectroscopy–based CAD which explicitly considers the following key characteristics .
Because CAD models are created by analysing patterns in archived datasets, the degree to which they are likely to
make accurate classifications of new observations in real life clinical situations relies on the generalisability of the
training sets used to develop them (Horsch 2011). Training sets that contain few lesions, or a restricted range of the
differential diagnoses encountered in clinical practice, are likely to produce models that misclassify new observations due to
inadequate learning. Other important attributes thought to influence diagnostic ability are the segmentation process (how the
lesion’s border is detected by the computer), which features are selected for analysis (akin to the selection of features for
analysis in the algorithms used in ELM dermoscopy, e.g. ABCD or 7–point), the algorithm used, and the type of information
produced by the CAD system (e.g. binary outputs indicating presence of malignancy, or visual images of lesions such as
macro– or microscopic photographs or graphical representations of highlighting suspect structures).
This review follows a generic protocol which covers the full series of Cochrane DTA reviews for the diagnosis of
melanoma (Dinnes 2015a) and for the diagnosis of keratinocyte cancers (Dinnes 2015b). The Background and
Methods sections of this review therefore use some text that was originally published in these protocols (Dinnes 2015a; 
Dinnes 2015b) and text that overlaps some of our other reviews (Dinnes 2018a; Dinnes 2018b; Ferrante di Ruffano 2018a).
Objectives 
To determine the accuracy of CAD systems for diagnosing cutaneous invasive melanoma and atypical intraepidermal
melanocytic variants in adults, and to compare the accuracy of CAD systems with that of clinician diagnosis using
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dermoscopy when dermoscopy is also evaluated in CAD studies.
To determine the accuracy of CAD systems for diagnosing BCC in adults, and to compare the accuracy of CAD systems with
that of clinician diagnosis using dermoscopy when dermoscopy is also evaluated in CAD studies.
To determine the accuracy of CAD systems for diagnosing cSCC in adults, and to compare the accuracy of CAD systems
with that of clinician diagnosis using dermoscopy when dermoscopy is also evaluated in CAD studies.
Secondary objectives
i. To determine the accuracy of CAD systems for diagnosing invasive melanoma alone in adults, and to compare the
accuracy of CAD systems with that of clinician diagnosis using dermoscopy
ii. To determine the accuracy of CAD systems for identifying any lesion requiring excision (due to any skin cancer or
high–grade dysplasia) in adults, and to compare the accuracy of CAD systems with that of clinician diagnosis using
dermoscopy
For each of the primary target conditions, to:
iii. To compare the diagnostic accuracy of CAD systems to clinician diagnosis using dermoscopy, where both tests have
been evaluated in the same studies (direct comparisons);
iv. To determine the diagnostic accuracy of individual CAD systems;
v. To compare the accuracy of CAD–based diagnosis to CAD–assisted diagnosis (CAD results used by clinicians as a
diagnostic aid)
vi. Where CAD systems are used as a diagnostic aid, to determine the effect of observer experience on diagnostic
accuracy.
Investigation of sources of heterogeneity
We set out to investigate a range of potential sources of heterogeneity across our series of reviews, as outlined in our
generic protocols (Dinnes 2015a; Dinnes 2015b) and described in Appendix 3; however, our ability to investigate these was
prevented by the available data on each individual test reviewed.
Methods 
Criteria for considering studies for this review
Types of studies 
We included test accuracy studies that assessed the result of the index test against that of a reference standard, including
the following:
studies where all participants received a single index test and a reference standard;
studies where all participants received more than one index test and reference standard;
studies where participants were allocated (by any method) to receive different index tests or combinations of index tests
and all receive a reference standard (between-person comparative studies (BPC));
studies that recruited series' of participants unselected by true disease status (referred to as case series for the purposes
of this review);
diagnostic case-control studies that separately recruited diseased and non-diseased groups (see Rutjes 2005), however
we did not include studies that compared results for malignant lesions to those for healthy skin (i.e. with no lesion present)
both prospective and retrospective studies; and
studies where previously acquired clinical or dermoscopic images were retrieved and prospectively interpreted for study
purposes.
We excluded studies from which we could not extract or derive 2x2 contingency data of the number of true positives, false
positives, false negatives and true negatives, or if studies included fewer than five skin cancer cases or fewer than five
benign lesions. Although the size threshold of five is arbitrary, such small studies are likely to give unreliable estimates of
sensitivity or specificity, and may be biased like small randomised controlled trials of treatment effects.
Participants
We included studies in adults with pigmented or non–pigmented skin lesions considered to be suspicious for melanoma or an
intraepidermal melanocytic variant or a keratinocyte skin cancer (BCC or cSCC). Studies examining adults at high risk of
developing skin cancer, including those with a family history or previous history of skin cancer, atypical or dysplastic naevus
syndrome, or genetic cancer syndromes were also eligible for inclusion.
We excluded studies that recruited only participants with malignant diagnoses.
We excluded studies conducted in children or which clearly reported inclusion of more than 50% of participants aged 16 and
under.
Index tests
Studies reporting accuracy data for tests using automated diagnosis were eligible for inclusion, whether diagnosis was
produced independently by the CAD system (system–based diagnosis), or by a clinician using a CAD system as a diagnostic
aid (computer–assisted diagnosis). CAD systems using any type of data capture were eligible, including imaging and
non–imaging modalities. All machine learning algorithms were included.
Studies developing new algorithms or methods of diagnosis (i.e. derivation studies) were included if they evaluated the new
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approach using a separate 'test set' of participants or images.
Studies were excluded if they:
evaluated a new statistical model or algorithm in the same participants or images as those used to train the model (i.e.
absence of an independent test set);
used cross-validation approaches such as 'leave-one-out' cross-validation (Efron 1983); or
evaluated the accuracy of the presence or absence of individual lesion characteristics or morphological features, with no
overall diagnosis of malignancy.
Although primary care clinicians can in practice be specialists in skin cancer, we considered primary care physicians as
generalist practitioners and dermatologists as specialists. Within each group, we extracted any reporting of special interest or
accreditation in skin cancer.
Target conditions
The primary target conditions were defined as the detection of:
any form of invasive cutaneous melanoma, or intraepidermal melanocytic variants (i.e., including melanoma in situ, or
lentigo maligna, which has a risk of progression to invasive melanoma),
BCC
cSCC
Two additional target conditions were considered in secondary analyses, namely the detection of:
any form of invasive cutaneous melanoma alone
any skin lesion requiring excision: all forms of skin cancer listed above, as well as melanoma in situ, lentigo maligna, and
lesions with severe melanocytic dysplasia.
Reference standards
The ideal reference standard is histopathological diagnosis in all eligible lesions. A qualified pathologist or
dermatopathologist should perform histopathology. Ideally, reporting should be standardised detailing a minimum dataset to
include the histopathological features of melanoma to determine the American Joint Committee on Cancer (AJCC) Staging
System (e.g. Slater 2014). We did not apply this as a necessary inclusion criterion, but extracted any pertinent information.
Partial verification (applying the reference test only to a subset of those undergoing the index test) was of concern given that
lesion excision or biopsy is unlikely to be carried out for all benign-appearing lesions within a representative population
sample. Therefore to reflect what happens in reality, we accepted clinical follow-up of benign-appearing lesions as an eligible
reference standard, whilst recognising the risk of differential verification bias (as misclassification rates of histopathology and
follow-up will differ).
Additional eligible reference standards included cancer registry follow-up and 'expert opinion' with no histology or clinical
follow-up. Cancer registry follow-up is considered less desirable than active clinical follow-up, as follow-up is not carried out
within the control of the study investigators. Furthermore, if participant-based analyses as opposed to lesion-based analyses
are presented, it may be difficult to determine whether the detection of a malignant lesion during follow-up is the same lesion
that originally tested negative on the index test.
All of the above were considered eligible reference standards with the following caveats:
all study participants with a final diagnosis of the target skin cancer disorder must have a histological diagnosis, either
subsequent to the application of the index test or after a period of clinical follow-up, and
at least 50% of all participants with benign lesions must have either a histological diagnosis or clinical follow-up to confirm
benignity.
Search methods for identification of studies 
Electronic searches 
The Information Specialist (SB) carried out a comprehensive search for published and unpublished studies. A single large
literature search was conducted to cover all topics in the programme grant (see Appendix 1 for a summary of
reviews included in the programme grant). This allowed for the screening of search results for potentially relevant
papers for all reviews at the same time. A search combining disease related terms with terms related to the test
names, using both text words and subject headings was formulated (Appendix 2). The search strategy was
designed to capture studies evaluating tests for the diagnosis or staging of skin cancer. As the majority of records
were related to the searches for tests for staging of disease, a filter using terms related to cancer staging and to
accuracy indices was applied to the staging test search, to try to eliminate irrelevant studies, for example, those
using imaging tests to assess treatment effectiveness. A sample of 300 records that would be missed by applying
this filter was screened and the filter adjusted to include potentially relevant studies. When piloted on MEDLINE,
inclusion of the filter for the staging tests reduced the overall numbers by around 6000. The final search strategy,
incorporating the filter (Appendix 4), was subsequently applied to all bibliographic databases as listed below. The final search
result was cross-checked against the list of studies included in five systematic reviews; our search identified all but one of the
studies, and this study is not indexed on MEDLINE. The Information Specialist devised the search strategy, with input from
the Information Specialist from Cochrane Skin. No additional limits were used.
We searched the following bibliographic databases to 29 August 2016 for relevant published studies:
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MEDLINE via OVID (from 1946);
MEDLINE In-Process & Other Non-Indexed Citations via OVID; and
EMBASE via OVID (from 1980).
We searched the following bibliographic databases to 30 August 2016 for relevant published studies:
the Cochrane Central Register of Controlled Trials (CENTRAL) Issue 7, 2016, in the Cochrane Library;
the Cochrane Database of Systematic Reviews (CDSR) Issue 8, 2016 in the Cochrane Library;
Cochrane Database of Abstracts of Reviews of Effects (DARE) Issue 2, 2015;
CRD HTA (Health Technology Assessment) database Issue 3, 2016;
CINAHL (Cumulative Index to Nursing and Allied Health Literature via EBSCO from 1960).
We searched the following databases for relevant unpublished studies:
CPCI (Conference Proceedings Citation Index) via Web of Science™ (from 1990);
Zetoc (from 1993)
SCI Science Citation Index Expanded™ via Web of Science™ (from 1900, using the "Proceedings and Meetings
Abstracts" Limit function).
We searched the following trials registers:
The US National Institutes of Health Ongoing Trials Register (www.clinicaltrials.gov);
NIHR Clinical Research Network Portfolio Database (http://www.nihr.ac.uk/research-and-impact/nihr-clinical-research-
network-portfolio/);
The World Health Organization International Clinical Trials Registry Platform (apps.who.int/trialsearch/).
We aimed to identify all relevant studies regardless of language or publication status (published, unpublished, in press, or in
progress). No date limits were applied.
Searching other resources 
We have screened relevant systematic reviews identified by the searches for their included primary studies, and included any
missed by our searches. We have checked the reference lists of all included papers, and subject experts within the author
team have reviewed the final list of included studies. No citation searching was conducted.
Data collection and analysis 
Selection of studies 
Titles and abstracts were screened by at least one author (JDi or NC), with any queries discussed and resolved by
consensus. A pilot screen of 539 MEDLINE references showed good agreement (89% with a kappa of 0.77)
between screeners. Primary test accuracy studies and test accuracy reviews (for scanning of reference lists) of any
test used to investigate suspected melanoma, BCC, or cSCC were included at initial screening. Inclusion criteria (Appendix
5) were applied independently by both a clinical reviewer (from one of a team of twelve clinician reviewers) and a
methodologist reviewer (JDi, NC or LFR) to all full text articles, disagreements were resolved by consensus or by a third
party (JDe, CD, HW, and RM). Authors of eligible studies were contacted when insufficient data were presented to allow for
the construction of 2x2 contingency tables.
Data extraction and management
One clinical (as detailed above) and one methodologist reviewer (JDi, NC or LFR) independently extracted data concerning
details of the study design, participants, index test(s) or test combinations and criteria for index test positivity, reference
standards, and data required to populate a 2x2 diagnostic contingency table for each index test using a piloted data
extraction form. Data were extracted at all available index test thresholds. Disagreements were resolved by consensus or by
a third party (JDe, CD, HW, and RM).
Authors of included studies were contacted where information related to final lesion diagnoses or diagnostic threshold were
missing. In particular, invasive cSCC (included as disease positive for one of our secondary objectives) is not always
differentiated from ‘in situ’ variants such as Bowens disease (which we did not consider as disease positive for any of our
definitions of the target condition).
Authors of conference abstracts published from 2013 to 2015 were contacted to ask whether full data were available.
Conference abstracts were marked as 'pending' and we will revisit them in a future review update.
Dealing with multiple publications and companion papers
Where multiple reports of a primary study were identified, we maximised yield of information by collating all available data.
Where there were inconsistencies in reporting or overlapping study populations, we contacted study authors for clarification
in the first instance. If this contact with authors was unsuccessful, we used the most complete and up-to-date data source
where possible.
Assessment of methodological quality
We assessed risk of bias and applicability of included studies using the QUADAS-2 checklist (Whiting 2011), tailored to the
review topic (see Appendix 6). The modified QUADAS-2 tool was piloted on a small number of included full text articles. One
clinical (as detailed above) and one methodologist reviewer (JDi, NC or LFR) independently assessed quality for the
remaining studies; any disagreement was resolved by consensus or by a third party where necessary (JDe, CD, HW, and
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RM).
Statistical analysis and data synthesis
Our unit of analysis was the lesion rather than the person. This is because (i) in skin cancer initial treatment is directed to the
lesion rather than systemically (thus it is important to be able to correctly identify cancerous lesions for each person), and (ii)
it is the most common way in which the primary studies reported data. Although there is a theoretical possibility of
correlations of test errors when the same people contribute data for multiple lesions, most studies include very few people
with multiple lesions and any potential impact on findings is likely to be very small, particularly in comparison with other
concerns regarding risk of bias and applicability. For each analysis, only one dataset was included per study to avoid multiple
counting of lesions. Where multiple CAD models or algorithms were assessed in an individual study, one was selected at
random using a random number generator. Where studies evaluated CAD as a diagnostic aid by clinicians with varying
degrees of experience, the dataset reporting the highest degree of clinical experience was selected. These selections were
conducted without reference to the corresponding accuracy data.
Accuracy of dermoscopy was estimated separately according to whether the diagnosis recorded was based on a
face–to–face (in-person) encounter or based on remote (image-based) assessment. Where multiple algorithms were
assessed in an individual study, dermoscopy datasets were selected on the following preferential basis:
i. ‘no algorithm’ reported; data presented for clinician’s overall diagnosis or management decision
ii. pattern analysis or pattern recognition
iii. ABCD algorithm (or derivatives of)
iv. 7-point checklist (also referred to as Glasgow/Mackie checklist)
v. Menzies algorithm
vi. 3-point checklist
As for CAD, dermoscopy datasets reporting the highest degree of clinical experience were preferentially selected from
studies reporting multiple results using clinicians of varying experience.
CAD study data were pooled for systems using similar methods of data acquisition; thus all studies using digital
dermoscopy based CAD (Derm-CAD) were considered similar and pooled, however spectroscopy-based CAD (Spectro-
CAD) systems analyse different data types and so were only pooled in these subgroups: multispectral imaging studies
(MSI-CAD), electrical impedance spectroscopy (EIS-CAD), and diffuse reflectance spectroscopy (DRS-CAD). For each
index test, algorithm or checklist under consideration, estimates of sensitivity and specificity were plotted on coupled
forest plots and in receiver operating characteristic (ROC) space. CAD thresholds are created by complex statistical
algorithms and a threshold is difficult to define. Therefore, we assumed results were binary for the purpose of pooling
results across similar CAD systems. We estimated summary operating points (summary sensitivities and specificities)
with 95% confidence and prediction regions using the bivariate model (Chu 2006; Reitsma 2005). Where
inadequate data were available for the analysis to converge, the model was simplified, first by assuming no
correlation between estimates of sensitivity and specificity and secondly by setting variance terms to zero if little or
no heterogeneity was observed on SROC plots (Takwoingi 2015).
Data on the accuracy of dermoscopy were extracted from all included studies that performed both CAD and
dermoscopy in the same patients. We performed test comparisons using two analytic strategies. First we
performed indirect comparisons by using all studies of the two tests. Second we made direct comparisons of CAD
and dermoscopy by including only comparative studies that assessed the accuracy of both tests in the same study
population to enable a robust comparison (Takwoingi 2013). To minimize the risk of bias in the direct comparison, studies
that performed either CAD or dermoscopy on a subsample of the total analysed population were excluded. In the
comparative meta-analyses of indirect and direct comparisons, we compared summary points by using a bivariate meta-
regression model that included test type as a covariate. Covariate terms were included for sensitivity and specificity. Model fit
was assessed using likelihood ratio tests to compare nested models. We computed estimates of absolute differences in
sensitivity and specificity using the bivariate model parameters and 95% confidence intervals were obtained using the delta
method. P values for the absolute differences were obtained using Wald tests. Univariate random-effects logistic regression
models incorporating test type as a covariate were fitted when there were few studies or a bivariate meta-regression analysis
did not converge.
For illustration of the meta-analytic findings in the summary of findings tables, we computed the numbers of true positives,
false positives, false negatives and true negatives, using the summary estimates of sensitivity and specificity together with
the lower quartile, median and upper quartile of the prevalence observed in the studies included in the meta-analysis.
Bivariate models were fitted using the xtmelogit command in STATA 15.
Investigations of heterogeneity
We examined heterogeneity between studies by visually inspecting the forest plots of sensitivity and specificity and summary
ROC plots. Due to limited data availability, we were unable to formally investigate heterogeneity using meta-regression.
Sensitivity analyses
The primary analysis included both CAD–based diagnoses and CAD–aided diagnoses. Sensitivity analyses excluding studies
of CAD–aided diagnoses were undertaken.
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Assessment of reporting bias
Because of uncertainty about the determinants of publication bias for diagnostic accuracy studies and the inadequacy
of tests for detecting funnel plot asymmetry (Deeks 2005), we did not perform tests to detect publication bias.
Results 
Results of the search
A total of 34,347 unique references were identified and screened for inclusion. Of these, 1051 full-text papers were reviewed
for eligibility for any one of the suite of reviews of tests to assist in the diagnosis of melanoma or keratinocyte skin cancer. Of
the 1051 full-text papers assessed, 848 were excluded from all reviews in our series (see Figure 5 PRISMA flow diagram of
search and eligibility results).
Of the 227 studies tagged as potentially eligible for this review of CAD (166 for Derm–CAD, 61 for Spectro–CAD), 42
publications were included (24 Derm–CAD and 18 Spectro–CAD). Exclusions were mainly due to the absence of a ‘test’ set
of lesions used to evaluate CAD's performance independently of the computer algorithm’s development (Derm–CAD n = 76,
Spectro-CAD n = 17); inability to construct a 2x2 contingency table based on the data presented (Derm–CAD n = 24,
Spectro-CAD n = 8); the use of ineligible index tests (Derm–CAD n = 18, Spectro-CAD n = 5) (for example: computers used
to measure lesions but not to diagnose them, e.g. Seidenari 2012); or not meeting our requirements for an eligible reference
standard (Derm–CAD n = 13, Spectro-CAD n = 9). Other reasons for exclusion included ineligible definition of the target
condition (Derm–CAD n = 10, Spectro-CAD n = 3) and CAD systems based on evaluating the presence of a single lesion
characteristic (Derm–CAD n = 17) (for example, a CAD system analysing the colour balance of a lesion). A list of the 185
publications excluded from this review with reasons for exclusion is provided in Characteristics of excluded studies, with a list
of all studies excluded from the full series of reviews available as a separate pdf.
The authors of 10 publications were contacted to provide additional detail on published 2x2 data for the accuracy of
CAD, with responses regarding four publications received to date. These did not result in the inclusion of any
additional studies, however did permit the inclusion of one additional dataset in an already–included study (Mollersen 2015
). One response highlighted an alternative publication that was independently ascertained by the project search, and
was included (Serrao 2006); two replies were unable to provide the information requested in relation to two study
publications, both of which were subsequently excluded due to incomplete 2x2 data. Attempts to contact authors of six
publications failed, resulting in the exclusion of those six studies from review. In addition to these 10 attempted
contacts, authors of one other publication (Walter 2012) were contacted as part of another review in this series, the
accuracy of visual inspection for the diagnosis of melanoma (Dinnes 2018a), to provided clarifications on methods used; the
author response enabled it to be included.
The 42 included studies reported on 39 cohorts of lesions and provided 63 datasets with 13,445 lesions and 2452
malignancies. The majority of studies (n = 24, 57%) contributed data on the diagnostic accuracy of digital dermoscopy–based
CAD systems (Derm–CAD), of which seven also compared the diagnostic accuracy of Derm–CAD with dermoscopic
diagnosis. The remaining 18 studies contributed data on the diagnostic accuracy of spectroscopy–based CAD (Spectro-
CAD), of which five provided comparative accuracy data with dermoscopy. A cross-tabulation of studies by CAD type,
reported comparisons and target conditions is provided in Table 2.
Studies were case series (n = 27, 64%), case control (n = 10, 24%), randomised controlled trial (n = 1, 2%), or of unclear
design (n = 4, 10%). Lesion selection was most commonly retrospective (n = 22, 52%) or prospective (n = 15, 36%), though
was unclear in five studies (12%). Studies included only pigmented (n = 29, 69%) or melanocytic lesions (n = 6, 14%), only
suspected melanomas (n = 4, 10%), or any lesions suspected of malignancy (n = 2, 5%). Patient characteristics such as age
and gender were reported by 15/42 studies.
Methodological quality of included studies
The majority of included studies were of methodological concern primarily due to lack of applicability to the current review
question, but also due to a high or unclear risk of bias in their design. Since there were no major differences in quality
according to CAD type, we provide an overview of the quality and applicability of all included studies regardless of CAD type.
The methodological quality of studies according to CAD type (Derm–CAD or spectroscopy–based CAD) is summarized in
Figure 6 and Figure 7.
The risk of participant selection bias was judged as high in 17 (40%) studies, due to the selection of lesions according
to their final diagnosis (case–control studies: n = 10, 24%), and/or to the inappropriate exclusion of lesions with
particular prognostic characteristics (n = 8, 19%), such as high-grade dysplastic lesions (Ferris 2015) or small/large
lesions (Malvehy 2014; Monheit 2011). Study eligibility criteria and participant exclusions were not reported clearly enough to
ascertain the risk of selection bias in 17 studies (40%); this meant that we could not determine whether consecutive or
random samples of lesions were recruited (n = 22, 52%), whether participants had been selected according to their final
diagnoses (use of 'case–control' selection, n = 5, 12%), or whether participant exclusions were appropriate (n = 22, 52%).
A single study (Sgouros 2014) was of low concern for the applicability of its participant sample to the current review
question: it included unexcised lesions and did not recruit participants with multiple lesions. All others (n = 41, 98%)
were of high concern due to the use of restricted participant groups and settings (n = 40, 95%), with study
populations limited to lesions selected for excision based on the clinical or dermoscopic diagnosis or selected
retrospectively from histopathology databases (n = 36, 84%). Six studies did not restrict inclusion to excised lesions,
however in three of these the non–excised lesions could not be extracted due to the absence of clinical follow–up in
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at least 50% of benign cases (Boldrick 2007; Bono 1996; Sgouros 2014). Fourteen studies were also of concern due to their
recruitment of participants with multiple lesions (including over 5% more lesions than participants). One of these, Dreiseitl
2009, provided patient–based 2x2 data as well as lesion–based data for the accuracy of a Derm–CAD system. These 2
analyses of the same population highlight the distortion that can occur in study populations that include multiple lesions per
patient: lesion–based sensitivity was lower than patient based sensitivity (74% versus 89%), however lesion–based
specificity was far higher (84% versus 48%) due to the inclusion of many disease negative lesions per patient.
Twenty–two (52%) studies did not report the number of participants included (precluding assessment of the inclusion of
multiple lesions). Of the 18 studies including model derivation, 6 (33%) used a wide range of skin conditions to train the
classification algorithm. Two (11%) used an inadequately narrow range (absence of non–dysplastic benign conditions), while
the remaining 10 (56%) provided inadequate detail of diagnoses included in the training set.
Over half the studies were at high (n = 14, 33%) or unclear (n = 10, 24%) risk of bias due to the methods used to
undertake the index test. Most studies (n = 40, 95%) blinded CAD results to the reference standard diagnosis though
almost half (n = 20, 48%) failed to clearly pre–specify the diagnostic threshold, of which 13 (30%) were
threshold–finding studies that provided accuracy data for the best threshold possible once index test results had
been examined. Most studies (n = 35, 83%) evaluated CAD in an independent population to that used to train the
classification algorithm, either by external validation (n = 23, 55%) or internal validation (randomised division of a
single study group into training and test sets: n = 12, 29%). An additional six (14%) studies used internal validation,
but failed to specify whether division of the study group was made randomly (i.e. not selected according to
diagnosis), while one study was at risk of bias by selecting which diagnoses to place in the train and test sets (Tomatis
2003).
Of the 18 studies that included CAD model derivation (training of the classification algorithm), eight (44%) accounted
for model overfitting by using a Support Vector Machine algorithm (Gilmore 2010; Mohr 2013; Stanganelli 2005),
performing a jack–knife calculation (Binder 1994; Burroni 2004), or another method (Rubegni 2002; Tomatis 2003; Tomatis
2005). One study specified that model optimisation was not incorporated (Garcia Uribe 2012) and 9 (50%) did not discuss
overfitting. The majority of studies (n = 32, 76%) were of high concern regarding the applicability of the index test, due to
their evaluation of an unestablished threshold (n = 23), lack of detail regarding the diagnostic threshold used (n = 16), and/or
the use of non–expert clinicians (n = 2) in studies evaluating CAD as a diagnostic aid (n = 7).
Almost all studies reported use of an acceptable reference standard (n = 37, 88%), and around half (n = 19, 45%) clearly
reported blinding of the reference standard to the CAD result. For the applicability of the reference standard, four reported
using expert diagnosis for some lesions (high concern) and 30 (71%) were unclear as to whether histopathology had been
interpreted by an experienced histopathologist or dermatopathologist.
Reporting of study flow and timing was generally poor with an unclear risk of bias in 28 (67%) studies, largely due to
ambiguity regarding the interval between the application of the index test and reference standard (excision for histology or
first follow–up visit) (n = 28). Thirteen (30%) studies were at a high risk of bias because they used different reference
standards according to diagnosis (differential verification) (n = 6) and/or did not include all participants in the analysis (n =
10), primarily due to technical difficulties with the CAD system (n = 6).
Eleven of the 15 studies comparing CAD with dermoscopy were at high (n = 2) or unclear (n = 9) risk of bias. Six reported
blinding between tests, two reported no blinding and seven were unclear. Half (n = 8) did not clearly report the interval
between tests.
Findings
The 24 studies evaluating a Derm–CAD system reported 23 cohorts of lesions providing 32 CAD datasets with 9602 lesions
including 1313 malignancies of which 1220 were melanomas, at least 83 BCCs (number not specified in one study,
Menzies 1996), and 9 cSCCs. The total number of study participants with suspicious lesions cannot be estimated
due to lack of reporting in study publications (reported in only 10 studies (with 2400 participants). Two publications
provided data for one cohort of lesions (Seidenari 1998; Seidenari 1999), the larger of the two studies (Seidenari 1999) was
included in the primary analysis with data from Seidenari 1998 contributing only to the direct comparison of
Derm–CAD with dermoscopy. A total of 17 different systems were evaluated, 3 by multiple independent studies:
Microderm (Barzegari 2005; Boldrick 2007; Serrao 2006), DB–MIPS (also called DB–Dermo MIPS) (Bauer 2000; Burroni
2004; Rubegni 2002; Seidenari 1998; Seidenari 1999; Stanganelli 2005; Wollina 2007), and Skin View (Cascinelli 1992;
Cristofolini 1997). The 17 systems differ in terms of the type of dermoscopy used to acquire images, the storage devices
used, features analysed and statistical classifier used (summarised in Table 3). The approach to computer–assisted support
also differed, with 21 studies (88%) evaluating a stand–alone automated diagnosis (‘system–based diagnosis’), and 3 studies
using Derm–CAD as a diagnostic aid to assist clinical decision–making.
The 18 publications evaluating a Spectro–CAD system reported 16 cohorts of lesions contributing 32 datasets with
6336 lesions including 1084 malignancies of which 934 were melanomas, 163 BCCs and 49 cSCCs. The total number
of study participants with suspicious lesions cannot be estimated due to lack of reporting in study publications (reported
in only 8 studies totaling 4484 participants). Four publications provided data for two patient cohorts (Bono 2002; Tomatis
2003 and Hauschild 2014; Monheit 2011), the larger studies (Monheit 2011; Tomatis 2003) were included in the primary
analysis, with data from Bono 2002 (same population as Tomatis 2003) and Hauschild 2014 (same population as Monheit
2011) contributing only to the direct comparison of Spectro–CAD with dermoscopy. These 18 studies reported on 5
different multispectral systems using DRSi: SpectroShade (Ascierto 2010; Tomatis 2005), Melafind (Friedman 2008; 
Gutkowicz Krusin 1997; Hauschild 2014; Monheit 2011; Wells 2012; Winkelmann 2016), SIAscope (Glud 2009; Terstappen
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2013), and ‘Telespectrophotometric System’ (Bono 1996; Tomatis 2003). One study evaluated a non–imaging diffuse
reflectance spectroscopy system: OIDRS (Garcia Uribe 2012), which used analysis of data from incidentally
reflected diffuse light. Nevisense was the only system to use electrical impedance spectroscopy (EIS), and was
evaluated in two large prospective studies; these had overlapping recruitment periods and study centres, thus the
possibility of overlap in analysed participants cannot be ruled out (Malvehy 2014; Mohr 2013). As for the Derm–CAD
systems, the Spectro–CAD systems differ in terms of the image acquisition and storage devices used, features
analysed, statistical classifier used, and the approach to computer–assisted support (i.e. whether used as a
stand–alone automated diagnosis, or as information to assist a clinician’s diagnostic decision) (Table 4).
Study results are summarised below according to target condition with forest plots of available study data provided in Figures
8-23. Results of meta–analysis are provided in Table 5 and Table 6.
Target condition: invasive melanoma and atypical intraepidermal melanocytic variants
The diagnostic accuracy of CAD assessment for the detection of invasive cutaneous melanoma or intraepidermal variants
was reported by 36 studies with a total of 14,451 lesions including 1889 melanomas. Of these, 23 studies evaluated a
Derm–CAD system (total 9082 lesions with 1094 melanomas) and 13 studies evaluated a Spectro-CAD system (total 5369
lesions with 795 melanomas).
Derm-CAD
Twenty–two studies were included in a meta–analysis to estimate the accuracy of dermoscopy–based CAD
systems in referral settings, regardless of the system manufacturer, algorithm used, or whether CAD was used as a
stand–alone automated diagnosis or as a diagnostic aid (Barzegari 2005; Bauer 2000; Binder 1994; Binder 1998; Blum
2004b; Boldrick 2007; Burroni 2004; Cascinelli 1992; Cristofolini 1997; Dreiseitl 2009; Ferris 2015; Gilmore 2010; 
Maglogiannis 2015; Menzies 2005; Mollersen 2015; Piccolo 2002; Piccolo 2014; Rubegni 2002; Seidenari 1999; Serrao
2006; Stanganelli 2005; Wollina 2007). One additional study was excluded from this analysis (Seidenari 1998) due
to suspected population overlap with an included study (Seidenari 1999). These 22 studies provided 23 datasets
for meta–analysis (Mollersen 2015 evaluated two CAD systems, Nevus Doctor and MoleExpert, in the same lesion
population). Eleven studies were model derivation studies, eight evaluating the resulting classification algorithm in an
independent population (random division of one study group into training and test sets: Binder 1994; Binder 1998; Blum
2004b; Burroni 2004; Ferris 2015; Maglogiannis 2015; Menzies 2005; Stanganelli 2005), and three providing
insufficient details to determine the independence of the test population (Cascinelli 1992; Gilmore 2010; Rubegni 2002
). The remaining 11 studies were external validation studies with prospective (Bauer 2000; Cristofolini 1997; Dreiseitl 2009; 
Wollina 2007), retrospective (Piccolo 2002; Piccolo 2014; Seidenari 1999; Serrao 2006), or unclear (Barzegari 2005; 
Boldrick 2007; Mollersen 2015) recruitment designs. Only one study did not use excision as an eligibility criterion (Dreiseitl
2009).
Across the 23 datasets, sensitivity ranged from 17% to 100% and specificity from 20% to 98%. A total of 8992 lesions
including 1063 melanomas were pooled, giving summary sensitivity of 90.1% (95% CI 84.0% to 94.0%) and summary
specificity of 74.3% (95% CI 63.6% to 82.7%) (Table 5 and Figure 8, Figure 9).
The prevalence of melanoma ranged from 1% (Dreiseitl 2009) to 52% (Gilmore 2010; Maglogiannis 2015), and the
number of melanomas missed ranged from 0 (Barzegari 2005; Piccolo 2014; Seidenari 1999) to 16 (Maglogiannis 2015
) (not reported in 4 studies). Clear identification of the target condition was not provided in 10 of the 22 studies (Binder 1994; 
Blum 2004b; Cascinelli 1992; Cristofolini 1997; Dreiseitl 2009; Gilmore 2010; Maglogiannis 2015; Piccolo 2002; Rubegni
2002; Stanganelli 2005), and the inclusion of melanoma in situ lesions as disease positive was assumed on the basis that
the disease positive group was described as ‘melanoma’ and not as ‘invasive melanoma’ or ‘malignant melanoma’. Of the 12
studies that clearly reported including in situ lesions (Barzegari 2005; Bauer 2000; Binder 1998; Boldrick 2007; Burroni 2004;
Ferris 2015; Menzies 2005; Mollersen 2015; Piccolo 2014; Seidenari 1999; Serrao 2006; Wollina 2007), the percentage of
the disease positive group (invasive melanoma and atypical intraepidermal melanocytic variants) described as being in situ
ranged from 12–50%. The number of missed in situ lesions was reported in 7 studies, with no missed lesions in 3
studies (Barzegari 2005; Piccolo 2014; Seidenari 1999) and between 7% (1 of 14, Ferris 2015) and 100% (3 of 3, Boldrick
2007) of in situ lesions misdiagnosed by the remaining studies.
Some studies reported difficulties in excluding a malignancy from clinically benign lesions, particularly non-
melanocytic pigmented lesions such as seborrhoeic keratoses which were reported as an included lesion by five
studies (Barzegari 2005; Cascinelli 1992; Ferris 2015; Menzies 2005; Mollersen 2015). Four of these provided
lesion diagnoses by CAD result, finding 41 of 61 seborrhoeic keratoses (67%) to have been falsely identified as
malignant, while a fifth study highlighted their problematic misclassification of this lesion by both Derm–CAD
systems (Mollersen 2015). Other notable false positive diagnoses include dysplastic melanocytic nevi (Binder 1994; Binder
1998; Cascinelli 1992; Ferris 2015; Seidenari 1999), actinic keratosis (Barzegari 2005), dermatofibroma (Barzegari 2005; 
Menzies 2005) and haemangioma (Menzies 2005).
One dataset from one study contributed data for the accuracy of a Derm–CAD system in self–referring patients
seeking advice for pigmented naevi (Wollina 2007) (Table 7). This prospective study evaluated the DB–MIPS system, a fully
integrated dermoscopy unit with internal stereomicroscope, storage database and pattern analysis software, giving it to
clinicians to use as a diagnostic aid. Although 3541 lesions (1308 patients) were examined, only the excised lesions (n =
466) were analysed by the authors, of which 357 were recruited in primary care clinics. These included 19 melanomas, and
283 dysplastic melanocytic naevi. The authors reported a sensitivity of 89.0% (95% CI 68.6% to 97.1%) and specificity of
84.0% (95% CI 79.7% to 87.5%).
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Derm–CAD versus Dermoscopy
Seven studies (32%) reported accuracy data comparing Derm–CAD with dermoscopy for the detection of invasive
melanoma and atypical intraepidermal melanocytic variants, providing 7 datasets (4104 lesions including 226
melanomas and no other malignancies). A further 4 studies reported accuracy data for dermoscopy in a subsample of
the total study population, and so were excluded from analysis (Blum 2004b; Ferris 2015; Menzies 2005; Stanganelli 2005).
Five of the seven studies compared Derm–CAD to diagnosis by expert dermoscopists using dermoscopic images
alone (Binder 1994; Gilmore 2010; Piccolo 2014; Seidenari 1998) or alongside clinical images (Piccolo 2002) in 765
lesions (153 melanomas). Two studies compared face-to-face dermoscopic diagnosis by an expert dermatologist with
Derm–CAD systems DB–MIPS (Bauer 2000) and Image J (Dreiseitl 2009).
The accuracy of Derm-CAD was compared with the accuracy of dermoscopy using:
(a) all 22 Derm-CAD studies (8992 lesions and 1063 melanomas) and the 5 image-based dermoscopy studies (765
lesions and 153 melanomas) in an indirect comparison (Figure 10 and Figure 11), and
(b) direct comparisons in the subset of 5 studies that evaluated both Derm-CAD and image-based dermoscopy (765 lesions
and 153 melanomas; Figure 12, Appendix 7).
In both comparisons similar sensitivities were observed but with lower specificity for CAD compared to dermoscopy,
however none of the observed differences were statistically significant (Table 6). For the indirect comparison, the difference
(95% CI) in summary sensitivities (Derm-CAD 90.1% versus dermoscopy 93.3%) was -3.21% (-11.2% to 4.79%), P = 0.43;
the difference (95% CI) in summary specificities (Derm CAD 74.3% versus dermoscopy 88.5%) was -14.1% (-34.4% to
6.06%), P = 0.17. For the direct comparison the difference (95% CI) in summary sensitivities (Derm–CAD 94.1% versus
dermoscopy 93.9%) was 0.17% (-6.61% to 6.95%), P = 0.96; the difference (95% CI) in summary specificities (CAD-Derm
80.8% versus dermoscopy 88.3%) was -7.44% (-28.4% to 13.6%), P = 0.49.
Contrasting differences in accuracy were produced by the two studies comparing Derm–CAD with face–to–face
dermoscopic diagnosis by an expert (Bauer 2000; Dreiseitl 2009; Table 8), however these differences were imprecise.
Spectro-CAD
Eight datasets were meta–analysed to estimate the accuracy of MSI-CAD systems in referral settings, regardless of
the system make, algorithm used, or whether CAD was used as a stand–alone automated diagnosis or as a
diagnostic aid (Friedman 2008; Glud 2009; Gutkowicz Krusin 1997; Monheit 2011; Tomatis 2003; Tomatis 2005; Wells 2012;
Winkelmann 2016). One other dataset (Hauschild 2014) was excluded from this analysis due to being a subgroup of
Monheit 2011. Four were model derivation studies (Friedman 2008; Gutkowicz Krusin 1997; Tomatis 2003; Tomatis 2005
), two of which validated the resulting classification algorithm in an independent population (Friedman 2008; Tomatis 2005
), and the remaining four were prospective (Glud 2009; Monheit 2011) or retrospective (Wells 2012; Winkelmann 2016
) external validation studies. Melanoma prevalence ranged from 7% (Monheit 2011 to 49% (Friedman 2008; Wells 2012
). These eight datasets evaluated 2537 excised lesions with 296 melanomas, with sensitivities ranging from 76% (Tomatis
2003) to 100% (Glud 2009; Gutkowicz Krusin 1997), and specificities ranging from 8% (Wells 2012) to 77% (Tomatis 2005
). The pooled sensitivity was 92.9% (95% CI 83.7% to 97.1%) and specificity was 43.6% (95% CI 24.8% to 64.5%) (Table 5, 
Figure 13 and Figure 14). The number of melanomas missed ranged from 0 (Glud 2009; Gutkowicz Krusin 1997) to
9 (Tomatis 2003), though the reporting of false positive diagnoses was poor so data could not be analysed.
One study evaluated a Spectro–CAD system based on the analysis of diffuse reflectance spectroscopy data, a
non–imaging CAD system called OIDRS (Garcia Uribe 2012). This model derivation study prospectively recruited 136
pigmented skin lesions with a melanoma prevalence of 7% (final diagnosis determined by histology following biopsy).
OIDRS was found to operate with a sensitivity of 90.0% (95% CI 59.6% to 98.2%) and specificity of 89.7% (95% CI
83.2% to 93.9%) (Table 9).
The two studies evaluating Nevisense, a CAD system using electrical impedance spectroscopy (EIS), included one
internal validation study (Mohr 2013) and one external validation study (Malvehy 2014) (Table 10). Pooling 2389
lesions with 368 melanomas, the summary sensitivity was estimated as 97% (95% CI 94.7% to 98.3%) and specificity
was 33.6% (95% CI 31.6% to 35.7%) (Table 5). Both studies reported considerable difficulties in the ability of Nevisense to
identify seborrhoeic keratoses, with 69/73 (95%) such lesions falsely identified as malignant. Other notable false positive
diagnoses included dysplastic melanocytic nevi, actinic keratoses and dermatofibroma.
One study evaluated the accuracy of an MSI–CAD system in an unreferred population (Walter 2012). A series of participants
with pigmented skin lesions who were presenting for a first clinical assessment were prospectively recruited and imaged by
GPs, using a SIAscope™ coupled with MoleMate, a multispectral imaging device with viewing platform and integrated
Primary Care Scoring Algorithm (developed by Emery 2010). Originally an RCT comparing patient referrals by GPs
using MSI–CAD (experimental arm) with GP clinical assessment only (control arm), we extracted the experimental arm
data as a prospective case series evaluating MSI–CAD against histology or clinical follow-up of at least 3 months for
lesions considered benign, as well as expert diagnosis without follow-up for some benign lesions. Overall 36
melanomas were identified and an additional 209 false diagnoses made amongst 766 included lesions; MSI–CAD
sensitivity was 100% (95% CI 82.4% to 100%) and specificity was 72% (95% CI 68.7% to 75.2%) (Table 7).
Spectro–CAD versus Dermoscopy
Six MSI–CAD studies (67%) also evaluated the accuracy of dermoscopy, providing 6 datasets (684 lesions and 229
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malignancies comprising 220 melanomas, 8 BCCs and no cSCCs). One of these compared Derm–CAD to in–person
dermoscopic diagnosis (Bono 2002), and five studies evaluated dermoscopy using expert dermoscopists (Friedman 2008; 
Glud 2009; Hauschild 2014) or dermatologists of unreported expertise (Wells 2012; Winkelmann 2016) to interpret
stored dermoscopic images of 371 lesions, including 154 melanomas. Four studies also provided additional
diagnostic information to clinicians in the form of clinical examination notes (Friedman 2008; Hauschild 2014; Wells 2012
) or clinical images (Winkelmann 2016).
The accuracy of MSI-CAD was compared with the accuracy of dermoscopy using:
(a) all 8 MSI-CAD studies (2401 lesions and 286 melanomas) and the 5 image-based dermoscopy studies (371
lesions and 154 melanomas) in an indirect comparison (Figure 15 and Figure 16), and
(b) direct comparisons in the subset of 5 studies that evaluated both MSI-CAD and image-based dermoscopy (371 lesions
and 154 melanomas; Figure 17, Appendix 7).
In both comparisons MSI–CAD was significantly more sensitive with lower specificity, though differences in specificity
were only significant for (b), the direct comparison (Table 6). For the indirect comparison (a), the difference (95% CI) in
summary sensitivities (MSI–CAD 92.9% versus dermoscopy 74.0%) was 18.9% (9.58, 28.2%), P = 0.003; the difference
(95% CI) in summary specificities (MSI–CAD 43.6% versus dermoscopy 58.7%) was -15.0% (-40.7% to 10.6%), P = 0.26.
For the direct comparison (b), the difference (95% CI) in summary sensitivities (MSI–CAD 96.8% versus dermoscopy 74.0%)
was 22.7% (15.2% to 30.2%), P < 0.001; the difference (95% CI) in summary specificities (MSI–CAD 29.8% versus
dermoscopy 58.7%) was -28.9% (-56.3% to -1.48%), P = 0.039.
Four of the five image–based dermoscopy studies used the MelaFind system (Friedman 2008; Hauschild 2014; Wells 2012; 
Winkelmann 2016), with the same impact on sensitivity (MelaFind 96.5% versus dermoscopy 72.5%; difference (95%
CI) of 23.9% (16.0% to 31.9%), P < 0.001) and specificity (MelaFind 22.8% versus dermoscopy 50.7%; difference (95%
CI) –27.9% (-50.1% to -5.66%), P = 0.014) (Table 6).
One study compared the accuracy of MSI–CAD to in–person diagnosis by an expert dermatologist (Bono 2002), and results
are presented in Table 8.
Derm–CAD versus Spectro–CAD
None of the studies directly compared the accuracy of Derm-CAD and MSI-CAD. An indirect comparison of MSI–CAD
(8 studies) and Derm–CAD (22 studies), demonstrated similar sensitivities (Derm–CAD 90.1% versus MSI–CAD 92.9%)
with a difference (95% CI) of 2.83% (-5.04% to 10.7%), P = 0.48. However, specificity was lower for MSI–CAD (43.6%)
compared to Derm-CAD (74.3%) with a difference of -30.7% (-53.8% to -7.64%), P = 0.009 (Table 6).
Secondary analyses for the detection of invasive melanoma and atypical intraepidermal melanocytic variants
Accuracy of individual Derm–CAD systems
Our ability to compare the accuracy of individual CAD systems was limited by lack of data. A sufficient number of
datasets to allow separate pooling was available only for the DB-MIPS system. Six studies evaluated the DB–MIPS
system, using varying classification algorithms, in a total of 1903 lesions including 502 melanomas (Bauer 2000; Burroni
2004; Rubegni 2002; Seidenari 1999; Stanganelli 2005; Wollina 2007; a seventh study, Seidenari 1998, was excluded from
this analysis due to population overlap with Seidenari 1999). Three were external validation studies (Bauer 2000; Seidenari
1999; Wollina 2007), and all six included only excised lesions. Summary estimates of sensitivity were 95.2% (95% CI
89.5% to 97.9%) and specificity 89.1% (95% CI 78.7% to 94.8%) (Table 5, Figure 8 and Figure 18).
Three external validation studies evaluated the MicroDERM system in a total of 793 lesions with 54 melanomas.
However, due to the limited number of studies and substantial variability between studies, we did not perform meta-
analysis. Sensitivities ranged from 17% (95% CI 0% to 64%) to 86% (95% CI 42% to 100%) and specificities from
50% (95% CI 46% to 54%) to 90% (95% CI 83% to 95%) (Barzegari 2005; Boldrick 2007; Serrao 2006). These
represent accuracy for thresholds using DANAOS scores of ≥ 6.5 (Serrao 2006), ≥ 7 (Boldrick 2007) and ≥ 7.34 (Barzegari
2005). The outlying sensitivity of 17% observed in Boldrick 2007 is likely due to a skewed sample of lesions since of the
1000 PSLs assessed in the study, only 18 received an eligible reference standard (histology, clinical follow–up was not
reported) and so could be included. The vast majority of the original sample (982/1000) were clinically diagnosed as benign
lesions not requiring excision.
Two studies evaluated the Skin View system in 220 excised lesions with 45 melanomas (Cascinelli 1992; Cristofolini 1997
). The earlier publication included a model validation phase using internal validation (Cascinelli 1992), while Cristofolini 1997
performed an external validation only. Summary estimates of sensitivity were 80.0% (95% CI 65.8% to 89.3%) and
specificity 47.4% (95% CI 40.1% to 54.8%) (Table 5 and Figure 8).
Accuracy of individual Spectro–CAD systems
Five MSI–CAD studies evaluated the MelaFind system in a total of 1798 lesions including 196 melanomas (Friedman 2008; 
Gutkowicz Krusin 1997; Monheit 2011; Wells 2012; Winkelmann 2016). Summary estimates of sensitivity were 97.1%
(95% CI 91.9% to 98.9%) and specificity 29.8% (95% CI 12.3% to 56.3%) (Table 5, Figure 11 and Figure 19).
Both EIS–CAD studies reported above evaluated the Nevisense system, in a total of 2389 lesions with 368 melanomas,
giving a summary sensitivity of 97.0% (95% CI 94.7% to 98.3%) and specificity of 33.6% (95% CI 31.6% to 35.7%).
CAD–only performance versus CAD–aided performance
In sensitivity analyses, we excluded studies that used CAD as a diagnostic aid. Three of the 22 Derm–CAD studies
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evaluated the Derm–CAD system as a diagnostic aid in referral settings (Bauer 2000; Piccolo 2014; Wollina 2007). Two of
the six DB–MIPS studies (both prospective, external validation studies) assessed the system as a diagnostic aid. For
MSI–CAD, one of the eight studies used CAD as a diagnostic aid in a referral setting (MelaFind, Winkelmann 2016). The
results of the sensitivity analyses are shown in Appendix 8. The results indicate very similar findings to the main analyses.
Direct evidence was available from one study (Dreiseitl 2009) which compared Derm–CAD computer diagnoses (CAD–only)
with diagnoses produced by clinicians using Derm–CAD as a diagnostic aid (CAD–aided). In an external validation study,
Dreiseitl 2009 compared CAD–only performance of MoleMax II analysed with the Image J software programme (using a
neural network classifier), with CAD–aided diagnosis performed by dermatologists with high experience, low experience, and
a third cohort with mixed experience. In this prospective study, 458 consecutive participants who were referred to a
secondary care centre for further investigation of 3021 suspicious pigmented skin lesions were included. While lesion–based
results were reported for the CAD–only diagnosis, only patient–based results were provided for its comparison to CAD–aided
diagnoses; it is notable that the lesion–based sensitivity and specificity for CAD-only diagnosis differ substantially from the
patient–based estimates for CAD-only diagnosis (74% versus 89% sensitivity, 84% versus 48% specificity), which is to be
expected when many more lesions were free of disease (true negatives n = 2512) than were patients (n = 207). The
within–study comparison to CAD-aided diagnosis are reported in Table 8.
A case–control reader study (Hauschild 2014) undertaken in a referred setting was the only direct comparison of an MSI
CAD–only diagnosis with MSI CAD–aided diagnosis. The study included 65 melanomas and 65 benign pigmented skin
lesions that had been excised to evaluate the ability of MelaFind to accurately recommend biopsy in pigmented skin lesions.
The study sample was a randomly selected subset of the consecutively recruited, prospective Monheit 2011 population.
Differences (95% CI) are reported in Table 8.
Target Condition: Basal Cell Carcinoma (BCC)
Derm–CAD
Four study populations from referred settings included BCC lesions (Cascinelli 1992; Ferris 2015; Menzies 1996; Mollersen
2015), however two did not provide adequate data to derive 2x2 data (Menzies 1996; Mollersen 2015) and one
included fewer than the minimum of five lesions to meet our inclusion criteria for this question (Cascinelli 1992). The
remaining study evaluated 11 BCCs amongst 173 dermoscopically atypical lesions using the output of an unnamed
CAD system (CAD–based diagnosis), in a retrospective case series. Three BCCs were missed giving a sensitivity of
73% (95% CI 43.4% to 90.3%) with 108 false positives giving a specificity of 33% (95% CI 26.5% to 40.9%) for the
detection of BCC (Ferris 2015). The study used dermoscopic images of skin lesions excised on the basis of clinical suspicion
of malignancy, and also included melanomas, cSCCs, seborrhoeic keratosis and benign melanocytic lesions. The very low
specificity was as a result of misclassification of seborrhoeic keratoses (7/11), low–grade dysplastic naevi (27/47) and lentigo
(8/10) as malignant lesions.
Spectro–CAD
Two studies evaluated the ability of a Spectro–CAD system to detect BCC lesions, both using the EIS–CAD
Nevisense system in patients with suspected melanoma referred for excision (Malvehy 2014; Mohr 2013) (Table 10). Of
2389 analysed lesions, all 69 BCCs were identified giving a summary sensitivity of 100% (95% CI 94.7% to 100%) and very
low specificity of 26.3% (95% CI 24.5% to 28.1%). Since both populations were recruited to rule out melanoma, few benign
keratotic lesions were included (including lichenoid keratosis (n = 4), seborrhoeic keratosis (n = 73) and actinic keratosis (n =
8)), a factor which may have contributed to the very low specificity.
Target Condition: Cutaneous Squamous Cell Carcinoma (cSCC)
The only study to evaluate the performance of a CAD system to detect cSCC used the EIS–based Nevisense
system in referred patients, identifying all 7 cSCCs amongst 1943 lesions to give a sensitivity of 100% (95% CI
59.0% to 100%) and specificity of 43.4% (95% CI 41.2% to 45.6%) (Malvehy 2014) (Table 10). The high sensitivity could
have been influenced by the study's melanoma–focused recruitment selection which resulted in very few benign differential
diagnoses being included (lichenoid keratosis (n = 4), seborrhoeic keratosis (n = 51) and actinic keratosis (n = 8)).
Secondary target conditions: invasive melanoma alone
The diagnostic accuracy of CAD assessment for the detection of invasive cutaneous melanoma alone was reported by seven
studies for a total of 1336 lesions with 236 invasive melanomas.
Of these, two studies evaluated Derm–CAD systems (total 950 lesions with 120 invasive melanomas): SolarScan (Menzies
2005) and an unnamed system (Menzies 1996), both of which included model derivation within the same population
(Menzies 1996 did not report the method of dividing lesions into train and test sets). Both also included pigmented
skin lesions referred for excision (Menzies 1996; Menzies 2005) of which one may have included BCCs amongst the
target disease negative group (Menzies 1996 included 18 BCCs in the full study population but did not report how many were
included in the independent test set). Melanoma prevalence was 10% in Menzies 2005 and 27% in Menzies 1996.
Meta–analysis of these studies provided a summary sensitivity estimate of 90.8% (95% CI 84.2% to 94.9%) and
summary specificity of 63.5% (95% CI 60.2% to 66.7%) (Table 5). Menzies 2005 also reported data for the primary target
condition, invasive melanoma and atypical intraepidermal melanocytic variants, with little difference in sensitivity (92.0%
invasive melanoma only versus 91.0%, –1.0% difference (95% CI –8.7% to 8.2%)) or specificity (61.5% invasive melanoma
only versus 65.1%, –3.6% difference (95% CI -8.7% to 1.5%)). Despite in situ lesions making up 39% (47/122) of disease
positives, similar proportions of in situ (5/47) and invasive lesions (6/75) were missed by the SolarScan.
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One Derm–CAD study, retrospective with uncertain design, also allowed a comparison with image–based
dermoscopy in 164 lesions containing 45 invasive melanomas (Menzies 1996). Observer experience was not reported.
Accuracy estimates were similar and are reported in Table 8.
Five studies evaluated an MSI-CAD system (total 386 lesions with 116 invasive melanomas), regardless of the
system make, algorithm used, or whether CAD was used as a stand–alone automate diagnosis or as a diagnostic
aid. All were conducted in lesions referred for excision, four solely in pigmented skin lesions (Ascierto 2010; Bono 1996; 
Friedman 2008; Hauschild 2014) and the fifth in any lesion clinically suspected of being a melanoma (Terstappen 2013
). Systems evaluated were MelaFind (Friedman 2008; Hauschild 2014), SpectroShade (Ascierto 2010),
Telespectrophotometric System (Bono 1996) and SIAscope, version V (Terstappen 2013).
Sensitivities ranged from 24% (Terstappen 2013) to 100% (Friedman 2008) and specificities from 29% (Friedman 2008
) to 84% (Terstappen 2013). The study producing the highest sensitivity and lowest specificity, Friedman 2008, excluded all
high grade dysplastic lesions and therefore included only melanomas, BCCs (n = 2), low grade dysplastic nevi (n = 32) and
other benign melanocytic lesions (n = 14). The lowest sensitivity and highest specificity were produced by Terstappen 2013
who further selected their population of clinically suspicious lesions to include only lesions with a positive CAD
result (SIAscope). Both datasets that evaluated the MelaFind system (Hauschild 2014; Friedman 2008) generated high
sensitivities (81% and 100%) and low specificities (39% and 29%). These five studies (386 lesions including 116
invasive melanomas) gave a summary sensitivity estimate of 76.5% (95% CI 43.0% to 93.3%) and summary specificity
of 60.7% (95% CI 38.5% to 79.2%) (Figure 20; Figure 21; Table 5).
In sensitivity analyses, we excluded one study that used CAD as a diagnostic aid, in a referral setting (Hauschild 2014). The
results of the sensitivity analysis are shown in Appendix 8. The results indicate very similar findings to the main analysis.
One study compared MSI–CAD (MelaFind) to diagnosis by expert dermoscopists using dermoscopic images in 99
lesions including 21 invasive melanomas, finding Melafind’s sensitivity to be higher (100% versus 81%) and
specificity lower (29% versus 45%) than dermoscopy (Friedman 2008) (Table 8).
One other study compared MSI–CAD (SpectroShade) to face–to–face diagnosis by expert dermatologists in 54
lesions with 12 invasive melanomas, finding SpectroShade’s sensitivity to be lower (67% versus 100%) and
specificity higher (76% versus 45%) than dermoscopy (Ascierto 2010) (Table 8).
The two studies evaluating the EIS–based Nevisense system produced accuracy data for 2389 lesions with 226
invasive melanomas, giving a summary sensitivity of 98.2% (95% CI 95.4% to 99.3%) and specificity of 38.0% (95% CI
36.0% to 40.1%) (Mohr 2013, Malvehy 2014) (Table 5).
A single study contributed data for the accuracy of detecting invasive melanoma in an unreferred setting, reporting the
use of MoleMate with SIAscope by GPs in 766 lesions with 14 invasive melanomas (Walter 2012). No melanomas were
missed: sensitivity 100% (95% CI 77.4% to 100%); although false positive findings were high giving a specificity of 72%
(95% CI 68.3% to 74.8%) (Table 7).
Secondary target conditions: any lesion requiring excision
Derm–CAD
Four datasets from three studies (Cascinelli 1992; Ferris 2015; Mollersen 2015) provided data to evaluate the
accuracy of Derm–CAD to detect any skin cancer or other atypical lesion requiring excision in referred settings.
Two were retrospective derivation studies using stored dermoscopic images to train either the Skin View system in
clinically suspect pigmented skin lesions referred for excision (Cascinelli 1992), or an unnamed system in lesions
suspected of malignancy also referred for excision (Ferris 2015). The third study conducted a head–to–head
external validation comparison of two systems, in a case series of pigmented and nonpigmented (if melanoma,
BCC, or SCC was a potential differential diagnosis) skin lesions scheduled for excision (Mollersen 2015). The
Nevus Doctor system was the subject of evaluation as a system still in development, being compared against the
commercially available Mole Expert. The three studies provided a total of 1087 lesions, the 186 malignancies
included 83 BCCs, 9 cSCCs and 1 adnexal carcinoma (Mollersen 2015). Sensitivities were high, ranging from 83%
(Cascinelli 1992) to 98% (Mollersen 2015, Nevus Doctor), while specificities were low and more varied ranging from
12% (Mollersen 2015 Nevus Doctor) to 59% (Cascinelli 1992). The lowest specificities (Nevus Doctor 12%, Mole Expert
13%) were produced by the study with the lowest disease prevalence (14%, Mollersen 2015). Mollersen 2015 also produced
the highest sensitivity and was the only study to include clinically obvious melanomas amongst its lesions.
These accuracy estimates did not differ substantially from those for the detection of the individual target conditions reported
above.
No data were available to compare these results with the use of standard dermoscopy to detect any skin cancer.
Spectro–CAD
Two datasets evaluated the performance of DRS–CAD systems in referred settings, both from one study (Garcia Uribe 2012)
evaluating the performance of the Oblique Incidence Diffuse Reflectance Spectrometry (OIDRS) system in two cohorts of
lesions (i.e. CAD algorithms trained separately in each cohort). Amongst 136 pigmented skin lesions including 25 lesions to
be excised (10 melanoma, 15 severe dysplastic lesions) OIDRS gave a sensitivity of 92% (95% CI 74.0% to 98.8%) and
specificity 86% (95% CI 78.9% to 91.6%); amongst 89 non–pigmented skin lesions including 64 lesions to be excised (39
BCC, 25 cSCC) OIDRS gave a sensitivity of 92% (95% CI 83.0% to 96.6%) and specificity 92% (95% CI 74.0% to 98.8%).
However, caution must be used to interpret these estimates as the spread of disease was different to that intended by our
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target condition definition of all malignancies: no malignancies other than melanoma were included in the pigmented
population, and no melanomas were included in the non–pigmented population.
The two EIS–CAD studies conducted in referred settings produced accuracy data for 2389 lesions with 644
malignancies or highly dysplastic lesions, giving a summary sensitivity of 93.5% (95% CI 91.3% to 95.1%) and
specificity of 32.6% (95% CI 30.4% to 34.8%) (Malvehy 2014; Mohr 2013) (Table 5). In addition to the malignancies
described above, one Merkel cell carcinoma was included (Malvehy 2014) and detected by Nevisense.
Two datasets provided data for the use of MSI–CAD in unreferred settings (Sgouros 2014; Walter 2012) (Table 7). While
both used a SIAscope™ device, Walter 2012 used the MoleMate analysis system incorporating the ‘primary care
scoring algorithm’ to analyse lesion images and arrive at a diagnosis (Walter 2012), while Sgouros 2014 also used the
primary care scoring algorithm but did not report how images were interpreted. Sensitivity was slightly higher in Walter 2012
study (92% versus 84% in Sgouros 2014) and specificity substantially so (72% versus 46% Sgouros 2014). In addition to the
probable use of different analysis software, this difference is likely explained by two factors, firstly CAD test results were used
in different ways, as a diagnostic aid to GPs (after a period of training) by Walter 2012 and as the diagnostic output for a
CAD–based diagnosis in Sgouros 2014. Second, our exclusion of 144 benign cases with no reference standard diagnosis
from Sgouros 2014 has created a highly selected (excised only) and unrepresentative study population in this study (low
sample size, n = 44, and high prevalence of malignancy, 70%). Of the 153 lesions considered benign after clinico-
dermoscopic assessment (of which nine were later excised), 122 were diagnosed as naevi, 23 as seborrhoeic keratoses,
seven as dermatofibroma and one as cherry angioma. SIAscopy gave a negative score (< 6) in 100 of these 153 lesions.
Discussion 
Summary of main results
Computer–assisted diagnosis has been evaluated using a wide range of computer systems that analyse lesion images
obtained by digital dermoscopy, lesion images obtained by multispectral imaging, or that analyse non–visual data from
electrical impedance or diffuse reflectance spectroscopy. These computer systems have employed a variety of classification
algorithms to scrutinise diverse selections of features. CAD sensitivity estimates were generally high, though with highly
variable specificity.
We present six main findings from our review:
1) Included studies inadequately address the review question due to an abundance of low quality studies, poor
reporting, and recruitment of highly selected groups of participants
This review aimed to assess the accuracy of computer–assisted diagnosis for detecting melanoma, BCC or cSCC in adults.
Most included studies focused on its use for detecting or ruling out melanoma in lesions scheduled for excision. Therefore
these studies do not reveal CAD’s ability to detect clinically missed melanomas, since most have excluded lesions clinically
diagnosed as benign. Only three studies, all of Derm–CAD systems, examined lesions not recommended for excision (and
thus potentially missed melanomas) using an adequate reference standard in clinically benign lesions.
Studies were poorly reported and generally of unclear to high risk of bias across all domains, particularly with regard to the
selection of study participants, the timing of CAD diagnosis in relation to the reference standard diagnosis, and
pre–specification of CAD thresholds. Most studies used restricted groups of participants and failed to provide details of
diagnostic thresholds sufficient for their reproducibility, leading to an almost universally poor clinical applicability of studies.
Poor reporting in the primary studies also hindered attempts to assess sources of heterogeneity, particularly with
regard to the lack of reporting CAD results according to the final diagnosis. A substantial number of included studies
(half of Derm–CAD studies and a third of Spectro–CAD studies) evaluated experimental versions of CAD systems, in
which classification algorithms were trained alongside preliminary assessments of test performance within the same
source population. The frequency of these internal validation studies causes high concern for the reliability of
accuracy estimates, chiefly because models are likely to give overly–optimistic results when training and testing
datasets are very similar in the spread of lesion types and severity, as is the case when the same source population is
used (Altman 2009). In addition, great caution should be employed when considering the applicability of these results to
current clinical practice, since the generalisability of a new model can only be estimated in external validation studies that
recruit new groups of patients from entirely new source populations.
Most study populations were restricted to excised lesions. Since lesions which are not excised are more likely to be
benign, and without an atypical morphological pattern that could be mistaken for a malignancy, their absence from
datasets may have reduced CAD specificity estimates from their likely performance in populations where CAD tests
would be used in clinical practice, namely those being referred for specialist assessment. Including the appropriate
spectrum of benign conditions is key to establishing the accuracy of any test (Lijmer 1999). Spectrum effects are often
observed when tests that are developed further down the referral pathway have lower sensitivity and higher specificity
when applied in settings with participants with limited prior testing (Usher-Smith 2016). However, this direction of effect is not
consistent across tests and diseases as Leeflang 2013 clearly demonstrates; the mechanisms in action are often more
complex than prevalence alone and can be difficult to identify. It is therefore crucial that tests are evaluated in lesions that
are representative of those in which the test will be used in practice. For tests such as CAD that use machine learning, a
representative participant population is vital for both training the algorithm and testing its validity. If a narrow range of benign
conditions is used to train a computer algorithm, the resulting CAD system is likely to struggle in discriminating new,
previously unseen benign lesions at the validation stage. Unfortunately, very poor reporting of the spectrum of conditions
included in studies prevents any assessment of whether mismatches have occurred between training and validation
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populations.
Limited data regarding the use of CAD as a diagnostic aid further limits the applicability of study results. Although CAD
systems are designed to be used as diagnostic aids, the majority of studies did not evaluate how CAD outputs were
interpreted and acted upon by clinicians in their diagnostic decision–making, but instead evaluated the accuracy of the CAD
system outputs as stand–alone tests.
2) CAD systems correctly identify melanoma in highly selected populations, but their low and very variable
specificity suggest they are unreliable as stand–alone diagnostic tests, especially in less selected populations
Reflecting the design aims of system developers, the vast majority of studies sought to evaluate the ability of CAD to identify
melanomas. The Summary of findings table 1 presents key results for the primary target condition of cutaneous invasive
melanoma or atypical intraepidermal melanocytic variants. For digital dermoscopy CAD systems, pooled results from 22
studies (8992 lesions, 1063 melanomas) provided a sensitivity of 90.1% (95% CI 84.0% to 94.0%) and specificity of 74.3%
(95% CI 63.6% to 82.7%). The Summary of findings table 1 illustrates how these estimates would affect diagnoses in a
hypothetical cohort of 1000 lesions clinically suspected of being melanomas. At the median melanoma prevalence of 20%
that might occur in a highly specialised melanoma referral clinic, digital dermoscopy CAD systems would on average miss 20
out of 200 melanomas and would result in 206 false positive diagnoses. At the lower and upper quartile melanoma
prevalence of 7% and 40%, 7 and 40 melanomas would be missed, with 239 and 154 false positive diagnoses respectively.
For multispectral imaging CAD systems, pooled results from 8 studies (2401 lesions, 286 melanomas) provided a
sensitivity of 92.9% (95% CI 83.7% to 97.1%) and specificity of 43.6% (95% CI 24.8% to 64.5%). In a hypothetical
cohort of 1000 lesions clinically suspected of being melanomas with melanoma prevalence of 20%, MSI–CAD
systems would on average miss 14 out of 200 melanomas and would result in 451 false positive diagnoses (Summary of
findings table 1). At the lower and upper quartile melanoma prevalence of 7% and 40%, 5 and 28 melanomas would be
missed, with 525 and 338 false positive diagnoses respectively.
These results demonstrate a consistently high sensitivity for the detection of invasive melanoma and atypical
intraepidermal melanocytic variants by CAD, regardless of type (Derm–CAD versus Spectro–CAD). However,
specificity tends to be low and varies considerably between studies, particularly for MSI–based systems. The
evidence certainly indicates that some benign lesions are more difficult to distinguish from malignancy using both
Derm–CAD and Spectro–CAD systems, particularly seborrhoeic keratoses which proved problematic for Derm–CAD
and EIS–CAD systems. However the reporting of benign diagnoses by CAD result was very poor, and omitted in 29
of the 42 included studies. As a result, the performance of MSI–CAD systems with regard to these lesions remains
uncertain. This difficulty in ruling melanoma out from seborrhoeic keratoses is also encountered when visual
examination and dermoscopy are employed, and for CAD systems is equally likely to be due to similarities in the
morphological appearance of these non-melanocytic pigmented lesions and melanomas (Menzies 2005; Mollersen 2015).
Poor reporting of other aspects of study conduct also limit our interpretation of the heterogeneity in specificity, however likely
causes include a wide variation in the spread of disease negative conditions included in study populations (both for training
algorithms and for validating them), as well as considerable variation in CAD system characteristics.
3) There is insufficient evidence to assess the accuracy of CAD systems in primary care settings
Insufficient data were available from primary care populations to draw firm conclusions, particularly for Derm–CAD with
only one included study which restricted inclusion to excised lesions only. For MSI–CAD, some suggestion of high
sensitivity was found, though the evidence–based was limited to 2 studies evaluating differing target conditions and
with differing approaches to the use of CAD results (CAD–based versus CAD–aided diagnosis). Limiting study
populations to excised lesions is particularly problematic in such settings, since the frequency and distribution of
disease is far removed from the range one would expect to see in patients who have received limited prior testing,
such as those self–referring to specialist pigmented lesion clinics. Only one study examined all individuals presenting
to generalist settings that had lesions which could not immediately be diagnosed as benign (Walter 2012). A second
study also included all such lesions (Sgouros 2014), however failed to provide non–excised lesions with any clinical
follow–up and so these lesions had to be excluded from our analysis.
4) Preliminary findings suggest CAD systems are at least as sensitive as assessment of dermoscopic images
for the diagnosis of invasive melanoma and atypical intraepidermal melanocytic variants
MSI–CAD was found to be significantly more sensitive than image-based dermoscopy (92.9% versus 74%, P = 0.003),
while direct comparisons indicate that it is also significantly less able to rule out truly benign lesions (29.8% versus
58.7%, P = 0.039). However indirect comparisons did not confirm this difference (43.6% versus 58.7%, P = 0.26) (Table 6
). Conversely, our evidence suggests Derm–CAD may not differ significantly from dermoscopy in its ability to identify
melanomas. However, we caution against drawing firm conclusions from these comparisons in the absence of
sufficient data from studies evaluating face–to–face dermoscopy, on the basis that another review in this series has
found such studies to demonstrate significantly higher accuracy for dermoscopy than those relying on review of
dermoscopic images (Dinnes 2018b).
5) The evidence–base for individual systems is too limited to draw conclusions on which might be preferred for
practice
Despite the large number of included studies, the evidence–base for the accuracy of individual systems to detect the primary
target condition of the detection (invasive melanoma and atypical intraepidermal melanocytic variants) remains low with
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meta–analysis possible for only two Derm–CAD systems (DB–MIPS and Skin View), one MSI–CAD system (MelaFind) and
one EIS–CAD system (Nevisense). Only one of these, DB–MIPS, demonstrated a high specificity (89.1%) alongside high
sensitivity (95.2%). Even though they evaluated the same CAD system, the six studies that were pooled for this estimate of
DB-MIPS were very varied in the classification algorithm used (ANN, SVM, K–NN, discriminant analysis, Euclidean
distances), disease prevalence (5% to 45%), use of CAD results (two studies evaluated DB–MIPS as a diagnostic aid and
four evaluated the DB–MIPS computer output) and range of disease negative conditions included (poorly reported, with a
mixture of common naevus, dysplastic naevus, and only one study including seborrhoeic keratoses). The clinical settings to
which this estimate applies therefore remains unclear.
We observed considerable variation in test characteristics across all CAD systems, such as hardware and software
technologies used, the types of classification algorithm employed, methods used to train the algorithms, and which lesion
morphological features were extracted and analysed. Wide variations in technology specifications were observed even within
the same CAD systems; for example the four studies evaluating the SIAscope (a commercially available MSI–CAD system)
captured between 4 and 8 optical reflectance images at varying wavelengths to inform the final image (not reported in 2
studies), using different SIAscopes (versions II and V, not reported in 2 studies) coupled to different software programmes
(the MoleMate™ in 2 studies, and not reported in 2 studies) utilising 2 different thresholds (the Moncrieff 2002 and Emery
2010 methods). This variation in CAD method, alongside limited reporting of important technological variables, was
encountered in all CAD systems evaluated in this review.
6) Evidence of the ability of CAD to detect keratinocyte cancers is very limited and studies are confined to
specialist settings
Only 3 studies included sufficient numbers of BCC cases for analysis; the one small retrospective study evaluating
Derm–CAD is insufficient to draw any conclusions. For EIS–CAD, the two large prospective studies were designed to
evaluate Nevisense’s ability to detect melanoma, thus neither recruited populations clinically applicable for keratinocyte
cancer detection, casting doubt on the generalisability of pooled estimates to clinical practice. Similarly, evidence for the
accuracy of cSCC detection is limited to one Nevisense study, of unlikely clinical applicability to the target condition.
Strengths and weaknesses of the review
The strengths of this review include an in-depth and comprehensive electronic literature search, systematic review methods
including double extraction of papers by both clinicians and methodologists, and contact with authors to allow study inclusion
or clarify data. A clear analysis structure focusing on estimating incremental gains in accuracy was adopted. A detailed and
replicable analysis of methodologic quality was undertaken.
In comparison with the four main existing systematic reviews, our review extends the time period searched for eligible studies
(from 2002 in Rosado 2003, from 2007 in Rajpara 2009 and Vestergaard 2008, and from 2011 in Ali 2012), includes all
eligible studies regardless of language (Ali 2012; Rosado 2003), the presence of melanocytic lesions (Rajpara 2009),
or use of a histological reference standard (Rajpara 2009). Although Vestergaard 2008 reviewed studies evaluating
multispectral imaging CAD, electrical impedance spectroscopy CAD, and digital dermoscopy–based CAD systems, ours is
the first review to meta-analyse data and provide pooled accuracy estimates for each of these three types of CAD system.
Ours is also the first review to include keratinocyte cancers as a target condition.
Our stringent application of review inclusion criteria meant that some studies included in previous reviews were excluded. For
example, those developing CAD systems and training new algorithms (‘derivation studies’) without assessing their
performance in an independent population were not included. Of the 30 studies included in Rosado 2003, we
excluded 23 studies including 17 derivation studies without independent test sets (16 Derm–CAD studies (Andreassi 1999; 
Binder 2000; Elbaum 2001; Ercal 1994; Ganster 2001; Green 1991; Green 1994; Hintz-Madsen 2001; Horsch 1997; Kahofer
2002; Pompl 2000; Rubegni 2001a; Sboner 2001; Schindewolf 1994; Schmid-Saugeon 2003; Smith 2000) and one
MSI–CAD study, Farina 2000). Three others were excluded for lack of clarity on the 2x2 contingency table (Schindewolf
1993), evaluating the diagnostic ability of a single feature (shape, Claridge 1992), and unclear reporting on CAD type
and eligibility of the reference standard (Lefevre 2000). Two others were conference abstracts, and so were not eligible
for analysis. Of the 12 Derm–CAD studies included in Rajpara, we excluded 4 derivation studies without independent
test sets (Green 1994; Manousaki 2006; Rubegni 2002a; Sboner 2001). Similarly, we excluded four of the nine Derm-CAD
studies in Ali 2012 due to the absence of independent test sets in derivation studies (Iyatomi 2006; Iyatomi 2008a; Iyatomi
2008b; Iyatomi 2010a), and another that did not evaluate diagnosis of the presence of skin cancer (Abbas 2011a).
Vestergaard 2008 also required studies to evaluate CAD systems in an independent test set, and consequently only one of
the nine studies included in Vestergaard 2008 was excluded, due to the absence of a reference standard test in
selected participants (Jamora 2003).
Our stringent exclusion of studies without an independent test population has resulted in the exclusion of all studies
evaluating non–imaging diffuse reflectance spectroscopy (DRS) systems (e.g. Wallace 2002). This class of
technologies used high spectral sampling to achieve a much higher resolution of spectral information from pigmented
skin lesions than is found in the included DRSi (multispectral imaging) studies, giving an apparent strong
performance for the detection of melanoma (Wallace 2000a; Wallace 2000b). Whether these promising results were
overly–optimistic due to their study design, or are genuine indicators diagnostic ability cannot be assessed by this review.
However, as technology improves we are likely to see systems with both imaging capability and high spectral sampling,
making further carefully-planned evaluation worthwhile.
The main concerns for the review are a result of the poor reporting of primary studies, limiting our assessment of
methodological quality, and in particular limiting an understanding of which malignant and benign conditions were correctly
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and incorrectly identified by the CAD systems. The poor reporting is of particular concern given the clear heterogeneity in all
aspects of study design, and consequently the clinical applicability of results is difficult to determine. Poor reporting also
precludes our ability to identify those studies that may have been well designed, but did not document their design and
conduct adequately.
Clear identification of the target condition was not provided in 9/22 Derm–CAD datasets or in 4/8 MSI–CAD datasets included
in our primary analyses for detection of invasive melanoma or atypical intraepidermal melanocytic variants. These studies
may or may not have included melanoma in situ lesions. Where studies included other invasive skin cancers in the study
population, we attempted to class any that were correctly identified as true negative results as opposed to false positives, on
the basis that removal of any skin cancer in the attempt to identify melanomas would not be a negative consequence of the
test. This relied on studies providing a disaggregation of test results according to final lesion classification and was not
always possible.
Our review is limited to studies published up to August 2016, and since computer–assisted diagnosis is a rapidly
developing field of technology, the review will have missed some important and more recent developments in the field
of machine learning with an application to the detection of skin cancer. Deep learning algorithms (Esteva 2017; Han 2018)
are one example where recent advances in computation have been applied to the development of new CAD systems for the
detection of skin cancer. In future, it is also probable that CAD systems using continuous machine learning algorithms (where
the CAD model continues to refine itself with exposure to clinical cases) will be developed.
Applicability of findings to the review question
The majority of data included in this review are unlikely to be applicable to the current clinical settings of primary care and
dermatology clinics that exist in many developed countries. The predominance of highly selected lesion groups, scarce
documentation of prior testing and frequency of internally validated derivation studies are likely to restrict the applicability of
accuracy estimates to clinical practice. Poor documentation of the final diagnoses used to train CAD systems prevents any
conclusion regarding the ideal target patient group, while very limited reporting of CAD results by final diagnosis does not
allow for recommendations to be made as to which CAD is most and least likely to perform well, further restricting the
transferability of results in practice.
Authors' conclusions 
Implications for practice 
The utility of CAD for the primary diagnosis of melanoma in patients referred to specialist care remains largely unknown,
since most included studies used CAD to detect malignancy in lesions already scheduled for surgical excision, most
commonly with a high clinical suspicion of melanoma. For the detection of melanoma in patients with clinically suspicious
lesions, the evidence consistently shows all CAD types to have high sensitivity. CAD systems could therefore by useful as a
back-up by specialists to assist in minimising the risk of missing melanomas. However, the evidence–base is currently too
poor to understand whether CAD system outputs translate to different clinical decision–making in practice, and our sensitivity
analysis suggests sensitivity may actually decrease when CAD is used as a diagnostic aid to triage unreferred patients. In
addition, any projected gains in the early detection of melanomas must be set against the costs and practicality of
implementing new systems.
Our evidence suggests MSI–CAD may be significantly more sensitive than dermoscopy. Given the paucity of data to allow
comparison with in–person dermoscopy studies, this finding should be considered as exploratory.
Insufficient data are available to provide conclusive comments on the accuracy of CAD in community settings, or its accuracy
to detect BCC and cSCC in any setting.
Implications for research 
Further prospective evaluation of the added value of CAD systems is warranted. Given the technological complexity and
variation of CAD systems, it is certainly challenging to evaluate them in a rigorous manner. Nonetheless studies are needed
to evaluate CAD in its intended position in the patient care pathway in comparison to routine clinical examination and
dermoscopy. For its use in specialist referral settings, studies should prospectively recruit all consecutive participants that
have been referred for investigation of potential malignancy; for melanoma this should include all pigmented skin lesions, and
for keratinocyte cancers any lesion at suspicion of being a BCC or cSCC. These studies should include lesions that are
clinically determined to be benign and not excised, using specialist follow–up of at least 6 months as the accuracy reference
standard. Comparisons with dermoscopy should consist of in–person diagnosis by dermatologists with expertise in
dermoscopy. In community care settings, studies should prospectively recruit all participants presenting to clinic with lesions
about which the clinician cannot clearly rule out malignancy, with clinical follow–up of all lesions which are not excised. To
understand the clinical validity of CAD systems, studies should further evaluate on how CAD system outputs are used to alter
clinical decision making in real world practice settings.
Future studies must also report CAD test results according to their final diagnosis so that its ability to distinguish between
morphologically difficult lesions can be established. Crucially, studies must report the full technological specifications of their
CAD systems, including which features were analysed as well as the diagnostic criteria and thresholds used to determine the
presence of malignancy. Information on the distribution of lesions used to train the CAD system in previous studies would
also be a welcome addition that would enable an interpretation of the system’s accuracy.
In terms of the development of new systems, or refinement of existing ones, cohorts of lesions should be selected so that
training sets contain the range of benign and malignant lesions that would be encountered in routine clinical practice. Full
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descriptions of included lesions should be reported, together with an indication of how diagnostic thresholds have been
selected. Validation of preliminary results should be assessed in independent populations, ideally from a different source to
that used for model development.
Any future research study needs to be clear about the diagnostic pathway followed by study participants, and should
conform to the updated Standards for Reporting of Diagnostic Accuracy (STARD) guideline (Bossuyt 2015).
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Differences between protocol and review 
Reviews on the accuracy of gene expression testing and volatile organic compounds could not be performed as planned due
to an absence of relevant studies.
For this review, inclusion criteria were amended to remove inclusion of participants "at high risk of developing melanoma,
including those with a family history or previous history of melanoma skin cancer, atypical or dysplastic naevus syndrome, or
genetic cancer syndromes" and "at high risk of developing BCC or cSCC, including those with a family history or previous
history of skin cancer or genetic cancer syndromes, such as basal cell naevus (Gorlin) syndrome" as these are not target
populations for CAD use.
One of the primary objectives and primary target conditions has been changed from diagnosing "cutaneous invasive
melanoma alone", to diagnosing "cutaneous invasive melanoma and atypical intraepidermal melanocytic variants", as the
latter is more clinically relevant to the practicing clinician. The diagnosis of the target condition of invasive melanoma alone
has instead been included as a secondary objective.
Studies using cross-validation, such as 'leave-one-out' cross-validation, were excluded rather than included as these
methods are not sufficiently robust and are likely to produce unrealistic estimates of test accuracy. To improve clarity of
methods, this text from the protocol: "We will include studies developing new algorithms or methods of diagnosis (i.e.,
derivation studies) if they use a separate independent ’test set’ of participants or images to evaluate the new approach. We
will also include studies using other forms of cross validation, such as ‘leave-one-out’ cross-validation ( Efron 1983 ). We will
note for future reference (but not extract) any data on the accuracy of lesion characteristics individually, e.g., the presence or
absence of a pigment network or detection of asymmetry" has been replaced with:
"Studies developing new algorithms or methods of diagnosis (i.e. derivation studies) were included if they evaluated the new
approach using a separate 'test set' of participants or images.
Studies were excluded if they:
evaluated a new statistical model or algorithm in the same participants or images as those used to train the model (i.e.
absence of an independent test set)
used cross-validation approaches such as 'leave-one-out' cross-validation (Efron 1983)"
We proposed to supplement the database searches by searching the annual meetings of appropriate organisations (e.g.,
British Association of Dermatologists Annual Meeting, American Academy of Dermatology Annual Meeting, European
Academy of Dermatology and Venereology Meeting, Society for Melanoma Research Congress, World Congress of
Dermatology, European Association of Dermato Oncology); however, due to volume of evidence retrieved from database
searches and time restrictions we were unable to do this.
For quality assessment, the QUADAS-2 tool was further tailored according to the review topic.
Due to lack of data, we could not perform the following analyses: restriction to analysis of per patient data, or comparison of
accuracy using diagnosis of stored images (image–based) with in–person diagnosis.
Upon closer review of the topic, but before examination of study data, we planned 4 additional secondary analyses than
those listed in the protocol: estimation of diagnostic accuracy for individual CAD systems; comparison of the accuracy of
CAD to dermoscopy where both tests have been evaluated in the same studies (direct comparisons); the comparison of
CAD–based diagnosis to CAD–assisted diagnosis (CAD results used by clinicians as a diagnostic aid); and where CAD
systems are used as a diagnostic aid, to determine the effect of observer experience on diagnostic accuracy.
We planned 3 additional heterogeneity investigations relating to population characteristics than those listed in the protocol
(Patient population: primary/secondary/specialist unit; Lesion type: any pigmented/melanocytic; Inclusion of multiple lesions
per participant), however we could not perform these investigations due to insufficient data.
Published notes 
Characteristics of studies
Characteristics of included studies 
Ascierto 2010
Patient Selection
#164a Computer assisted diagnosis techniques (dermoscopy and spectroscopy-based) for the diagnosis of skin cancer...
26 / 268
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection Not reported (states
in a period of 1 year)
Country Italy
Test set derived: The training set consisted
of 78 PSL images, comprising 19 MMs and
59 naevi of comparable size. The test set
consisted of 383 lesions, including 18 MMs
thinner than 0.75 mm (8 in situ).The 59
naevi belonging to the training set were
randomly selected from routine material,
whereas the 424 naevi of the test set
represented consecutive cases.
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Clinically relevant cutaneous
pigmented lesions, undergoing dermoscopy and
excision; only melanocytic lesions meeting at least two
clinical ABCDE criteria underwent dermoscopy
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: Clinical suspicion of malignancy without
dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: None reported
Sample size (patients): No. eligible: 54/ No. included: 54
Sample size (lesions): 54
Participant characteristics: 
Age (yrs): 
- Median: 41/ Range: 19-73 years
Gender: - Male: 19 males
Lesion characteristics NR
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Was an adequate spectrum of cases used to train the algorithm? No
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
1.Dermoscopy
Method of diagnosis: - In person diagnosis
Prior test data: Clinical examination and/or case notes
Diagnostic threshold: - Qualitative - Very high risk - Lesion with a pigment network and any of the
classical ELM features specific for melanoma (pseudopods, radial streaming, blue-gray veil, atypical
vessel, etc.)High risk - Lesion with a pigment network and subtle newELM features that may suggest
melanoma but often are also seen in atypical nevi.
Diagnosis based on: Unclear NR; evaluations made by expert dermatologists
Number of examiners Not reported
Observer qualifications: - Dermatologist
Experience in practice: - High experience or ‘Expert’
Experience with index test: - High experience /‘Expert’ users 'expert dermatologists'
2.Computer Assisted Diagnosis - Spectroscopy based
MSI-CAD system: SpectroShade (MHT, Verona Italy) (classifier not reported)
System details:
The system provides information including a series of 15 multispectral images into the near infrared
bandwidth. Three spectral areas play a major role in quantification of parameters: 584 nm, 650-750
nm, 750-950 nm.
No derivation aspect (external validation study)
Lesion characteristics assessed: Seven parameters: mean reflectans, MR; variegation, V; area, A;
dark area ratio, DAR; dark island reflectance, DA; dark distribution factor, DDF
Additional predictors included: 
- No further information used
Method of diagnosis: 
- In person diagnosis
- CAD-based diagnosis
Prior/other test data: 
- Clinical examination and/or case notes
- Dermoscopy
CAD output:
- Diagnostic category: 1 no melanoma, 2 doubtful melanoma, 3 suspected melanoma, 4 probable
melanoma
Diagnostic threshold: 
- Threshold not reported
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
#164a Computer assisted diagnosis techniques (dermoscopy and spectroscopy-based) for the diagnosis of skin cancer...
28 / 268
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
Disease positive: 12 MM; Disease negative:
42
TARGET CONDITION (Final diagnoses)
Melanoma (in situ and invasive, or not
reported): 12
'Benign' diagnoses: 42
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results likely to correctly classify the target
condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
No exclusions reported
Time interval to reference test: "Before surgery, all
patients were investigated by clinical and
epiluminescence microscopy (ELM) screenings"
Time interval between index test(s): As above
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Barzegari 2005
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Not reported
Period of data collection NR
Country Iran
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Pigmented skin lesions with a clinical
diagnosis of melanocytic lesion <=15mm diameter referred
to dermatology clinic for diagnostic evaluation or cosmetic
reasons
Setting: Secondary (general dermatology)
Prior testing: 
Clinical suspicion of malignancy without dermatoscopic
suspicion
- Patient request for evaluation/excision
Setting for prior testing: Not reported
Exclusion criteria: >15mm
Sample size (patients): No. included: 91
Sample size (lesions): No. included: 122
Participant characteristics: 
Age (yrs): 
- Mean: 32.3/ Range: 6-94
Gender: - Male: 30; 33%
Lesion characteristics NR
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Was an adequate spectrum of cases used to train the algorithm?
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Computer Assisted Diagnosis - Dermoscopy based
Derm-CAD: microDERM (DANAOS software, ANN classifier)
System details:
The system consists of a special camera, which had ability to take images at ×15, ×20, ×30, and ×50
magnifications and contains a 752 × 582 pixel chargecoupled device. The image analysis software
was Visiomed AG (Ver. 3.50) based on an ANN that was trained using images collected in a Europe-
wide multicenter study (DANAOS).
No derivation aspect (external validation study)
Lesion characteristics assessed: 
- Lesion features analysed not described
Additional predictors included: 
- No further information used
Method of diagnosis: 
- In person diagnosis
– CAD-based diagnosis
Prior/other test data: 
- Clinical examination and/or case notes
CAD Output: 
The software produces a score per lesion ranging from 0 to 10.
Diagnostic threshold: 
- 2x2 data for more than one diagnostic threshold
- Threshold determined based on ROC analysis; threshold chosen on basis of similarity to other
microDERM studies: 7.34
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
Disease positive: 6; Disease negative: 116
Target condition (Final diagnoses) 
Melanoma (invasive): 3; Melanoma (in situ):
3
Sebhorrheic keratosis: 2; Benign naevus:
104; Dysplastic naevus 7 DF 1 AK
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results likely to correctly classify the target
condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
1. Excluded participants: None;
3. Time interval between index test(s):
Consecutive
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Bauer 2000
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Not reported. Appears
retrospective? But refers to a "campaign for the
early diagnosis of cutaneous melanoma (CM) by
three dermatologists according to the ABCD
system and using ELM evaluation (Stanganelli
1995)
Period of data collection January 1996 to February
1997
Country Italy
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Pigmented skin lesions examined
during a campaign for the early diagnosis of cutaneous
melanoma (CM)
Setting: Secondary (general dermatology) From
authors' institution
Prior testing: Not reported "campaign for the early
diagnosis of cutaneous melanoma (CM)"
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): No. included: 311
Sample size (lesions): No. included: 315
Participant characteristics: NR
Lesion characteristics NR
Thickness/depth: 14 <0.75 mm, 10 0.75 to 1.5 mm, and
6 >1.5 mm (n=42 melanoma)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Was an adequate spectrum of cases used to train the algorithm?
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
1. Dermoscopy
No algorithm possibly Pattern analysis
Method of diagnosis: - In person diagnosis
Prior test data: Clinical examination and/or case notes
Diagnostic threshold: 
- Qualitative - Presence of malignancy; threshold not detailed but ELM parameters included irregular
and multi component pigmentary network pattern, peripheral dark network patches, sharp network
margin, pseudopods, radial streaming, blue-grey areas, pigment dots (blotches, black dots, brown
globules), black dots at periphery, whitish veil, depigmentation and hypopigmented areas, erythema,
telangiectasia, comedo-like openings, milia-like cysts, red-blue areas. (ABCD appears to related to
naked eye exam)
Diagnosis based on: Consensus (3 observers) "the evaluation was uniform as the diagnosis was made
by consensus amongst the dermatologists (Stanganelli 2005).When they disagreed a fourth
dermatologist, an expert in the diagnosis of PSLs, was consulted."
Number of examiners 3
Observer qualifications: - Dermatologist
Experience in practice: Not described
Experience with index test: Not described
Any other detail The dermatologists had all been trained in the recognition of PSLs during a training
course on the clinical diagnosis of naevi and melanomas
2. Computer Assisted Diagnosis - Dermoscopy based
Derm-CAD system: DB–MIPS (Biomips engineering, Italy) (ANN classifier)
System details: DBDermoMIPS (Dell'Eva-Burroni), which consists of a stereomicroscope
(magnification ranging from 36 to340), a high resolution 3CCD RGB video cameraand a 486/33 MHz
personal computer equippedwith a 300 Mb hard disk and 16 Mb of RAM. Thedigital images of the
lesions, shown on a secondRGB video monitor, are framed at 768 3 576 truecolour pixels and saved
onto a 230 Mb magnetooptic removable disk.
derivation aspect (study type)
Lesion characteristics assessed: 
- Once the borders of the lesion have been automatically detected, the system evaluates 38 variables
(grouped into geometries, colours and Burroni's islands of colours). Suspect areas of the lesion are
highlighted by means of a proper algorithm called `Burroni's islands filter' based on a local histogram
equalization to produce a new enhanced image in which the darker areas have been enhanced and
the shades in the green-blue dominant areas (when present) are more evident.
Additional predictors included: 
- No further information used
Method of diagnosis: 
- Dermoscopic images
- CAD-aided diagnosis (test operator not reported)
Prior/other test data: 
- No further information used
CAD output:
- Diagnosis suggested (e.g. melanoma, benign melanocytic nevus)
Diagnostic threshold: 
- Threshold not reported
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Low risk
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B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Unclear
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Disease positive: 42; Disease negative: 273
TARGET CONDITION (Final diagnoses)
Melanoma (invasive): 30; Melanoma (in situ): 12
Severe dysplasia: 25 'atypical' dysplastic; 212
Benign naevus; 36 nonmelanocytic (SK, thrombosed
angioma)
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Unclear
Were the reference standard results likely to correctly classify the
target condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Excluded participants: none reported
After dermoscopy and CAD, all lesions
excised and examined histologically
Time interval between index test(s):
consecutive
Time interval to reference standard: not
reported
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Binder 1994
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection not reported
Country Austria
Test set derived From a sample of 200 PSL, two
databases were randomly created for learning
and testing purposes. The database was also
provided with the histological diagnosis.
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Images of pigmented skin lesions
randomly selected from a pigmented skin lesion
image database.
Setting: Secondary (general dermatology)
Prior testing: - Selected for excision (no further
detail)
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): NR
Sample size (lesions): 200 included (100 test set)
Participant characteristics: 
Lesion characteristics: NR
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Was an adequate spectrum of cases used to train the algorithm? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
1.Dermoscopy
(Modified) pattern analysis
Method of diagnosis: - Dermoscopic images
Prior test data: No further information used
Diagnostic threshold: - Qualitative -
Diagnosis based on: Consensus (2 observers)
Number of examiners 3
Observer qualifications: - Dermatologist
Experience in practice: - High experience or ‘Expert’
Experience with index test: - High experience /‘Expert’ users
Any other detail The images were obtained by photographing the PSL on 24x36 mm colour slide film,
with oil immersion, using a Wild binocular stereomicroscope M 650 (Wild Heerbrugg AG, Switzerland)
at a final magnification of x16 using flashlight illumination.
2. Computer Assisted Diagnosis - Dermoscopy based
Derm-CAD system: name not reported (ANN classifier)
System details:
Computer analysis of stored images captured using digital stereomicroscope
Derivation study (internal validation)
Approach to feature selection An input layer of nodes represented external data (ELM characteristics),
an output layer represented the class identity (diagnoses). The network processed data by accepting
input patterns (the value 0 for "ELM criterion not present") and the value 1 for "ELM criterion present"
into the input layer. During the learning process each input pattern (ELM pattern) had a known output
pattern (histological diagnosis as the gold standard of truth) the network was expected to produce.
Lesion characteristics assessed: 
– Features analysed as present or absent (pattern analysis): Pigment network, brown globules, radial
streaming, pseudopods, black dots, margin, pigmentation, depigmentation
Additional predictors included: 
- Unclear
Method of diagnosis: 
- dermoscopic images
- CAD-based diagnosis
Prior/other test data: 
- NR
CAD output:
- NR
Diagnostic threshold: 
- Threshold not reported
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development? Yes
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
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Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
Disease positive: 40; Disease negative: 60
TARGET CONDITION (Final diagnoses)
Melanoma (in situ and invasive, or not
reported): 40
Benign naevus: 60 (30 CN, 30 DN)
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Were the reference standard results likely to correctly classify the target
condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
Time interval between index test(s): not
reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Binder 1998
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: 
- Case series
Data collection: 
- Retrospective image selection / Prospective
interpretation
Period of data collection: NR
Country: Austria
Test set derived: Computer generated random
numbers split data into learning and testing sets;
relative proportion of cases in each set was
"about 80% and 20%, respectively".
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Pigmented skin lesions with available
oil immersion dermoscopic images
Setting: 
- Secondary (general dermatology)
Prior testing: 
- Selected for excision (no further detail)
Setting for prior testing: 
- Unspecified
Exclusion criteria: Study exclusion criteria:
None reported
Sample size (patients): NR
Sample size (lesions): 120 (29 test set)
- No. included: 120
Participant characteristics: NR
Thickness/depth: 
- Other: median 0.72mm (range 0.3 to 1.4mm) for 39
melanomas
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Was an adequate spectrum of cases used to train the algorithm?
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Computer Assisted Diagnosis - Dermoscopy based
Derm-CAD system: IBAS 2000 workstation (Zeiss, Oberkochen, Germany) (ANN classifier)
System details:
Digital image analysis workstation attached to Wild binocular stereomicroscope M 650 (Wild
Heerbrugg AG, Switzerland). The images were obtained by photographing the PSLs on 24 X 36 mm
colour slide film using a Wild binocular stereomicroscope M 650 (Wild Heerbrugg AG, Switzerland) at
a final magnification of 16X or 25 X using flashlight illumination.
Derivation study (internal validation)
Approach to feature selection: A three-layer, feed-forward neural-network with 16 input nodes and
three hidden nodes was trained with a back propagation algorithm. Each morphological input feature
was assigned a numerical value that was scaled so that each input ranged from 0 to 1. The network
was trained to yield a value from 0 to 1 in the output nodes. The node yielding the greatest numerical
output was then used as the classification result (the winning node).
- artificial neural networks Two different ANNs were trained: the first classified between CN and DN as
benign lesions versus MM as a malignant lesion in a dichotomized model, whereas the second
classified between the three entities of PSL examined, i.e. CN versus DN versus MM. Data for only the
first ANN have been extracted
Lesion characteristics assessed: 
– Analysis of 16 morphometric parameters from the lesion and the border image: lesion area and
perimeter: minimum polar distance, maximum polar distance, aspect ratio, circularity shape factor,
variances of grey, number different colours, range different colours. Border features and area:
maximum and minimum border width, ratio of border area to lesion area, ratio of border perimeter to
lesion perimeter.
Additional predictors included: 
- No further information used
Method of diagnosis: 
- dermoscopic images
- CAD-based diagnosis
Prior/other test data: 
- No further information used
CAD output:
- Dichotomous decision: MM vs. Benign (CN or DN).
Diagnostic threshold: 
- The network was trained to yield a value from 0 to 1 in the output nodes. The node yielding the
greatest numerical output was then used as the classification result.
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development? Unclear
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
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B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard 
- Histological diagnosis alone
Histology (not further described) 
- No. patients/lesions: 29/120 lesions included in test
set
- Disease positive: 10
- Disease negative: 19
TARGET CONDITION (Final diagnoses)
- Melanoma (in situ and invasive, or not reported): 39
in whole dataset; 5 in situ10 MM in test test; number
in situ not reported
- Other: common naevi and dysplastic naevi: 19
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Yes
Were the reference standard results likely to correctly classify the
target condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Exclusion of lesions from analysis: 6 lesions
excluded due to incorrect segmentation results
Time interval to reference test: NR; "after
photography"
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? High risk
Notes
Notes  
Blum 2004b
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection 11 Nov 1998 - 2
Mar 2000
Country Germany
Test set derived For validation of a new
CAD procedure the complete collection (837
melanocytic lesions) was divided into two
equal random subgroups n1 (training set)
and n2(test set).
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Melanocytic skin lesions imaged
prospectively at the Pigmented Lesion Clinic of the
Department of Dermatology, University of Tuebingen,
Germany.
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: Not reported
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: images from mucous membrane
areas were excluded
Sample size (patients): NR
Sample size (lesions): No. eligible: 837/ No. included:
837 (test set 418)
Participant characteristics: NR
Lesion characteristics 
Thickness/depth: 
- ≤1mm: Median breslow thickness for all melanomas
0.78mm (range 0.10-3.50)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Was an adequate spectrum of cases used to train the algorithm? Unclear
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
1. Dermoscopy
7FFM
7 point checklist
ABCD
Menzies criteria
Method of diagnosis: - Dermoscopic images.
Prior test data: No further information used
Diagnostic threshold: Not reported
Diagnosis based on: - Single observer
Number of examiners 1
Observer qualifications: - Dermatologist
Experience in practice: Not described
Experience with index test: Not described
Any other detail The colour video camera MediCam 400 with Y ⁄ C 1signal exit had a 1/4-inch charged-
couple device shooting element with 470 000 pixels (picture elements). The focal area for the
dermoscopic pictures was defined from 3.5 cm diameter up to infinity. The focal area for the
dermoscopic pictures could be positioned continuously by zoom from 3.2 mm to approx. 1.0 cm,
corresponding to a x20–70 magnification on a 17-inch monitor. Lesions ≤12 mm diameter could be
imaged completely. The glass plate contacting the skin was always moistened with disinfectant spray
According to the established dermoscopic classification rules (ABCD rule, Menzies’ score, seven-point
checklist and seven features for melanoma) the lesions were prospectively classified as benign or
malignant melanocytic lesions by the principal investigator(A.B.).27–30
2.Computer Assisted Diagnosis - Dermoscopy based
Derm-CAD: System name NR (Vision algebra classifiers)
System details:
Computer analysis of stored images captured using digital microscope
Derivation study (internal validation)
The analytical parameters of the digital dermoscopy analysis were reduced by means of a factor
analysis. In a second step, the impact of the different parameters was examined by logistic regression
analysis. The number of parameters included in the multi-variate analysis was limited in relation to the
number of malignant melanomas: in the sample of large, partially imaged lesions it was restricted to
six parameters and for small, completely imaged lesions it was limited to three parameters.
Lesion characteristics assessed: 
- Analysis of 64 analytical parameters including: a large number of morphological parameters such as
margin, geometric parameters (surface area, extent, largest diameter and largest orthogonal
diameter), invariant moments, symmetry, colours (red, green, blue and grey value), texture (energy,
entropy, correlation, inverse difference moment and inertia), number of regions, focus and difference
of the lesion and its convex cover.
Additional predictors included: 
- Unclear
Method of diagnosis: 
- Dermoscopic images
- CAD-based diagnosis
Prior/other test data: 
- Unclear
CAD output:
- NR
Diagnostic threshold: 
- Threshold not reported
Computer-assisted diagnosis
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development? Unclear
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis plus
follow up
Histology Disease positive: 84; Disease negative:
185
Clinical FU plus histology of suspicious lesions -
unexcised lesions were analysed independently
by two of the investigators 2-3 times in 6 months
on the basis of dermoscopic criteria. These
lesions were classified as benign without any
suspicion of malignancy by dermoscopic criteria,
and follow-up records for at least 6 months
showed no evidence of malignancy. Disease
negative: 568
TARGET CONDITION (Final diagnoses)
Melanoma (invasive): 71; Melanoma (in situ): 9;
Lentigo maligna 4
'Benign' diagnoses: 766
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results likely to correctly classify the target
condition (disease negative)? No
Could the reference standard, its conduct, or its interpretation have
introduced bias? High risk
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B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? No
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? High
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? High risk
Notes
Notes  
Boldrick 2007
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: 
- Case series
Data collection: 
- Prospective
- Retrospective CAD
Period of data collection January 2002 and
August 2005
Country USA
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Study inclusion criteria Patients
>=18years of age
Setting: 
- Specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: 
- Clinical and/or dermatoscopic suspicion
Setting for prior testing: 
- Unspecified
Exclusion criteria: Study exclusion criteria:
None reported
Sample size (patients): 
- No. eligible: 83
- No. included: 12
Sample size (lesions): 
- No. eligible: 1000
- No. included: 18
Participant characteristics: Participant characteristics
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Was an adequate spectrum of cases used to train the algorithm? Unclear
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Computer Assisted Diagnosis - Dermoscopy based
CAD-Derm-Other MicroDerm/DANAOS
Derm-CAD system: MicroDERM (DANAOS software, ANN classifier)
System details:
Dermoscopy unit with internal camera containing DANAOS analysis system. T The hand unit
contained a miniature charged coupled device (3CCD) with a camera with a resolution of 768 3 576
(440,000) pixels. Digital images were stored and compresed using JPEG format.
No derivation aspect (external validation study)
Lesion characteristics assessed: 
– Dermoscopic features of PSLs based on the ABCD rule
Additional predictors included: 
- None reported
Method of diagnosis: 
- Dermoscopic images
- CAD-based diagnosis
Prior/other test data: 
- No further information used
CAD output:
- DANAOS score indicating risk of malignancy
Diagnostic threshold: 
- DANAOS score
– 2x2 data for more than one diagnostic threshold
- Per patient data reported. Threshold selected on basis of similarity to other microDERM studies:
DANAOS score of ≥7
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
#164a Computer assisted diagnosis techniques (dermoscopy and spectroscopy-based) for the diagnosis of skin cancer...
46 / 268
A. Risk of Bias
Target condition and reference standard(s)
Reference standard 
- Histological diagnosis alone
Histology (biopsy) 
- No. patients/lesions: 18PSL
- Disease positive: 6 MM
- Disease negative: 12
TARGET CONDITION (Final diagnoses)
- Melanoma (invasive): 3
- Melanoma (in situ): 2
- Lentigo maligna 1
- Severe dysplasia: 1
- Mild/moderate dysplasia: 6
- Benign naevus: 5
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Unclear
Were the reference standard results likely to correctly classify the
target condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Exclusion of lesions from analysis:
Review team - only 18 lesions had an
adequate reference standard; 982
clinically dx benign lesions without a
reference standard were not extracted.
interval between index test and reference
standard: NR
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Bono 1996
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Unclear
Data collection: Not reported
Period of data collection between March
1993 and Oct 1994
Country Italy
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Unclear
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Pigmented skin lesions at the Instituto
Nazionale Tumori of Milan.
Setting: Specialist unit (skin cancer/pigmented lesions
clinic) Instituto Nazionale Tumori of Milan
Prior testing: Not reported
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): No. eligible: 45
Sample size (lesions): No. eligible: 54/ No. included: 43
Participant characteristics: NR
Lesion characteristics: Site - Face/Ears: 3 (6%)/ Trunk:
39 (72%)/ Limbs: 12(22%); 10 MM ≤1mm depth; median
size: 10mm (4 to 40mm)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Was an adequate spectrum of cases used to train the algorithm?
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Computer Assisted Diagnosis - Spectroscopy based
MSI-CAD system: Telespectrophotometric System (Linear discriminant classifier)
System details:
Digital camera coupled with an illumination system with interference filters and computer for storage
and analysis of multispectral images
No derivation aspect (external validation study)
Described in prior study Marchesini 1995
Lesion characteristics assessed: 
– From each spectral image, three parameters, i.e. mean reflectance, variegation index and lesion
area; were derived at the corresponding wavelength
Additional predictors included: 
- None reported
Method of diagnosis: 
- Spectroscopic images
- CAD-based diagnosis
Prior/other test data: 
- Unclear
CAD output:
- NR
Diagnostic threshold: 
- Threshold not reported
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Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Unclear
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard 
Histological diagnosis - Disease positive: 18;
Disease negative: 25
Expert opinion - Disease negative: 11
TARGET CONDITION (Final diagnoses)
Melanoma (in situ and invasive, or not reported):
18
Mild/moderate dysplasia: 8 dysplactic nevi
Benign naevus: 17 common melanocytic nevi
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results likely to correctly classify the target
condition (disease negative)? No
Could the reference standard, its conduct, or its interpretation have
introduced bias? High risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? No
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? High
Flow and Timing
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A. Risk of Bias
Flow and timing
Excluded participants: only 43 lesions had
complete clinical and histological
information. 11 lesions not surgically
removed had only clinical diagnosis (benign)
and were not included in the final accuracy
analysis
Time interval to reference test: not reported
Time interval between index test(s): not
reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? No
Could the patient flow have introduced bias? High risk
Notes
Notes  
Bono 2002
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection June 1998-March
2000
Country Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Cutaneous pigmented lesions with
clinical and/or dermatoscopic features that suggetsed a
more or less important suspcion for CM
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: 
- Location/site of lesion Awkwardly situated lesions eg
interdigital space, ears, nose or eyelids. Lesions on
scalp excluded due to hair interference with reflectance
- lesion size obvious large, thick melanomas
Sample size (patients): No. included: 298
Sample size (lesions): No. included: 313
Participant characteristics: Mean age: 40y (10-86y);
Male: 122; 41%
Lesion characteristics: Lesion site: Head/Neck: 3%;
Trunk: 61%; Limbs: 36%; Thickness ≤1mm: 70%
(46/66); for 55 invasive MM: median thickness 0.64mm,
range 0.17-3.24mm. Median diameter: 11mm (3-31mm)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Was an adequate spectrum of cases used to train the algorithm? Yes
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
1.Visual inspection (VI) No algorithm (Training in the unit is based on ABCD but subjective experience
of the clinician used for diagnosis)
Method of diagnosis: - In person diagnosis
Prior test data: N/A in person diagnosis
Diagnostic threshold: Clinical diagnostic criteria based on subjective experience; emphasise lesion
colour over dimensions. Diagnosis of suspect CM made when the level of suspicion was 'roughly 50%
or more'.ABCD (asymmetry, border, colour, dimension) criteria have been the basis of training at the
unit, but is not implemented in diagnosis; preferred emphasis on colour rather than dimensional
character
Diagnosis based on: - Single observer (n=1)
Observer qualifications: Surgical oncologists
Experience in practice: - High experience or ‘Expert’; over 5 years
2.Dermoscopy No algorithm
Method of diagnosis: - In person diagnosis
Prior test data: Clinical examination and/or case notes
Diagnostic threshold: Presence of at least one of the following criterion: radial streaming, pseudopods,
grey-blue veil, regression and erythema, whitish veil, black dots at the periphery (if network present),
thick irregular network or milky-red background with red dots.
Test observers as described for Visual Inspection (above)
Experience with index test: - Experience (years) over 5 years
Any other detail Dermatoscopy performed by a hand-held monocular microscope equipped with an
achomatic lens permitting a magnification of x10 (Heine Delta 10).
3.Computer Assisted Diagnosis - Spectroscopy based
CAD-Spect-Other Described as; referenced to
MSI-CAD system: 'telespectrophotometry' (Linear discriminant classifier)
System details:
The TS consists mainly of a charge-coupled device camera that is provided with a set of 17
interference filters and a personal computer to allow imaging of cutaneous pigmented lesions at
selected wavelengths from 420 to 1040nm. The acquired 17 spectral images are stored in the
personal computer for offline processing. Intensity levels as well as the dimensions of the image
picture elements (pixels) were calibrated according to aset of four reflectance standards and a
geometric reference frame, respectively. Details on the system's feautres have been reported
elsewhere (Marchini 1995).
No derivation aspect (external validation study)
Derivation described in Marchesini 1995
Lesion characteristics assessed: 
– For each spectral image, five parameters (lesion descriptors) based on ABCD and related to colour
and shape of the imaged lesion were evaluated: mean reflectance, variegation index, roundness,
border irregularity.
Additional predictors included: 
- No further information used
Method of diagnosis: 
- In person diagnosis
- CAD-based diagnosis
Prior/other test data: 
- None
CAD output:
- NR
Diagnostic threshold: 
- Threshold not reported
Computer-assisted diagnosis
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
TARGET CONDITION (Final diagnoses)
Melanoma (invasive): 55; Melanoma (in situ):
11; BCC: 6
'Benign' diagnoses: 241;151 compound
naevus, 24 junctional naevus, 12 dermal
naevus, 12 lentigo simplex, 10 dysplastic
naevus, 8 spindle-cell naevus, 8 sebhorrheic
keratosis, 5 blue naevus, 3 spitz naevus, 8
other.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results likely to correctly classify the target
condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded lesions from analysis: none
reported
Intervals between tests: Appears
consecutive but not fully clear
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Burroni 2004
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: 
- Case control
Data collection: 
- Retrospective image selection / Prospective
interpretation
Period of data collection 1999-2003
Country Italy
Test set derived For the 3 linear classifiers: lesions
from each centre (Rome and Siena) were randomly
allocated to training and test sets. Linear classifier 1
was constructed from the Rome tarining set and
tested on all lesions from Siena; Linear classifier 2
was constructed on the Siena training set and tested
on all lesions from Rome; Linear classifier 3 was
constructed on training sets from both centres and
tested on test sets from both centers. For the K-
nearest-neighbour (K-nn) classifiers, a separate
trianing set of lesions were selected from the image
databases of several institutions that iused the same
ELM instrumentation, i.e., IDI-Rome; Siena University
Dermatology Clinic; IDI-Capranica; and the Italian
Cancer League Clinics of Grosseto, Livorno, Arezzo,
Trento, and Siena. It was then tested on all lesions
from both centers as described above.
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
#164a Computer assisted diagnosis techniques (dermoscopy and spectroscopy-based) for the diagnosis of skin cancer...
55 / 268
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Study inclusion criteria All melanomas
undergoing ELM and excision at the two centers
(1999-2003) and random sample of surgically removed
benign melanocytic lesions, inlcuding 85 histologically
atypical nevi.
Setting: 
- Secondary (general dermatology) Dept Dermatology,
University of Siena
- Specialist unit (skin cancer/pigmented lesions clinic)
Instituto Dermatopatico dell'Immacolata (IDI), a research
hospital for skin diseases in Rome
Prior testing: 
- Selected for excision (no further detail)
Setting for prior testing: 
- Secondary (general dermatology) Siena
- Specialist unit (skin cancer/pigmented lesions clinic)
Rome
Exclusion criteria: Study exclusion criteria:
None reported
Sample size (patients): NR
Sample size (lesions): 
- No. included: 821 (475 from Siena; 346 from Rome)
Participant characteristics: Participant characteristics
Thickness/depth: 
- Other: 178 (48% of 372 MM) <=0.75mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Was an adequate spectrum of cases used to train the algorithm? Unclear
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
3. Computer Assisted Diagnosis - Dermoscopy based
Derm-CAD system: DB-Mips system (KNN and Linear discrimination classifiers)
Classifier selected at random for analysis in review: KNN
System details:
dermoscopy unit, internal steromicroscope, internal DB, pattern analysis system
Derivation study (internal validation)
Linear classifier 3 was constructed on training sets from both centres and tested on test sets from both
centers. For the K-nearest-neighbour (K-nn) classifiers, a separate trianing set of lesions were
selected from the image databases of several institutions that iused the same ELM instrumentation,
i.e., IDI-Rome; Siena University Dermatology Clinic; IDI-Capranica; and the Italian Cancer League
Clinics of Grosseto, Livorno, Arezzo, Trento, and Siena. It was then tested on all lesions from both
centers as described above.
Discriminant analysis used to identify features for which there was a significant (t test) difference
between melanomas and non-melanomas and, within these diagnostic classes, no significant
difference between centers. Details provided. Selected variables were: geometric variables - area*,
variance of contour symmetry*, fractality of borders*color variables - mean skin-lesion gradient*,
variance of border gradient*, and border interruptions*. texture variables - mean contrast and entropy*
of lesionislands of color variables - dark area*, blue-gray area*, transition region imbalance*
Lesion characteristics assessed: 
38 parameters belonged to four categories (referenced to Soyer 2000): geometries; colors; textures;
and islands of color (i.e., color clusters inside the lesion). These were all described in detail.
Additional predictors included: 
- No further information used
Method of diagnosis: 
- In person diagnosis
- CAD-based diagnosis
Prior/other test data: 
- None reported
CAD output:
- Diagnosis suggested (e.g. melanoma, benign melanocytic nevus)
Diagnostic threshold: 
- Threshold not reported
The method of receiver operating characteristic curves was used to identify the threshold value for a
fixed sensitivity of 95%
The prevalence of melanomas among the first 100 closest neighbors was determined, and the lesion
was assigned to the melanoma group if the prevalence was higher than a threshold value T 100 . The
method of receiver operating characteristic curves was used to identify the T 100 value necessary for
a sensitivity of 98%"
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development? Yes
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
#164a Computer assisted diagnosis techniques (dermoscopy and spectroscopy-based) for the diagnosis of skin cancer...
57 / 268
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard 
- Histological diagnosis alone
Histology (excision) 
- No. patient/lesions: 821 (475 Siena; 346 Rome)
- Disease positive: 372 (217 Siena; 155 Rome)
- Disease negative: 449 (258 Siena; 191 Rome)
TARGET CONDITION (Final diagnoses)
- Melanoma (invasive): 302
- Melanoma (in situ): 70 (higher % at Siena than in
Rome)
- Severe dysplasia: 85 (architectural disorder and
melanocytic atypia)
- Benign naevus: 364
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Yes
Were the reference standard results likely to correctly classify the target
condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: none
Intervals between tests: not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Cascinelli 1992
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: 
- Case series
Data collection: 
- Prospective
- Not reported
Period of data collection Mar-Dec 1991
Country Italy
Test set derived: Derivation of tets set not
described.Training set: 169 lesions; 124 benign and 45
malignant lesions, Test series: 44 images, 33 benign
lesions and 12 malignant, of which 10 were melanoma.
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Study inclusion criteria Training
set: Pigmented cutaneous lesions were referred to
Institute for a second opinionTest set: not described
Setting: 
- Secondary (general dermatology) Surgical
Oncology
Prior testing: 
- Describe if other Training set: Referred for second
opinion; basis not reportedTest set: not described
Setting for prior testing: 
- Unspecified
Exclusion criteria: Study exclusion criteria:
None reported
Sample size (patients): 
- No. included: Training set: 165, Test set: not
described
Sample size (lesions): 
- No. included: Training set: 169, Test set: 44
Participant characteristics: Participant characteristics
Age (yrs): 
- Other Training set: 17 aged <20; 59 aged 21-40;
66 aged 41-60; 23 aged >61Test set: not described
Gender: 
- Male: Training set: 70; 42%Test set: not described
Lesion site: 
- Head/Neck: Training set: 7.7%
- Trunk: Training set: 45.5%
- Limbs: Training set: 46.7%
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Was an adequate spectrum of cases used to train the algorithm? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
Computer Assisted Diagnosis - Dermoscopy based
Derm-CAD system: Skin View (classifier NR)
System details:
Computerised image analysis system, digital television, videocamera. Connection with the computer is
through a digitizing board able to process colour images
Derivation study (internal validation)
Lesion characteristics assessed: 
– Features of ABCD system plus clinical data (anatomic site, months of growth, size, shape, colour,
ulceration or regression)
– 8 binary indicators generated: shape, clinical data, size, colour, darkness, saturation, border, and
texture (all described).
Additional predictors included: 
- Predictors included clinical data, which takes into account anamnestic data provided by the
clinician (change in size, change in colour) and an objective evaluation made by the clinician
(presence of regression, presence of ulceration);
Method of diagnosis: 
- Dermoscopic images
- CAD-based diagnosis
Prior/other test data: 
- none reported
CAD output:
- CAD–based diagnosis
Diagnostic threshold: 
- Malignant lesion -≥2 positive indicators
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population? Unclear
Was model overfitting accounted for during model development? Unclear
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard 
- Histological diagnosis alone
Histology (excision) 
- No. patient/lesions: Test set only: 44
- Disease positive: 12
- Disease negative: 32
TARGET CONDITION (Final diagnoses)
- Melanoma (in situ and invasive, or not reported):
10
- BCC: 2
- 'Benign' diagnoses: 32
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Yes
Were the reference standard results likely to correctly classify the target
condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: NR
Time interval to reference test: not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Unclear
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Cristofolini 1997
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection Nov 1992 to Sept
1993
Country Italy
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients with small and flat
common and atypical pigmented skin lesions
recruited during a health campaign for the early
diagnosis of CM underwent clinical diagnosis,
computerized analysis by SVS and subsequent skin
biopsy.
Setting: Secondary (general dermatology)
Prior testing: No prior testing
Setting for prior testing: Secondary (general
dermatology)
Exclusion criteria: None reported
Sample size (patients): 176 included
Sample size (lesions): 176 included
Participant characteristics: NR
Lesion characteristics: NR
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Was an adequate spectrum of cases used to train the algorithm?
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Computer Assisted Diagnosis - Dermoscopy based
Derm-CAD system: Skin View (classifier NR)
System details:
Computerised image analysis system, digital television, videocamera. Connection with the computer is
through a digitizing board able to process colour images
No derivation aspect (external validation)
Lesion characteristics assessed: 
– Features of ABCD system plus clinical data (anatomic site, months of growth, size, shape, colour,
ulceration or regression)
: 1 shape (asymmetry); 2 clinical data (changes through time, regression, ulceration); 3 size (mm); 4
colour (distribution of hue); 5 darkness (percent of black mixed with the hue); 6 saturation (percent of
white mixed with the hue); 7 border (sharpness of transition between lesion and healthy skin; 8 texture.
Additional predictors included: 
- Clinical data
Method of diagnosis: 
- dermoscopy images
- CAD-based diagnosis
Prior/other test data: 
- none reported
CAD output:
- CAD–based diagnosis
Diagnostic threshold: 
- ≥2 of 8 binary (on/off) indicators indicates malignancy
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Low risk
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B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Visual inspection
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
- Disease positive: 35
- Disease negative: 141
TARGET CONDITION (Final diagnoses)
Melanoma (in situ and invasive, or not
reported): 35
Other: 141 melanocytic nevi
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results likely to correctly classify the target
condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: not reported
Time interval to reference test: 'subsequent
skin biopsy'
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
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Notes
Notes  
Dreiseitl 2009
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection Test set: Feb-Nov
2004
Country Austria
Test set derived Study focuses on test set
but gives detail of separate study in which
classifier was trained
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients presenting at pigmented skin
lesion clinic at Dept Dermatology which serves as a
secondary and tertiary referral centre
Setting: Specialist unit (skin cancer/pigmented lesions
clinic) The pigmented skin lesion unit of the Department
of Dermatology at the Medical University of Vienna
serves as a secondary and tertiary referral center.
Prior testing: Not reported
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: None reported
Sample size (patients): No. eligible: 511; No. included:
458 with complete information
Sample size (lesions): No. eligible: 3827; No. included:
3021
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Was an adequate spectrum of cases used to train the algorithm? Yes
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Dermoscopy No algorithm
Method of diagnosis: In person diagnosis
Prior test data: Clinical examination and/or case notes
Diagnostic threshold: Not reported
Diagnosis based on: Single observer (n=1)
Observer qualifications: Expert dermatologist
Experience in practice: High experience or ‘Expert’
Experience with index test: High experience /‘Expert’ users
3. Computer Assisted Diagnosis - Dermoscopy based
Derm-CAD system: Image J (NIH, Bethesda, USA) (ANN classifier)
System details:
image analysis coupled with dermoscope MoleMax II
No derivation aspect (external validation)
Described in prior study Hable 2004 (PhD thesis)
Lesion characteristics assessed: 
29 Features analysed from 38 extracted features describing shape, form and colour. Approach to
feature selection Prior study: A stepwise feature selection method used to identify 29 features relevant
for the classification process.
Additional predictors included: 
- No further information used
Method of diagnosis: 
- In person diagnosis
- CAD-based diagnosis
– CAD–aided diagnosis
Test observers: 
- Single observer
Number of examiners 6
Observer qualifications: 
- Other (describe) The educational training of the 6 participating physicians ranged from no training in
dermatology to 4 years training in dermatology.
Experience in practice: 
- Mixed experience (low and high experience combined) educational training of the 6 participating
physicians ranged from no training in dermatology to 4 years training in dermatology.
Experience with index test: 
- Mixed experience (low and high experience combined) No physician was specifically trained in
dermatoscopy.
Prior/other test data: 
- Clinical examination and/or case notes
CAD output:
- 2 outputs: 1) Visual rendering of analysis showing coloured areas. 2) Excision vs. no excision
decision (system considers the green zone of the scale as benign (0 to 0.1), the yellow zone
suspicious (0.1 to 0.4), and the red zone malignant (0.4 to 1)).
Diagnostic threshold: 
- scale 0–1: 0–0.1 = benign, 0.1–4 = suspicious, >0.4 = malignant
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? High risk
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B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? No
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis plus
follow up
Histology (excision); No. patient/lesions: Not
reported
Clinical FU plus histology of suspicious lesions
Length of FU: 6 months; No. patients: Not reported
TARGET CONDITION (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 27
patients; 31 lesions
'Benign' diagnoses: 431 patients; 2990 lesions
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Yes
Were the reference standard results likely to correctly classify the target
condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Excluded participants: 806 lesions (53
patients) with inadequate follow-up
Intervals between tests: not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? No
Could the patient flow have introduced bias? High risk
Notes
Notes  
Ferris 2015
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Unclear Some dermoscopic images
were collected prospectively and some were
obtained from collection of existing images;
selection process not described.
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection not reported
Country USA
Test set derived Some dermoscopic images used
to train the classifier were obtained from publicly
available or purchased image libraries, these
were not included in the reader study or used to
test the performance of the classifier. The image
set was randomly divided into 2 by diagnosis, with
half used for training and half used for testing,
with the exception that all high-grade dysplastic
nevi were exclusively assigned to the training set
to increase the representation of dermoscopic
features that could be present in melanoma.
Results are presented only for the test set.
Was a consecutive or random sample of patients enrolled? No
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Dermoscopic images of skin
lesions excised on the basis of clinical suspicion of
malignancy, with available histologic diagnoses
Setting: Secondary (general dermatology)
Prior testing: Clinical and/or dermatoscopic
suspicion; Selected for excision (no further detail)
Setting for prior testing: Secondary (general
dermatology)
Exclusion criteria: high-grade dysplastic nevi were
not included in the test set
Sample size (patients): No. eligible: not reported;
No. included: not reported
Sample size (lesions): No. eligible: 473 (includes
273 randomised to training set and 27 non-biopsied
lesions); No. included: CAD- Derm- test set 173
lesions; Dermscopy- 65 lesions
Participant characteristics: None reported
Lesion characteristics: Test set: mean lesion
thickness 0.76 mm, median 0.5 mm, range 0.2-2.98
mm); Reader study: mean 0.93 mm, median 0.74
mm, range 0.2 to 2.98 mm.
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Was an adequate spectrum of cases used to train the algorithm? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Computer Assisted Diagnosis - Dermoscopy based
Derm-CAD system: name NR (Digital forest classifier)
System details:
Computer analysis of stored images captured using different dermoscopy/camera combinations
Derivation study (internal validation)
Lesion characteristics assessed: 
–54 features analysed, such as border irregularity, eccentricity, length of major and minor axes, and
colour histogram properties. Variations of some features described in Zortea et al (2014) were
included.
Additional predictors included: 
- unclear
Method of diagnosis: 
- Dermoscopic images
- CAD-based diagnosis
Prior/other test data: 
- Unclear
CAD output:
- Severity score (the fraction of decision trees (n=1000) in which the path ends in ‘‘malignant’’. Lesion
classified as malignant if its image traced a path to a malignant node in at least 40% of the trees)
Diagnostic threshold: 
- 0.4; a lesion was classified as malignant if its image traced a path to a malignant node in at least
40% of the decision trees.
Computer-assisted diagnosis
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development? Unclear
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Details: All lesions were biopsied based on clinical
suspicion of malignancy. All histologic diagnoses were
rendered by at least 1board-certified dermatopathologist
and were used as the reference standard for diagnosis
Disease positive: Derm 25MM; CAD 39MM / Disease
negative: Derm=40; CAD= 134
Target condition (Final diagnoses) 
Melanoma (invasive): Derm = 15; CAD = 25; Melanoma (in
situ): Derm = 10; CAD = 14; BCC: CAD= 11; cSCC:
CAD=3
Mild/moderate dysplasia: CAD = 47; Derm= 16.
Sebhorrheic keratosis: CAD=11; Derm=4. Benign naevus:
CAD=42; Derm= 14.Other: CAD=10 lentigines, 5 blue nevi,
2 Spitz nevi, 2 angiomas, and 1 dermatofibroma; Derm = 2
blue nevi, 4 lentigines
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Were the reference standard results likely to correctly classify
the target condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation
have introduced bias? Unclear risk
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B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
1. Excluded participants: none reported
2. Time interval to reference test: 'Dermoscopic
images of skin lesions were collected before
biopsy'
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Friedman 2008
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection NR; lesions selected in
July 2005
Country US
Test set derived MelaFind data randomly split
into training and test sets however Melafind has
previously been evaluated, the only difference
here being that only small lesions were included.
Would argue that full dataset can reasonably be
included here rather than test set only
Was a consecutive or random sample of patients enrolled? No
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
!nclusion criteria: A database of images of pigmented skin
lesions <=6mm was used to sample images of melanoma
and non melanoma lesions; high-grade dysplastic nevi
were excluded.
Setting: A digital dermoscopic database acquired by
Electro-Optical Sciences Inc for the development and
testing of MelaFind; 26 clinical sites have contributed
Prior testing: Selected for excision (no further detail) All
lesions excised or underwent shave biopsy
Setting for prior testing: Not reported
Exclusion criteria: High-grade dysplastic nevi were
excludedPreviously biopsied, ulcerated, or bleeding lesions
also excluded, as were those on mucosal surfaces and
lesions that contained foreign matter (eg, tattoos).
Sample size (patients): No. included: 94
Sample size (lesions): No. eligible: 1977; No. included: 99
Participant characteristics: None reported
Lesion characteristics 21 invasive MM: median thickness
0.32mm (0.10, 1.40mm). Lesion size: Range: 2mm to
22mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Was an adequate spectrum of cases used to train the
algorithm?
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Dermoscopy No algorithm
Method of diagnosis: Dermoscopic images
Prior test data: Clinical examination and/or case notes sex, age, and lesion location
Diagnostic threshold: Not reported. 2x2 reported for: diagnostic sensitivity and specificity, i.e
melanoma vs not melanoma and biopsy sensitivity and specificity, i.e excise lesion vs not excise. Each
reader had to answer the question: “Is this lesion a melanoma?” and “Would you biopsy/excise this
lesion?” with a reason for biopsy. If readers indicated that they would biopsy the lesion because they
were sure it was melanoma or to rule out melanoma, then the case was considered true positive (TP)
Diagnosis based on: Average; mean and median reported (n=10)
Observer qualifications: 9 dermatologists; 1 nurse practitioner specializing in dermatology
Experience in practice: High experience or ‘Expert’
Experience with index test: High experience /‘Expert’ users
2. Computer Assisted Diagnosis - Spectroscopy based
MSI-CAD system: MelaFind (EO Sciences, USA) ( 6 constrained linear classifiers)
System details:
Multispectral imaging system with integrated image analysis software; device takes images in vivo
External validation study
Derivation described in prior study Gutkowicz-Krusin 1997; Elbaum 2001; Gutkowicz-Krusin 2000.
Lesion characteristics assessed: 
– NR
Additional predictors included: 
- None reported
Method of diagnosis: 
- Spectroscopic images
- CAD-based diagnosis
Prior/other test data: 
- No further information used
CAD output:
- Binary output: excise or follow–up
Diagnostic threshold: 
A lesion is recommended for biopsy to rule out melanoma only if all scores are above the threshold
value.
- Threshold not reported
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
#164a Computer assisted diagnosis techniques (dermoscopy and spectroscopy-based) for the diagnosis of skin cancer...
72 / 268
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Disease positive: 49; Disease negative: 50
Target condition (Final diagnoses)
Melanoma (invasive): 21; Melanoma (in situ): 28;
BCC: 2
Mild/moderate dysplasia: 32 low grade dysplastic;
Sebhorrheic keratosis: 2; 14 other benign
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Were the reference standard results likely to correctly classify the target
condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Interval between tests: not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Garcia Uribe 2012
Patient Selection
#164a Computer assisted diagnosis techniques (dermoscopy and spectroscopy-based) for the diagnosis of skin cancer...
73 / 268
A. Risk of Bias
Patient Sampling
Study design: 
- Case series
Data collection: 
- Prospective
Period of data collection not reported
Country USA
Test set derived Of the 407 pigmented skin
lesions, 271 were used for the training sets of
ANN classiﬁers (Tables 1 and 2) to separate
malignant melanoma from varieties of nevi. The
remaining 136 data sets were used to test the
efﬁcacy of the ANN classiﬁers. The
nonpigmented lesions consisted of BCCs, SCCs,
benign actinic keratoses, and seborrheic
keratoses. Among the 266 nonpigmented lesions,
177 were used to train the ANN classiﬁer and the
remaining 89 were used for testing
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Study inclusion criteria not reported
Setting: 
- Specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: 
- Not reported
Setting for prior testing: 
- Unspecified
Exclusion criteria: Study exclusion criteria:
None reported
Sample size (patients): NR
Sample size (lesions): 136 included
Participant characteristics: 
- Pigmented (%): 407 pigmented lesions (60%)
- Non-pigmented (%): 266 nonpigmented (40%)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Was an adequate spectrum of cases used to train the algorithm? Yes
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Computer Assisted Diagnosis - Spectroscopy based
DRS-CAD system: OIDRS (ANN classifier)
System details:
Light probe coupled to imaging spectrograph, camera, and computer to store images. The system was
built onto a portable cart; it was easily moved to the patient examination rooms. To target both small
and large skin lesions, we constructed an optical fi ber probe using micromachining technology. The
probe consisted of 3 source fibers and 2 linear arrays of 12 collection fibers within an area of 2. The
collection fibers were coupled to an imaging spectrograph that generated an optical spectrum from 455
to 765 nm for the collection channel. A charge-coupled device (CCD) camera collected the spectral
images, which were stored on a com- puter for data analysis. The data collection took less than 5
minutes, and it did not interfere with the standard health care provided to the patients
Derivation study (internal validation)
A physician identified the lesion(s) to be measured before the scheduled biopsy. To average out the
effect of structural anisotropy of the skin tissue, the measurement of each lesion was repeated 4 times
to obtain images from different orientations. To provide self-references, the same measurements were
also repeated on the neighboring healthy skin tissues. The anisotropy is defined as the variation of the
measurements when conducted in different directions. After the measurements were completed, a
biopsy was carried out for each skin lesion and submitted for histopathologic analysis.
Lesion characteristics assessed: 
– NR
Additional predictors included: 
- Unclear
Method of diagnosis: 
- In person diagnosis
- CAD-based diagnosis
Prior/other test data: 
- Unclear
CAD output:
- Diagnostic category (e.g. CN, MM, DN, BCC, cSCC)
Diagnostic threshold: 
- Threshold not reported
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
Was the CAD model evaluated in an independent study population? Unclear
Was model overfitting accounted for during model development? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard 
- Histological diagnosis alone
TARGET CONDITION (Final diagnoses)
- Melanoma (in situ and invasive, or not
reported): 10
- Severe dysplasia: 15
- Mild/moderate dysplasia: 83
- Benign naevus: common nevi 28
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results likely to correctly classify the target
condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: not reported
Time interval to reference test: Biopsy was done
after the CAD-OIDRS measurements were taken
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Unclear
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Gilmore 2010
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection 2003-2008
Country Austria
Test set derived: Not reported. Training set: 65
melanomas and 65 dysplastic naevi, Test set:36
melanomas and 33 dysplastic naevi.
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Polarised dermoscopic images of
atypical melanocytic lesions were obtained from the
Department of Dermatology at the Medical
University of Graz in Austria; describes database as
a "database may be considered a random, but
representative, cohort" but does not describe
method of selection
Setting: Secondary (general dermatology)
Prior testing: Clinical and/or dermatoscopic
suspicion atypical melanocytic lesions.
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): No. included: NR
Sample size (lesions): No. included: 199: Derivation
set n=130 Test set n= 69
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Was an adequate spectrum of cases used to train the algorithm? No
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
Dermoscopy No algorithm; dermoscopic method of diagnosis not reported
Method of diagnosis: Dermoscopic images
Prior test data: No further information used
Diagnostic threshold: Not reported - subjective impression; excise or not
Diagnosis based on: Single observer (n=1)
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’
Experience with index test: High experience /‘Expert’
Any other detail images captured using a DermLite FOTO lens (3Gen LLC; Dana Point, CA, USA)
coupled to a digital camera (Nikon CoolPix4500; Nikon Corporation, Tokyo, Japan) without flash using
the camera’s auto setting
Computer Assisted Diagnosis - Dermoscopy based
Derm-CAD system: name NR (SVM classifier)
System details: Computer analysis of stored images captured using digital microscope
Derivation study (internal validation)
"Feature data from the training set were first normalised to zeromean and unit variance. We then
reduced the dimensionality of this set by taking the first three principal components, corresponding to
the points to the left and including the infection point of the hyperbolic eigenvalue curve." Training set
(p832): "At each step, corresponding to a unique parameter regime, we took 60 random data points
(30 of each class) from our 130 training data points to derive a model, and then we tested that model
on 30 randomly chosen data points from the same data set. To assess the effectiveness of the model
in classification, we performed a tenfold cross-vali- dation. Because we are using only a subset of the
total training set to derive each model Ð this is loosely analo- gous to the subset selection procedure
known as chunking - finding the optimal solution is computationally fast. Each tenfold cross-validation
took approximately 200 s using Mathematica 6.0 on a Macintosh G4 with 4MB of RAM."
Lesion characteristics assessed: 
– 14 features investigated: 1. Asymmetry 1 (mean int.)*2. Asymmetry 2 (mean int.) *3. Asymmetry 3
(variance red) *4. Asymmetry 4 (variance red) *5. Variance red *6. Variance green*7. Variance blue *8.
Mean red *9. Mean green *10. Mean blue*11. Mean intensity *12. Range red intensity*13. Range
green intensity*14. Range blue intensity*
Additional predictors included: 
- No further information used
Method of diagnosis: 
- Dermoscopic images
- CAD-based diagnosis
Prior/other test data: 
- unclear
CAD output:
- NR
Diagnostic threshold: 
- Threshold not reported
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Was the CAD model evaluated in an independent study population? Unclear
Was model overfitting accounted for during model development? Yes
Could the conduct or interpretation of the index test have introduced bias? High risk
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B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? No
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Details: ""All lesions were excised and examined
microscopically by expert dermatopathologists using
standard histopathologic diagnostic criteria"
Disease positive: 36=test set and 65=derivation set
Disease negative: 33=test set and 65=derivation set
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not reported): 36 test set
and 65 derivation set
Dysplastic naevi 33 test set and 65 derivation set
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without
knowledge of the results of the index tests? Yes
Were the reference standard results likely to correctly classify
the target condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation
have introduced bias? Low risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Excluded participants: none reported
Intervals between tests: not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Glud 2009
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection Jan to Apr 2007
Country Denmark
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients referred for excision
biopsy of pigmented lesions where the diagnosis of
melanoma could not be excluded on clinical
investigation
Setting: Secondary (other); Dept Plastic Surgery and
Burn Unit
Prior testing: Clinical suspicion of malignancy
without dermatoscopic suspicion
Setting for prior testing: Secondary (not further
specified); Department of Plastic Surgery and Burn
Unit
Exclusion criteria: None reported
Sample size (patients): No. included: 65
Sample size (lesions): No. included: 83
Participant characteristics: Median age 47 yrs (18 to
90y); Male - 29; 45%
Lesion characteristics: melanoma thickness 0.29
mm to 2.18mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Was an adequate spectrum of cases used to train the algorithm?
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
1. Dermoscopy No algorithm
Method of diagnosis: Dermoscopic images
Prior test data: No further information used
Diagnostic threshold: Not reported -"dermoscopic images were examined by an experienced
dermatologist"
Diagnosis based on: Single observer (n=1)
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’
Experience with index test: High experience /‘Expert’ users
Any other detail The dermoscopic and SIAgraphic images were obtained by SIAscope II (Amon
Clinica, Cambridge, UK) and stored using the proprietary Dermetrics software (Astron Clinica).
2. Computer Assisted Diagnosis - Spectroscopy based
MSI-CAD system: SIAscope II (Astron Clinica, UK )(classifier NR)
System details:
Skin lesion is interrogated with light of different wavelengths and the reflection spectra are analyzed by
proprietary algorithms showing distribution, position and quantity of melanin, blood , and collagen
within the papillary dermis (the SIAgraphs).
No derivation aspect (external validation)
Derivation described in prior study – See Moncrieff 2002, Govindan 2007
Lesion characteristics assessed: 
– Analysis of dermal melanin, erythematous blush, lesion asymmetry, collagen 'holes', blood commas,
or irregularities in the collagen
Additional predictors included: 
- None
Method of diagnosis: 
- Spectroscopic images, SIAgraphic images
- CAD-based diagnosis
Prior/other test data: 
- Unclear
CAD output:
- Binary (based on Australian Scoring System): ‘strong chance of melanoma' or 'low risk of melanoma'
Diagnostic threshold: 
Australian Scoring System
- Threshold not reported
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
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Dermoscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
(excision biopsy)
Details: Breslow thickness and Clark level were
determined by standard histopathologic
examination. Tumor staging was performed as
described by Balch et al according to the 2001
melanoma staging system.
Disease positive: 12; Disease negative: 71
Target condition (Final diagnoses) 
Melanoma (invasive): 7; Melanoma (in situ): 5; 1
melanoma metastasis (incl as benign)
Sebhorrheic keratosis: 1; Benign naevus: 57;
'Benign' diagnoses: bowens 1 haemangioma 1
lentigo simplex 2 epidermal naevi 2 DF 6
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Unclear
Were the reference standard results likely to correctly classify the target
condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Participant excluded from analysis: none
reported
Interval between tests: not reported
Interval to reference standard: Images
taken prior to biopsy
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
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Notes  
Gutkowicz Krusin 1997
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: 
- Unclear
Data collection: 
- Retrospective image selection / Prospective
interpretation
Period of data collection NR
Country US (from authors' institution)
Test set derived NR. The "classifier was then tested
blindly on an independentset of 28 images of
melanocytic lesions on slides provided by Dr. A. w.
Kopf."
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Unclear
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Study inclusion criteria Lesions
suspected of early melanoma or atypical
melanocytic nevus
Setting: 
- Secondary (general dermatology) From authors'
institution
Prior testing: 
- Selected for excision (no further detail) No details;
all lesions excised
Setting for prior testing: 
- Unspecified
Exclusion criteria: Study exclusion criteria:
None reported
Sample size (patients): 
- No. included: NR
Sample size (lesions): 
- No. included: 104; 76 training; 28 test set
Participant characteristics: Participant characteristics
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Was an adequate spectrum of cases used to train the algorithm? No
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
Computer Assisted Diagnosis - Spectroscopy based
MSI-CAD system: MelaFind precurser (Multiparametric linear classifier)
System details:
Digital camera and illumination assembly coupled to a computer, with separate image analysis
Derivation study (internal validation)
Lesion characteristics assessed: 
– Lesion asymmetry, border, gradient, centroid, texture, colour
Additional predictors included: 
- No further information used
Method of diagnosis: 
- spectroscopic images
- CAD-based diagnosis
Prior/other test data: 
- No further information used
CAD output:
- NR
Diagnostic threshold: 
- Threshold not reported
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Was the CAD model evaluated in an independent study population? Unclear
Was model overfitting accounted for during model development? Unclear
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard 
- Histological diagnosis alone
Histology (not further described) 
- No. patients/lesions: 28 in test set
- Disease positive: 5
- Disease negative: 23
TARGET CONDITION (Final diagnoses)
- Melanoma (in situ and invasive, or not reported): 5
- Benign naevus: 23
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Yes
Were the reference standard results likely to correctly classify the
target condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: NR
Time interval to reference test: NR
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Hauschild 2014
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case control; all lesions in this
study were imaged and analysed by MelaFind in
a previous study (Monheit 2011).
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection NR
Country US-data from Monheit 2011 study
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Subset of pigmented skin lesions
evaluated in the Monheit et al trial; melanoma and
non-melanoma randomly selected; none were
ulcerated, non-pigmented, or located on excluded
anatomic sites.
Setting: Lesions sampled from Monheit trial "Seven
clinical sites with 23 investigators participated in this
trial. Three sites were academic institutions
(University of Pittsburgh, Duke University, and
Northwestern University), and 4 sites were
dermatologic practices highly experienced in
managing PLs."
Prior testing: - Selected for excision (no further
detail)
Setting for prior testing: Not reported
Exclusion criteria: ulcerated, non-pigmented, or
located on excluded anatomic sites
Sample size (patients): No. included: 130
Sample size (lesions): No. eligible: 1632 lesions in
Monheit trial; No. included: 130
Participant characteristics: None reported
Lesion characteristics: site - Head/Neck: 22.3%; -
Trunk: 41.5%; - Upper limbs/shoulder: 20%; - Lower
limbs/hip: 16.2%. Median thickness (melanomas)
0.39mm (range 0.12 to 1.2mm)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Was an adequate spectrum of cases used to train the algorithm?
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
1. Dermoscopy No algorithm
Method of diagnosis: Clinical photographs and dermoscopic images
Prior test data: Clinical examination and/or case notes. Lesion images consisted of a clinical overview
at 53 cm/21 inches, a clinical close-up at 20 cm/8 inches, and a dermatoscopic image. Clinical exam
information consisted of 24 items regarding patient demographics and risk factors for melanoma such
as: personal or family history of melanoma, number of atypical nevi, Fitzpatrick skin type, number of
severe sunburns before and after age 20, etc.
Diagnostic threshold: Not reported. Responses to the questions regarding whether or not the
dermatologist would biopsy the lesion and reason for biopsy were used to determine dermatologist
sensitivity and specificity
Diagnosis based on: Average (Arm 1: 101 board certified dermatologists; Arm 2 (MelaFind): further
101 board certified dermatologists; Arm 3: 9 Pigmented Skin Lesion (PSL))
Observer qualifications: Dermatologist (Experts (Arm 3) prospectively identified by the Principal
Investigator based on field standing prior to participant recruitment)
Experience in practice: High experience or ‘Expert’; >90% had more than 10 years experience in
practice
Experience with index test: High experience /‘Expert’ users. All except 6 were trained in dermoscopy
use; 155/202 always or almost always used dermoscopy for PSLs
2. Computer Assisted Diagnosis - Spectroscopy based
MSI-CAD system: MelaFind (classifier NR)
System details:
Multispectral imaging system with integrated image analysis software; device takes images in vivo
No derivation aspect (reader study)
Lesion characteristics assessed: 
– NR
Additional predictors included: 
- None reported
Method of diagnosis: 
- Spectroscopic images
- CAD-based diagnosis
Prior/other test data: 
- Clinical examination and/or case notes Study presents system based diagnosis plus MelaFind
combined with dermatologist decision which was also infomred by clinical exam info
CAD output:
- Binary output: (1) positive, (lesion should be considered for biopsy to rule out melanoma); and (2)
negative (lesion should be considered for later evaluation)
Diagnostic threshold: 
- Threshold not reported
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
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A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
Histology (not further described). Disease
positive: 65; Disease negative: 65
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not
reported): 65
'Benign' diagnoses: 65
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Were the reference standard results likely to correctly classify the target
condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
participants excluded from analysis: none
Time interval between index tests: unclear
Time interval to reference standard: unclear
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Maglogiannis 2015
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: case-control
Data collection: retrospective
Period of data collection: Not reported
Country: Greece
Random division of 208 lesions into train and
test sets (equal numbers)
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: lesions excised (no further details)
Setting: Specialist - Department of Plastic Surgery
and Dermatology (Athens)
Prior testing: lesions excised (no further details)
Setting for prior testing: Not specified
Exclusion criteria: none reported
Sample size (patients): NR
Sample size (lesions): 208 lesions,
Participant characteristics: Participant characteristics
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Was an adequate spectrum of cases used to train the algorithm? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Computer Assisted Diagnosis - Dermoscopy based
Derm-CAD system: name NR (SVM polykernel c=5 classifier, selected at random for this review)
System details:
Computer analysis of digital dermoscopy images captured using the Molemax II dermatoscope
Derivation study (internal validation)
Five classifiers trained: Multilayer perceptron, kNN, Random forest, SVM polykernel c=5, SVM PUK
kernel.
Lesion characteristics assessed: 
– features corresponding to the number, size and asymmetry of dots: (a)Number of dots, (b) Total
Number of pixels in dots, (c) mean number of pixels in dots, (d) variance of num. pixels in dots ,(e)
fraction of lesion area occupied by dark dots. Asymmetry: radial, angular, primary axis.
Additional predictors included: 
- None reported
Method of diagnosis: 
- Dermoscopic images
- CAD-based diagnosis
Prior/other test data: 
- No further information used
CAD output:
- NR
Diagnostic threshold: 
- Threshold not reported
Computer-assisted diagnosis
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development? Unclear
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
Disease positive: 50 MM; Disease negative:
54
TARGET CONDITION (Final diagnoses)
Melanoma (in situ and invasive, or not
reported): 50
'Benign' diagnoses (not further specified): 54
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Were the reference standard results likely to correctly classify the target
condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
No exclusions reported
Time interval to reference test: No details
reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Malvehy 2014
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective; dermoscopic
images assessed remotely from the patient
Period of data collection: March 2010 and
November 2011
Country: conducted at five American and 17
European investigational sites (Sweden,
Germany, Austria, Hungary, U.K. and Spain);
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: All patients with skin lesions
selected for total excision to rule out melanoma;
dermatologists were encouraged to enrol a mix of
lesions with an even distribution of low-, medium
and high-risk lesions.
Setting: Secondary; authors institutions primarily
listed as Dept Dermatology with one "Dermatology
Clinical Research Center"
Prior testing: Selected for excision
Exclusion criteria: lesions < 2 mm or > 20 mm and
those located: on acral skin, e.g. sole or palm; areas
of scars, crusts, psoriasis, eczema or similar skin
conditions; hair-covered areas, e.g. scalp, beards,
moustaches or whiskers; genitalia; in an area that
has been previously biopsied or subjected to any
kind of surgical intervention or trauma; mucosal
surfaces; with foreign matter, e.g. tattoo or splinter;
acute sunburn; or skin surface not measurable, e.g.
lesion on a stalk; surface not accessible, e.g. inside
ears, under nails or not intact (measurement area),
Sample size (patients): No. eligible: 1951; No.
included: 1611
Sample size (lesions): No. eligible: 2416; No.
included: 1943
Participant characteristics: For Nevisense sample:
median age: 48y (range 18 to 91); male 47.5%;
97.5% of white ethnicity. Fitzpatrick skin types: I
(7.3%); II (48.6%); III (37%); IV (9.8%); V (1.4%); VI
(0.1%)
Lesion characteristics: median Breslow thickness of
0.57 mm (153 invasive melanomas);
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Was an adequate spectrum of cases used to train the algorithm?
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
#164a Computer assisted diagnosis techniques (dermoscopy and spectroscopy-based) for the diagnosis of skin cancer...
91 / 268
Index tests
Computer Assisted Diagnosis - Spectroscopy based
EIS-CAD system: Nevisense (SciBase III, Sweden) (SVM classifier)
System details:
Electrical Impedance spectroscopy imaging system with integrated image analysis software. The
system measures the overall electrical resistance and reactance at 35 different frequencies
derivation aspect (study type)
Lesion characteristics assessed: 
– NR
Additional predictors included: 
- None reported
Method of diagnosis: 
- Spectroscopic images
- CAD-based diagnosis
Prior/other test data: 
- None considered by CAD for diagnosis
CAD output:
- The system computes both a score (0–10) and a dichotomous output (EIS negative/positive) at a
fixed cut-off.
Diagnostic threshold: 
- Score: The fixed threshold is set at 4, i.e. scores < 4 are EIS negative and scores of ≥ 4 are EIS
positive.
– Prior study (Mohr 2013) used dichotomous outcome but recommended score output
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Visual inspection
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?
If a threshold was used, was it pre-specified?
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias?
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication?
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question?
Dermoscopy
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?
If a threshold was used, was it pre-specified?
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias?
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication?
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question?
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological diagnosis
alone
Details: Lesions were excised and underwent usual
histopathology at investigational site. A further
histopathological evaluation was undertaken for study
purposes by a panel of three experienced
histopathologists who evaluated
each lesion independently; blinded from the
investigational site’s original histopathology diagnosis.
If they agreed, the diagnosis was considered as the
histopathological gold standard (HGS); if there was
significant disagreement regarding malignancy the
slides were submitted to two additional experts whose
diagnosis was then chosen as the HGS if they reached
agreement. In case of disagreement by the two
additional reviewers, the corresponding lesion was
excluded from the efficacy analysis.
Disease positive: 478; Disease negative: 1440
Target condition (Final diagnoses) 
153 invasive melanomas, 112 melanoma in situ,
48 BCC, 1 invasive cSCC; 1 Merkel cell carcinoma
157 severely dysplastic, 988 mild to moderate
dysplasia, 352 benign nevi, 5 spitz nevi, 51 seborrheic
keratosis, 6 cSCC in situ; 8 AK; 61 other
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge
of the results of the index tests? Unclear
Were the reference standard results likely to correctly classify the
target condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Participant exclusions: 473 excluded from Nevisense
analysis; all reasons listed; primary reason was
investigator oversight or the inability to render a final
histopathological diagnosis; 74 exclusions were
device-related (60 with inadequate reference
measurement quality and 14 to device failure).
Index test to reference standard interval: Appears
consecutive; prospective recruitment with imaging and
then "eligible and evaluable lesions were excised and
subjected to the investigational site’s histopathology
evaluation and managed accordingly." "A
postprocedure follow-up either by a telephone call or
at a participant’s visit to the investigational site was
conducted at 7 +/- 3 days after the Nevisense
evaluation, at which time the patient was evaluated for
any adverse events."
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? High risk
Notes
Notes  
Menzies 1996
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Unclear Describes including
melanomas and randomly selected clinically
atypical nonmelanoma lesions
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection NR
Country Australia
Test set derived NR; describes 'division' into a
training set and a test set.
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Unclear
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Pigmented skin lesions from the
Sydney Melanoma Unit with dermoscopic images and
histological diagnoses; melanomas and randomly
selected clinically atypical nonmelanoma lesions were
included.
Setting: Specialist unit (skin cancer/pigmented lesions
clinic) From authors' institution
Prior testing: Clinical suspicion of malignancy without
dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: unequivocal nonmelanoma excluded
Sample size (patients): No. included: NR
Sample size (lesions): No. included: 385 (training set
221, test set 164)
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Was an adequate spectrum of cases used to train the algorithm? Unclear
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
1. Dermoscopy Menzies criteria
Method of diagnosis: Dermoscopic images
Prior test data: No further information used
Diagnostic threshold: Two negative features of melanoma (i.e. cannot be found).Point and axial
symmetry of pigmentation Presence of only a single colourNine positive features of melanoma were
used (at least one feature found). Multiple (5-6) colors Blue-white veil Multiple brown dots Multiple
blue/gray Peripheral black dots or globules A broadened network Pseudopods Radial streaming
Scarlike
Diagnosis based on: Unclear (n=NR)
Observer qualifications: Not reported likely dermatologists
Experience in practice: Not described
Experience with index test: Not described
2. Computer Assisted Diagnosis - Dermoscopy based
Derm-CAD system: Name not reported (CART classifier)
System details:
Computer analysis of stored images captured using digital microscope. Pigmented skin lesions were
photographed in vivo by means of immersion oil and a camera (Dermaphot, Heine Ltd). The surface
microscopic images were studied on a viewer (Kodak Ektagraphic Viewer, Model 575AF, Eastman
Kodak Co, Rochester, NY).
Derivation study (Internal validation)
Lesion characteristics assessed: 
Approach to feature selection A classification and regression tree constructed on the training set
produced a 7-node tree
Negative Features: Point and axial symmetry of pigmentation
Presence of only a single colour.
Positive Features: Blue-white, veil, Multiple brown dots, Pseudopods, Radial streaming, Scarlike
depigmentatlon, Peripheral black dots/globules, Multiple (5-6) colors, Multiple blue/gray dots,
Broadened network
Additional predictors included: 
- Unclear
Method of diagnosis: 
- Dermoscopic images
- CAD-based diagnosis
Prior/other test data: 
- Unclear
CAD output:
- NR
Diagnostic threshold: 
- Presence of indicative features (Melanoma = 0/2 morphologically negative features AND at least 1/9
positive morphological features)
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population? Unclear
Was model overfitting accounted for during model development? Unclear
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
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B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Histology (not further described); Disease positive:
107; Disease negative: 278
Target condition (Final diagnoses) 
Melanoma (invasive): 107; BCC: 18
?Ephilis lentigo 17; Sebhorrheic keratosis: 23;
Benign acquired nevi - 58; Dysplastic nevi - 105;
Blue nevi 11; Spiz nevi 6; spindle cell nevus 2;
dermatofibroma 2; hemangioma 13; solar keratosis
9; other 14
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Yes
Were the reference standard results likely to correctly classify the
target condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Exclusions from analysis: none reported
Time interval to reference test: Not
reported
Time interval between index test(s): Not
reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? High risk
Notes
Notes  
Menzies 2005
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection June 1998 to
September 2003
Country Multicentre (Australia, US, Germany)
Test set derived: study population divided at
ratio 2:1 for training:test sets; divison
randomised but stratified by diagnostic category
and Breslow.
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Pigmented skin lesions imaged
using SolarScan at 9 different clinical centers
including specialist referral centers and private skin
cancer clinics; only the 78 lesions from the Sydney
Melanoma Unit included in the VI/Dermoscopy
evaluation. In all but 1 clinic site, the sole indication
for imaging was that the pigmented lesion was to be
excised, usually because of a clinical suspicion
Setting: Private skin cancer clinics in Australia
staffed by general practitioners
Prior testing: In 8/9 clinics, included lesions were to
be excised, usually because of a clinical suspicion.
"However, clinics were inconsistent in imaging
excised lesions from their own practices, with some
clinics obtaining images of lesions with a
predominately high probability of melanoma."
Setting for prior testing: Private care
Exclusion criteria: awkwardly situated lesions (eg,
eyelids, some parts of the pinna, some genital sites,
and perianal and mucosal surfaces); acral lesions;
non-pigmented pure amelanotic lesions (based on
dermoscopy imaging); benign non melanocytic
lesions excluded from one classifier. Poor quality
index test image - lesions outside the field of view
(24x18 mm), contamination of calibration surfaces,
or excess artifacts (hair, air bubbles, or movement
artifacts). Ulcerated lesions, or diagnosed as
pigmented basal cell carcinoma, pigmented Bowen
disease, or squamous cell carcinoma
Sample size (patients): No. included: NR
Sample size (lesions): No. eligible: 2430/ No.
included: 1644 training; 786 test set
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Was an adequate spectrum of cases used to train the algorithm? Yes
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
1. Visual inspection (VI)
Method of diagnosis: 
Prior test data: 
Diagnostic threshold: 
Diagnosis based on: 
Number of examiners
Observer qualifications: 
Experience in practice: 
Experience with index test: 
2. Dermoscopy No algorithm
Method of diagnosis: Dermoscopic images
Prior test data: Clinical examination and/or case notes clinical photographs and patient histories
Diagnostic threshold: Not reported. No details on lesion characteristics used; data can be extracted at
two thresholds:- correct diagnosis of melanoma (in situ or invasive) - excise decision
Diagnosis based on: Average (n=13)
Observer qualifications: GP 3; Dermatology registrar 3; Dermatologist 4 (one local practising
dermatologists (Sydney), plus 3 international dermoscopy experts who headed pigmented lesion
clinics)
Experience in practice: Mixed experience (low and high experience combined)
Experience with index test: Mixed experience
Any other detail had clinical and dermoscopy photographic images (taken with a Heine Dermaphot
camera, Heine Ltd, Herrsching, Germany)
3. Computer Assisted Diagnosis – Dermoscopy based
Derm-CAD system: SolarScan (Polartechnics Lts, Australia) (Linear discriminant analysis classifier)
System details:
Dermoscopy video unit with internal algorithm for image analysis. The algorithm model used by
SolarScan is an optimized set offixed discriminant variables with associated weighting factors and
relationships features (Australian Patent application No.20022308395 and Australian Patent No.
2003905998).
Derivation study (internal validation)
Described in prior study Menzies 2001, referenced.
Various properties of color, pattern, and geometry were extracted from the segmented lesion
images.The patient history features (see below) and 103 image analysis variables, in combination with
the diagnostic weights (based on a linear representation (range, 0.25-20) of correctly classifying the
lesion as benign or melanoma), were used in the training set to model 2 diagnostic algorithms.
Lesion characteristics assessed: 
103 automated image analysis variables extracted: consisting of various properties of colour, pattern,
and geometry. Number analysed not reported.
Additional predictors included: 
- Predictors included whether the lesion had, within the previous 2 years, bled without being scratched,
changed in colour or pattern, or increased in size
Method of diagnosis: 
- Dermoscopic images
- CAD-based diagnosis
Prior/other test data: 
- None reported
CAD output:
- Probability of melanoma, with cut–off (not provided) for benign vs. melanoma
Diagnostic threshold: 
- Threshold not reported
Computer-assisted diagnosis
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development? Unclear
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis plus follow
up
Histology (not further described): 71% of total dataset
(n = 1725), presumably including all disease positive
Clinical FU plus histology of suspicious lesions;
Length of FU: 3 mo. 26% of full dataset (n = 632)
Expert opinion. 3% of image set were diagnosed
clinically but not excised
Target condition (Final diagnoses). All numbers are
for complete dataset
Melanoma (invasive): 238; Melanoma (in situ): 144
Benign naevus: 1835 benign melanocytic; Other: 213
benign nonmelanocytic, incl 140 SK
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Unclear
Were the reference standard results likely to correctly classify the
target condition (disease negative)? No
Could the reference standard, its conduct, or its interpretation have
introduced bias? High risk
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B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? No
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? High
Flow and Timing
A. Risk of Bias
Flow and timing
Exclusions from analysis: None
Time interval to reference test: Not
reported
Time interval between index test(s): Not
reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? High risk
Notes
Notes  
Mohr 2013
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective; dermoscopic images
assessed remotely from the patient
Period of data collection: January 2009 to
November 2010*
Country: conducted at 19 private and/or academic
dermatological centres located in Germany,
Hungary, Sweden, Switzerland, and U.K.
* some overlap in study population with Malvehy
2014 possible (no author reply), as ascertained by
similar recruitment centres and overlapping
periods of data collection.
Test set derived: Data randomised into train set
(approximately 40% of data) and test set
(approximately 60%).
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Adults of any ethnic group, aged at
least 18, with one or more primary skin lesion(s), at
least 2 mm in diameter, located on normal uninflamed
skin and requiring full excision for histopathological
analysis.
Setting: Secondary; authors institutions primarily listed
as Dept Dermatology with one "Division of Imaging
and Technology"
Prior testing: Selected for excision
Exclusion criteria: > 8 lesions per patient; metastatic or
recurrent; patients with lesions under finger and toe
nails, in sites where the electrode could not reach, e.g.
between toes, those lesions with abnormal reference
areas (usually inflammatory skin disease like eczema
and psoriasis), those with lesion in scars or striae,
crusted lesions and those previously subjected to any
surgical procedure.
Sample size (patients): No. eligible: NR; No. included:
1134
Sample size (lesions): No. eligible: NR; No. included:
1300
Participant characteristics: NR
Lesion characteristics: median Breslow thickness of
0.43 mm (67 invasive melanomas);
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Was an adequate spectrum of cases used to train the algorithm? Yes
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Computer Assisted Diagnosis - Spectroscopy based
EIS-CAD system: Nevisense predecessor (SciBase, Sweden) (SVM classifier)
System details:
Electrical impedance was measured with the SciBase III electrical impedance spectrometer, equipped
with a spring-loaded probe and a disposable five-bar electrode. The system measures bio-impedance
of the skin at 35 different frequencies, logarithmically distributed from 1.0 kHz to 2.5 MHz, at four
different depths utilizing 10 permutations.
Derivation study (internal validation)
Classification algorithm calibration and testing was conducted in two stages. In the first stage of
development, the data were randomized into two cohorts for calibration and verification, utilizing 40%
and 0% of the available data respectively. In the second stage approximately 55% of the data were
used for calibration and the whole data set was used for verification (second algorithm, not extracted).
Lesion characteristics assessed: 
The electrical impedance data obtained from each measurement represented a very large data set
consisting of the complex ratio of voltage to current, composed of the magnitude and phase shift at 35
frequencies for 10 permutations yielding a data set of 700 variables for each measurement. By
combining permutations and frequencies, a large EIS feature space could be constructed. The
features’ ability to differentiate between melanoma and benign cutaneous lesions was then ranked
and, by means of cross-validation, the optimum number of features was extracted.
Additional predictors included: 
- None reported
Method of diagnosis: 
- Stored EIS measurements
- CAD-based diagnosis
Prior/other test data: 
- None reported
CAD output:
- Dichotomous outcome: malignant vs. benign
Diagnostic threshold: 
- Threshold not reported
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
If a threshold was used, was it pre-specified? Unclear
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development? Yes
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?
If a threshold was used, was it pre-specified?
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias?
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B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication?
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question?
Dermoscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?
If a threshold was used, was it pre-specified?
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias?
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication?
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question?
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological diagnosis
alone
Details: Lesions were excised and underwent usual
histopathology at investigational site. A further
histopathological evaluation was undertaken for study
purposes by a panel of three experienced
histopathologists who evaluated
each lesion independently using information from
clinical diagnosis and histopathology referral reason;
blinded from the investigational site’s original
histopathology diagnosis. If they agreed, the diagnosis
was considered as the histopathological gold standard
(HGS);
Disease positive: 166 Disease negative: 280 (TOTAL
446 in test set, after exclusions from analysis)
Target condition (Final diagnoses) 
67 invasive melanomas, 30 melanoma in situ,
21 BCC, 4 cSCC
38 severely dysplastic, 185 moderate dysplasia, 64
benign nevi, 22 seborrheic keratosis, 9 other
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge
of the results of the index tests? Unclear
Were the reference standard results likely to correctly classify the
target condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Participants exclusions from analysis: 549/1300
lesions excluded from analysis, mainly due to poor
reference measurement quality (n=290). Other
reasons were: Screening failure 2, Protocol violations
72, No measurements performed 35, Unable to map
lesions with measurements 9, Lesion not excised 18,
Poor histopathology 11, No consensus diagnosis
reached by pathologists 20. Expanded Exclusions:
Bleeding, traumatized or ulcerated lesion 38 Lesion
located on acral skin 11, Surface area not measurable
34, Insufficiently covered with measurements 2, No
clinical suspicion of melanoma 5, Hair-bearing areas 2.
An additional 6 lesions excluded by review team: 6
undefined thickness mel excluded from MM1 to give
total sample of 446–6=440
Time interval to reference test: Consecutive, excision
within 2 weeks of EIS measurements; prospective
recruitment: "After obtaining informed consent from
each patient, eligible lesions destined for excision
were measured with the SciBase III electrical
impedance spectrometer (SciBase AB, Stockholm,
Sweden). After a maximum of 14 days the lesions
were surgically excised and subjected to
histopathological evaluation."
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? High risk
Notes
Notes  
Mollersen 2015
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Unclear
Period of data collection: March to
December 2013
Country: Germany
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Adult patients scheduled for
excision of a pigmented skin lesion and those with
nonpigmented skin lesions if melanoma, BCC, or
SCC was a potential differential diagnosis. The
presence of hairs and bubbles, lesion size,
inadequate segmentation, etc. were not used as
exclusion criteria.
Setting: Private dermatology practice
Prior testing: Scheduled for excision on basis of
clinical diagnosis, because of concern about
malignancy or when requested by the patient for
other reasons (no further details)
Setting for prior testing: Unspecified
Exclusion criteria: None reported
Sample size (patients): Eligible NR, Included 516
Sample size (lesions): Eligible NR, Included 877
Participant characteristics: median age: 53y (range
18 to 93); male 53%
Lesion characteristics: median Breslow thickness of
0.50 mm (23 invasive melanomas); maximum
Breslow thickness 2.25mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Was an adequate spectrum of cases used to train the algorithm?
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
#164a Computer assisted diagnosis techniques (dermoscopy and spectroscopy-based) for the diagnosis of skin cancer...
107 / 268
Index tests
1. Computer Assisted Diagnosis – Dermoscopy based
Derm-CAD system: Nevus Doctor (classifier NR)
System details:
Computerised image analysis system coupled to digital dermoscope. ND takes a dermoscopic image
from the Canon/DermLite device as input and classifies the lesion. ND is still in an experimental
phase.
All skin lesions were photographed prior to excision with a digital camera (Canon G10, Canon Inc.,
Tokyo, Japan) with an attached dermoscope (DermLite FOTO, 3Gen LLC, California, USA) and with a
videodermoscope (DermoGenius ultra, DermoScan GmbH, Regensburg,Germany).
No derivation aspect (external validation study)
Described in previous study Mollersen 2015 in press, reference #37
Lesion characteristics assessed: 
– NR
Additional predictors included: 
- None reported
Method of diagnosis: 
- Dermoscopic images
- CAD-based diagnosis
Prior/other test data: 
- Clinical diagnosis
CAD output:
- Probability of malignancy
Diagnostic threshold: 
- CAD system tuned to 95% melanoma sensitivity
2. Computer Assisted Diagnosis – Dermoscopy based
Derm-CAD system: MoleExpert (classifier NR)
System details:
ME (MoleExpert micro Version 3.3.30.156) takes a dermoscopic image from the DermoGenius device
as input. ME is intended for use on melanocytic lesions only.
All skin lesions were photographed prior to excision with a digital camera (Canon G10, Canon Inc.,
Tokyo, Japan) with an attached dermoscope (DermLite FOTO, 3Gen LLC, California, USA) and with a
videodermoscope (DermoGenius ultra, DermoScan GmbH, Regensburg,Germany).
No derivation aspect (external validation study)
No information provided (ME is a commercial system developed by others and used as a comparator
in this study)
Lesion characteristics assessed: 
– Features of ABCD system plus other features (not listed), e.g. color variation and gray veil.
Additional predictors included: 
- None reported
Method of diagnosis: 
- Dermoscopic images
- CAD-based diagnosis
Prior/other test data: 
- Clinical diagnosis
CAD output:
- Number between −5.00 and 5.00, where high values indicate suspicion of melanoma
Diagnostic threshold: 
- CAD system tuned to 95% melanoma sensitivity
Computer-assisted diagnosis
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Details: All excised lesions were examined by a
dermatopathologist. In the case of a malignant diagnosis, a
second dermatopathologist examined the excised lesion
and a consensus diagnosis was set.
Disease positive: 107; Disease negative: 278
Target condition (Final diagnoses) 
Melanoma: invasive 25, in situ 19; BCC: 70, cSCC 6,
adnexal carcinoma 1
Benign diagnoses: 38 benign non melanocytic; 13 collision
tumours; 13 AK; 11 Bowen's disease; 79 Sebhorrheic
keratosis; 595 benign nevus
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Were the reference standard results likely to correctly classify
the target condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation
have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Exclusions from analysis: one lesion lacking clinical
diagnosis; of 875 lesions with histopathological
diagnosis, four were excluded because ME did not
give an output (one naevus, one seborrheic keratosis,
one BCC, and one SCC) and one was excluded
because the Canon/DermLite image was lost
(melanoma in situ)
Time interval to reference test: Not reported
Time interval between index test(s): Appears
consecutive
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? High risk
Notes
Notes  
Monheit 2011
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: January 2007 to
July 2008
Country: US
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Pigmented skin lesions scheduled for
biopsy in toto, with diameter >=2mm
Setting: Specialist unit (skin cancer/pigmented lesions
clinic). Three sites were academic institutions and 4
sites were dermatologic practices highly experienced in
managing PLs.
Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Unspecified
Exclusion criteria: Difficult to diagnose lesions;
Location/site of lesion anatomic site of pigmented lesion
not accessible to the device; within 1 cm of the eye; or
on palmar, plantar, or mucosal (eg, lips, genitals)
surface or under nails; lesion size diameter <2 mm or
>22 mm excluded
Previous history of skin cancer/ prior treatment at site
lesion previously biopsied, excised, or traumatized
Other characteristic known allergy to isopropyl alcohol;
skin not intact (eg, open sores, ulcers, bleeding); in an
area of visible scarring; or containing foreign matter (eg,
tattoo ink, splinter, marker).
Sample size (patients): Eligible: 1383, Included 1257
Sample size (lesions): Eligible: 1831, Included 1632
Participant characteristics: Median age 46y (Range
7-97y); Male 575 (45.7%); Ethnicity: White 1232 (98%),
Black or African American 2 (0.2%), Asian 17 (1.4%),
Other 6 (0.5%). Thickness/depth: ≤1mm: 69/70 invasive
MM (99%), 1.01-2.00mm: 1/70 (1%).
Median Breslow 0.36 mm (70 invasive MM)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Was an adequate spectrum of cases used to train the algorithm?
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
MSI-CAD system: MelaFind (EO Sciences, USA) (classifier NR)
System details:
Multispectral imaging system with integrated image analysis software; device takes images in vivo.
MelaFind takes images at 10 spectral bands, between 430–950nm.
No derivation aspect (external validation study)
The properties of these images as well as image analysis methods have been previously
described.15-21 (Gutkowicz-Krusin 1997, 2000, 2007 and Elbaum 2001)
Lesion characteristics assessed: 
–NR
Additional predictors included: 
- None
Method of diagnosis: 
- In person diagnosis
- CAD-based diagnosis
Prior/other test data: 
- No further information used
CAD output:
- Binary output: (1) positive, (lesion should be considered for biopsy to rule out melanoma); and
(2) negative (lesion should be considered for later evaluation)
Diagnostic threshold: 
- Threshold not reported
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?
If a threshold was used, was it pre-specified?
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias?
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication?
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question?
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard 
- Histological diagnosis alone
Histology (not further described) 
- No. patients/lesions: 1632
Disease positive: 175, Disease negative: 1457
Target condition (Final diagnoses)
Melanoma: invasive 70, in situ 57; BCC: 23; cSCC:
10, Severe dysplasia: 43
Benign diagnoses: 998 Mild/moderate dysplasia; 93
Sebhorrheic keratosis, 217 Benign naevus, 5 atypical
melanocytic hyperplasia (AMH) or atypical
melanocytic proliferation (AMP), 16 actinic keratosis,
10 other keratosis, 76 lentigo, 14 other
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Unclear
Were the reference standard results likely to correctly classify the
target condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Exclusions from analysis: 20 lesions with the
prebiopsy dermatologic diagnosis of melanoma
were excluded from the primary MelaFind
analysis; 1 withdrew, 3 clinician deemed inelig,
14 dermatopath deemed inelig, 19 missing/inad
histol slides, 162 imaging failed (operator errors,
too many bubbles, lesion not centred), 36
MelaFind or camera malfunction, 61operator or
MelaFind error (lesion too small to visualise,
automatic segmentation falied).
Time interval to reference test: Unclear
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? High risk
Notes
Notes  
Piccolo 2002
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection NR; 6-month period
Country Italy
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Pigmented lesions excised because of
equivocal dermoscopic findings or at the patient’s request
Setting: Secondary (general dermatology); from authors'
institution
Prior testing: Dermatoscopic suspicion; Patient request for
evaluation/excision
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): No. included: 289
Sample size (lesions): No. included: 341
Participant characteristics: Mean age 33.6y, range 3–83y;
Male gender: 127 (43.9%); Fitzpatrick phototype I to II
(31.4%); Type III (42.2%); Type IV-V (26.4%)
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Was an adequate spectrum of cases used to train the algorithm?
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
1. Dermoscopy No algorithm
Method of diagnosis: Clinical photographs and dermoscopic images Cases were clinically and
dermoscopically evaluated on a high-resolution colour monitor, in a random sequence
Prior test data: Unclear Not specifically described but appears to be images only
Diagnostic threshold: Not reported
Diagnosis based on: Single observer (n=2)
Observer qualifications: Dermatologist; Resident clinician with minimal training in PSLs
Experience in practice: High experience or ‘Expert’ 5 years of experience; Low experience or recently
qualified minimal training in PSLs (6 months of experience, comprising 8 h of specialized training on
three consecutive days and 2h per week in the routine of dermoscopy)
Experience with index test: Mixed
Any other detail: stereomicroscope with magnifications varying from x 6 to x 40
2. Computer Assisted Diagnosis - Dermoscopy based
Derm-CAD system: DEM-MIPS (Digital Epi Microscopy Melanoma Image Processing Software;
Biomips SRL, Siena, Italy) (ANN classifier)
System details:
DEM-MIPS is designed to evaluate different colorimetric and geometric parameters of a lesion
automatically in real time. All digital images of PSLs were collected in a Truevision Advanced Graphic
Array format file with a size of 887 kB for each image. Digital dermoscopic images were framed at x 16
magnification before analysis with DEM-MIPS
No derivation aspect (External validation study)
Described in prior study "DEM-MIPS is based on an ANN trained with 100 PSLs (50non-melanomas
and 50 melanomas) and is designed toevaluate different colorimetric and geometric parametersof a
lesion automatically in real time." No citation given
Lesion characteristics assessed: 
– Evaluates colorimetric and geometric features (not reported).
Additional predictors included: 
- None reported
Method of diagnosis: 
- Dermoscopic images
- CAD-based diagnosis
Prior/other test data: 
- No further information used
CAD output:
- NR
Diagnostic threshold: 
- Threshold not reported
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
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B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Histology (not further described); Disease positive: 13;
Disease negative: 328
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not reported): 13
Sebhorrheic keratosis: 3; Benign naevus: 316; Other: 7
dermatofibromas, 2 angiomas
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge
of the results of the index tests? Unclear
Were the reference standard results likely to correctly classify the
target condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing Time interval to reference test: nr
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Piccolo 2014
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection: September 2010 and
October 2013
Country: Italy
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Dermoscopically atypical pigmented
skin lesions selected from the archives of the
Dermatology Department at the University of L’Aquila,
Italy.
Setting: Secondary (general dermatology)
Prior testing: Not reported
Setting for prior testing: Not reported
Exclusion criteria: Location/site of lesion - acral sites
and the face
Sample size (patients): No. included: 165
Sample size (lesions): No. included: 165
Participant characteristics: Mean age 43.5 yrs (range
12 to 84 years); Male gender: 59.4%
Lesion characteristics: lesion site - upper extremities
18 (11%); lower extremities 53 (32.1%); 62 (37.5%)
on the back; 32 (19.4%) on the chest. Melanoma
thickness 87.9% (29/33) <0.75mm; 12.1% (4/33) >1.5
mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Was an adequate spectrum of cases used to train the algorithm?
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
1. Visual inspection (VI)
Method of diagnosis: 
Prior test data: 
Diagnostic threshold: 
Diagnosis based on: 
Number of examiners
Observer qualifications: 
Experience in practice: 
Experience with index test: 
2. Dermoscopy ABCD
Method of diagnosis: Dermoscopic images
Prior test data: No further information used
Diagnostic threshold: Semi-quantitative. Total dermoscopic score is calculated (TDS) - a PSL with a
TDS <4.75 benign, TDS 4.75 to 5.45 suspicious of malignancy, TDS >5.45 highly suggestive of
melanoma.
Diagnosis based on: Single observer (n=4)
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Index tests
Observer qualifications: 3 dermatologists and 1 GP with different degrees of dermoscopic experience
Experience in practice: Mixed
Experience with index test: Experience scored using following criteria: Following criteria assessed:
number of years specializing in dermoscopy (score: 1, 0-1 year; 2, 2-5 years; 3, >5 years); number of
pigmented skin lesions assessed by dermoscopy on a daily basis (1,<10 lesions/day; 2, 11-20 lesions;
3, 21-30 lesions; 4, >30 lesions); number of relevant workshops/ seminars attended (1, 0-1
workshops/seminars; 2, 2-5 workshops/seminars; 2, >5 workshops/seminars); and the number of
authored publications on dermoscopy (1, 0-1publications; 2, 2-5 publications; 3, 6-10 publications; 4,
>10 publications).
Observer 4 considered low experience (underwent dermoscopic training by studying an interactive
atlas of dermoscopy between T0 and T1); Observer 1 High experience /‘Expert’; Observers 2 and 3 );
moderately experienced
3. Computer Assisted Diagnosis - Dermoscopy based
Derm-CAD system: Nevuscreen ® (Arkè s.a.s., Avezzano, Italy) (classifier NR)
System details:
Digital database containing image analysis software, coupled to digital dermoscope. Nevuscreen
software automatically analyses ABCD features
No derivation aspect (external validation study)
Lesion characteristics assessed: 
–ABCD features. After image scanning, each pixel is classified in accordance with the main
dermoscopic colour to which it is closest. Once the different colour regions are identified, DDA can
also calculate asymmetry by considering the overall asymmetry parameter.**Differential dermoscopic
structures Pigment network, Globules, Streaks, Black dots and Structureless areas represent notable
criteria in dermoscopic evaluation. Various digital filters (median filters, essentially)are used to obtain a
morphological analysis for recognizing particles of various dimensions, which are subsequently
evaluated for size and shape and compared to numerous sample images. Once the different
structures have been recognized, their asymmetry is calculated as a contribution to the overall
asymmetry parameter
Additional predictors included: 
- Clinicians use CAD output to assist their diagnosis
Method of diagnosis: 
- In person diagnosis
- CAD-aided diagnosis
Prior/other test data: 
4 test operators 4
Operator qualifications: 
- GP
- Dermatologist
Experience in practice: 
- Mixed experience (low and high experience combined)
Experience with index test: 
- Mixed experience (low and high experience combined)
CAD output:
- TDS
Diagnostic threshold: 
-Total Dermoscopy Score: <4.75 benign, 4.75–5.45 suspicious, >5.45 highly suggestive of melanoma
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Low risk
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B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? No
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
Target condition (Final diagnoses) 
Melanoma (invasive): 23; Melanoma (in
situ): 10
Benign naevus: 105 Clark nevi; 19
Spitz/Reed nevi; 5 blue nevi; 3 dermal nevi.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Were the reference standard results likely to correctly classify the target
condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: reference test
conducted first not clear what the time interval
is between this and the current index test(s)
Time interval between index test(s): not clear-
looks like it was simultaneous
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Rubegni 2002
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection: 1996 to 2001
Country: Italy
Test set derived: NR "To train the SLP-ANN, 550
of the 588 available cases were used (30 nevi
and 200 melanomas in 550 sessions, each with
2 subsets); 549 cases were used for training,
and 1 case at a time was used to check
overfitting and stepwise feature selection. A third
small, independent subset consisting of the
other 17 melanomas and 21 nevi was used to
test SLP-ANN diagnostic performance on data
not used in the training process."
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Excised PSL, clinically atypical
(asymmetrical with variegated color), flat and
impalpable. All were difficult to diagnose and
therefore suitable for morphologic and parametric
evaluation of early melanoma.
Setting: Secondary (general dermatology)
Prior testing: Clinical suspicion of malignancy
without dermatoscopic suspicion; Selected for
excision (no further detail) Described as clinically
atypical and difficult to diagnose
Setting for prior testing: Secondary (general
dermatology)
Exclusion criteria: Difficult to diagnose lesions:
Location/site of lesion acral, lesion size only 0.4–1
cm in diameter were included; non-melanocytic
appearance pink skin lesions (amelanotic melanoma
and classical Spitz nevi); Blue nevi were excluded,
as were lentigo maligna, lentigo maligna melanoma
Sample size (patients): No. included: 588 included
(one per pt)
Sample size (lesions): No. eligible: 4200 PSL
excised; No. included: 588 included (38 in test set)
Participant characteristics: Mean age 49y (+/- 15y);
Male: 40% (of full sample; n=588); 100%
Pigmented.
Median Breslow 0.4 mm (157 invasive melanomas)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Was an adequate spectrum of cases used to train the algorithm? Yes
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
Computer Assisted Diagnosis - Dermoscopy based
Derm-CAD system: DB-Mips (Biomips Engineering, Italy) (ANN classifier)
System details:
Dermoscopy unit, internal stereomicroscope, internal DB, pattern analysis system. Lesions were
imaged by ELM at a magnification of 16 with the DBDermo-Mips apparatus.
Derivation study (internal validation)
Described in prior study Andreassi 1999
Lesion characteristics assessed: 
– Approach to feature selection: Computer-aided stepwise technique to choose the number of
discriminant features for optimum generalization.
The parameters, as previously described,19 belonged to 4 categories: geometries, colors, textures
and islands of color. Geometric: area, maximum and minimum* diameters, radius, variance of contour
symmetry, circularity*, fractality of borders and ellipsoidality. Color: mean values of red*, green and
blue inside the lesion; mean values of red, green* and blue of healthy skin around the lesion; deciles of
red*, green and blue inside the lesion; quartiles of red, green and blue* inside the lesion, mean skin-
lesion gradient*, variance of the border gradient, border homogeneity and interruptions of the border.
Texture: mean contrast* and entropy of lesion as well as contrast and entropy fractality. Islands of
color: peripheral dark regions*; dark area; imbalance of dark region; green area; red area; dominant
green region imbalance; blue-gray area; blue-gray regions; transition area*; transition region
imbalance*; background area*; background region imbalance*; red, green and blue multicomponent;
and number of red, green and blue percentiles inside the lesion.
Additional predictors included: 
- No further information used
Method of diagnosis: 
- Dermoscopic images
- CAD-based diagnosis
Prior/other test data: 
- None reported
CAD output:
- Diagnosis suggested (e.g. melanoma, benign melanocytic nevus)
Diagnostic threshold: 
- Threshold not reported
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Was the CAD model evaluated in an independent study population? Unclear
Was model overfitting accounted for during model development? Yes
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Histology (not further described) 
- Details: Histopathologic diagnosis of melanoma and
nevi was made according to the criteria of the NIH
Consensus Conference (1992). Histopathologic diagnosis
discordance was c9%. These were classified as
melanoma or nevi when at least 2 of 3 dermopathologists
agreed on the diagnosis.
No. patients/lesions: 588, 38 in test set
Disease positive: 17; Disease negative: 21
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 17
Benign diagnoses: 21 (not further specified)
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without
knowledge of the results of the index tests? Yes
Were the reference standard results likely to correctly classify the
target condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation
have introduced bias? Low risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Exclusions from analysis: None reported
Time interval to reference test: NR but
appears consecutive
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Seidenari 1998
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection NR; 4 year period
Country: Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Melanomas and benign pigmented
skin lesions from a larger series of pigmented skin
lesions used to develop a new automated classifier;
all melanomas with x20 magnification images were
included plus a random sample of benign lesions
with the same magnification. For the larger series,
lesions were referred by dermatologists or general
physicians because of one or more PSL that were
difficult to interpret on clinical grounds alone,
numerous PSLs, or because the patients were at
increased risk for melanoma or had had a malignant
PSL in the past.
Setting: Secondary
Prior testing: Clinical suspicion of malignancy
Setting for prior testing: Primary; Secondary
(general dermatology)
Exclusion criteria: None reported
Sample size (patients): Not reported
Sample size (lesions): No. eligible: 917; No.
included: 100
Participant characteristics: None reported
Lesion characteristics: Melanoma thickness: ≤1mm :
70.8% (n=46), <1 mm 58.5% (n=38). mean
thickness 0.73 ± 0.69 mm;
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Was an adequate spectrum of cases used to train the algorithm? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
1. Dermoscopy No algorithm
Method of diagnosis: Dermoscopic images; (obtained via videomicroscopy)
Prior test data: No further information used; "Images appeared in a random sequence on the computer
screen, and no information about the patient (such as history, skin site, age of the patient, evolution of
the lesion) was given to the evaluators"
Diagnostic threshold: Clinical diagnosis
Diagnosis based on: Single observer (n=2)
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with dermoscopy: Low - one 'untrained' dermatologist; High - one routinely used
videomicroscopy
Any other detail For instrumental examination a 10- (39 cases), 20- (501 cases), or 50-
fold–magnification (377 cases) was chosen according to the size of the lesion, enabling the whole
lesion to be seen on the monitor. For the study, the 31 MM with x20 magnification were selected plus a
random sample of 59 benign
2. Computer Assisted Diagnosis - Dermoscopy based
Derm-CAD system: DB–MIPS (Biomips Engineering, Italy) (Multivariate discriminant analysis
classifier)
System details: Digital videomicroscope equipped with a dedicated program for the diagnosis of
melanocytic PSL by evaluating digital features referring to benign and malignant PSL images. For this
study an NTSC VMS-110A videomicroscope (Scalar, Mitsubishi, Tama-shi, Tokyo, Japan) was used.
No derivation aspect (external validation study)
Lesion characteristics assessed: 
– Radius, area and perimeter of the lesion, symmetry and circularity, fractality (shape), texture
analysis, colour expressed as red, green and blue components, skin lesion gradient, 'dark areas'
inside the lesion. All described in detail.
Additional predictors included: 
- Unclear – For each patient personal data and information such as the site of the lesion, the
magnification , the clinical and the histological diagnosis were recorded. Unclear how these were used
Method of diagnosis: 
- Dermoscopic images
- CAD-based diagnosis
Prior/other test data: 
- Unclear, not reported
CAD output:
- Graphical output and numerical output of features provided. Diagnosis suggested (e.g. melanoma,
benign melanocytic nevus)
Diagnostic threshold: 
- Threshold not reported
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development? Yes
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
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Visual inspection
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?
If a threshold was used, was it pre-specified?
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias?
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication?
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question?
Dermoscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?
If a threshold was used, was it pre-specified?
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias?
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication?
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question?
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Details: describes using "conventional
histopathologic criteria."
Disease positive: 31; Disease negative: 59
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not reported): 31
'Benign' diagnoses: 59 "nonmelanoma cases
consisted of nevi including dysplastic nevi"
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Yes
Were the reference standard results likely to correctly classify the target
condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval:
Not described
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Seidenari 1999
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection: NR
Country: Italy
Test set derived: Not clearly reported but
appears that the training set was randomly
sampled, but the melanomas in the training set
were supplemented with images of lesions of
comparable size but thicker than 0.75 mm,
randomly selected from other melanoma images.
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Pigmented skin lesions with 20x
magnification images
Setting: Secondary (general dermatology) From
authors' institution
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Unspecified
Exclusion criteria: None reported
Sample size (patients): NR
Sample size (lesions): No. eligible: 461; No.
included: 383 in test set, 78 in train set
Participant characteristics: thickness ≤1mm: 18
(100%) <0.75 mm (eight in situ)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Was an adequate spectrum of cases used to train the algorithm? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
Computer Assisted Diagnosis - Dermoscopy based
Derm-CAD system: DB–MIPS (Biomips Engineering, Italy) (Multivariate discriminant analysis
classifier)
System details:
Dermoscopy unit, internal stereomicroscope, internal DB, DB–MIPS pattern analysis system –
integrated database stores the patient's data and the description of the lesion along with the image
icons. 38 features analysed (grouped into geometries, colours and Burroni's islands of colours).
Derivation study (internal validation)
Lesion characteristics assessed: 
– The borders of the lesion were automatically identified, plus estimation of radius, area and perimeter
of the lesion, symmetry and circularity, fractality (shape) , texture analysis, colour expressed as red,
green and blue components, skin lesion gradient, 'dark areas' inside the lesion. All described in detail
– Approach to feature selection DBDermo-MIPS software. Discriminant analysis enables the
identification of variables that are important for distinguishing between the groups in the training set in
order to develop a procedure for predicting group membership for new cases in which group
membership is undetermined (test set). Using the training set data, a threshold score was established
that enabled the attribution of each malignant lesion to the right group (100% sensitivity). The same
value was employed for discriminating benign and malignant lesions belonging to the test set.
Additional predictors included: 
- Unclear For each patient personal data and information such as the site of the lesion, the
magnification , the clinical and the histological diagnosis were recorded. Unclear how these were used
Method of diagnosis: 
- In person diagnosis
- CAD-based diagnosis
Prior/other test data: 
- Unclear
CAD output:
- NR
Diagnostic threshold: 
- Threshold not reported. Using the training set data, a threshold score was established that enabled
the attribution of each malignant lesion to the right group (100% sensitivity). The same value was
employed for discriminating benign and malignant lesions belonging to the test set.
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard 
- Histological diagnosis alone
Histology (not further described) 
- No. patients/lesions: 461 (383 in training set)
- Disease positive: 18
- Disease negative: 365
Target condition (Final diagnoses):
Melanoma: invasive 10, in situ 8
'Benign' diagnoses: 365 non-melanoma cases
consisted of benign naevi including common naevi
and clinically dysplastic naevi (> 5 mm in diameter,
irregular or ill-defined border, irregular pigmentation)
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Unclear
Were the reference standard results likely to correctly classify the
target condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Exclusions from analysis: None
Time interval to reference test: Not
reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Serrao 2006
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective
Period of data collection: September 2002 to
September 2005
Country: Portugal
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Melanocytic lesions from patients with multiple
atypical naevi, personal/familiar melanoma history or doubtful
cases on clinical inspection who were referred to a Dermoscopy
Unit
Setting: Specialist dermatoscopy unit (skin cancer/pigmented
lesions clinic)
Prior testing: Clinical suspicion of malignancy without
dermatoscopic suspicion. Mixed population; high risk and/or
clinically suspicious
Setting for prior testing: Secondary (general dermatology)
Exclusion criteria: Unequivocal appearance/diagnosis. All
clearly benign lesions by clinical examination were not referred
Sample size (patients): No. eligible: 1186; No. included: 344
Sample size (lesions): No. included: 652
Participant characteristics: Mean age 40 years (SD± 14), age
range: 11 to 84 years; 49% in the 35-64 age group, 33% aged
25 to 34 years old, 3% aged under 18; Male: 33% (114); High
risk characteristics: History of melanoma/skin cancer (%) 19%,
Family history of melanoma (%) 3%, 24% history of dysplastic
nevi; Lesion site: Trunk: back 56% chest 20%, Lower limbs/hip:
13%; Thickness/depth: ≤1mm: 29/41 plus 8 in situ; >1mm: 3
Are the included patients and chosen study setting
appropriate? No
Did the study avoid including participants with multiple
lesions? No
Was an adequate spectrum of cases used to train the
algorithm?
Are there concerns that the included patients and setting
do not match the review question? High
Index Test
Index tests
Computer Assisted Diagnosis - Dermoscopy based
Derm-CAD system: microDERM (Visiomed AG, Germany) (ANN classifier)
System details:
Dermoscopy unit with internal camera containing analysis system. DANAOS software combines
analytical system based on ABCD with database of 21,000 PSLs. The system has an integrated filter
that reduces influence of hairs in the analysis of lesions.
No derivation aspect (external validation study)
Described in prior study Fidalgo 2003
Lesion characteristics assessed: 
– lesions assessed for about 50 parameters (geometrical, colour and internal pattern)
Additional predictors included: 
- None reported
Method of diagnosis: 
- Dermoscopic images
- CAD-based diagnosis
Prior/other test data: 
- Unclear
CAD output:
- DANAOS score indicating risk of malignancy
Diagnostic threshold: 
- High risk DANAOS score (> 6.5); data also presented for score of >7.5
Computer-assisted diagnosis
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
Details: Criteria used for excision were:
· Dermoscopic suspicious lesions, irrespective
of the DANAOS score.
· All lesions with high risk DANAOS score (>
6.5)
· Significant dermoscopic or clinical
architectural change, irrespective of the
DANAOS score.
Disease positive 41; Disease negative 611
Target condition (Final diagnoses)
Melanoma: invasive 32; in situ 9
Benign diagnoses: 472 Benign naevus, 139
dysplastic naevus
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results likely to correctly classify the target
condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Exclusions from analysis: None
Time interval to reference test: Unclear;
CAD performed in advance of histology
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Sgouros 2014
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: 3 mo period; dates
not specified
Country: Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Pigmented skin tumours, clinically
suspicious for the diagnosis of melanoma, basal cell
carcinoma (BCC) or squamous cell carcinoma (SCC)
and the inability to establish a definite diagnosis on
clinical grounds only.
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: Clinical suspicion of malignancy without
dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: None reported
Sample size (patients): No. eligible: 180
Sample size (lesions): No. eligible: 188; No. included: 44
excised (authors included remaining 144 non-excised
lesions but these only received expert diagnosis with no
FU so not eligible for our review)
Participant characteristics: Mean age 43yrs (range: 2 to
95) (n = 188); Male: 97 (51.6%).
Are the included patients and chosen study setting appropriate? Yes
Did the study avoid including participants with multiple lesions? Yes
Was an adequate spectrum of cases used to train the algorithm?
Are there concerns that the included patients and setting do not
match the review question? Low concern
Index Test
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Index tests
Computer Assisted Diagnosis - Spectroscopy based
MSI-CAD system: SIAscope (MedX Health Corp, Canada) (classifier NR)
System details:
Spectrophotometric imaging system with hand–held skin probe (SIAscope, version NR) and integrated
software
No derivation aspect (external validation study)
Derivation described in prior study Moncrieff 2002
Lesion characteristics assessed: 
Analysis of dermal melanin, erythematous blush, lesion asymmetry, collagen 'holes', blood commas, or
irregularities in the collagen
Additional predictors included: 
- None
Method of diagnosis: 
- In person diagnosis
- CAD-based diagnosis
Prior/other test data: 
- Clinical examination and/or case notes
- Dermoscopy
CAD output:
- SIAgraph and PCSA (see below)
Diagnostic threshold: 
- Primary care scoring algorithm (PCSA) (Emery 2010); score >= 6 regarded as suspicious.
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Histology (excision) 
No. patient/lesions: 44
Disease positive: 31; Disease negative: 13
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 18
BCC: 10, cSCC: 3
'Benign' diagnoses: 14
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Unclear
Were the reference standard results likely to correctly classify the target
condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: 144 with only expert
final diagnosis (excluded by Review team)
Time interval between index test(s): Appears
consecutive
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Stanganelli 2005
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection /
Prospective interpretation **Dataset previously
used in Stanganelli 2000
Period of data collection NR
Country Italy
Test set derived A training set of 22 melanomas
and 218 melanocytic nevi was randomised from
the dataset. The test set was formed by the
complement (the remaining 20 melanomas and
217 nevi). A further subset of images from the
original dataset, consisting of 31 melanomas
and 103 nevi, was used for the comparison
between observers and CAD; derivation of the
subset not reported.
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Unclear
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Melanocytic lesions from patients
referred to the Skin Cancer Unit and undergoing clinical
and dermoscopic evaluation.
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: None reported
Sample size (patients): No. eligible: 1556 referred / No.
included: NR
Sample size (lesions): No. eligible: 3274 / No. included:
477 melanocytic lesions; 237 in test set and 134 in
comparison between CAD and human operators
Participant characteristics: None reported
Lesion characteristics: Melanoma thickness 61.2%
<0.75mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Was an adequate spectrum of cases used to train the algorithm? Unclear
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Computer Assisted Diagnosis - Dermoscopy based
Derm-CAD system: DB–MIPS (Biomips Engineering, Italy) (SVM classifier)
System details:
Dermoscopy unit, internal steromicroscope, internal DB, pattern analysis system. Automatic Data
Analysis for Melanoma early detection (ADAM) software which analyses boundary shape, texture and
colour distribution
Derivation study (internal validation)
see also Stanganelli 1995 and Stanganelli 2000
Lesion characteristics assessed: 
– (ADAM) software is based on a quite recent mathematical technique of shape representation: the
Size Functions. "These are very general invariants designed to capture, in a formal and quantitative
way, the essential behaviour of some specified aspects (the so called measuring functions) of a signal
(27, 28). In the present case, the examined signal is the image of a melanocytic lesion, and the
aspects concerned are: boundary shape, texture and color distribution. Size Functions are
standardized objects, easy to compute, to store and to compare. So the study is performed on the Size
Function instead of the original image. Thisyields a great simplification and, above all, a greatly
focussed analysis. The Size Function obtained from a curve with the distance from point C as
measuring function is shown in Figure 1"
Additional predictors included: 
- No further information used
Method of diagnosis: 
- Dermoscopy images
- CAD-based diagnosis
Prior/other test data: 
- None reported
CAD output:
- Low risk, intermediate risk or high risk of melanoma
Diagnostic threshold: 
- Threshold not reported
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
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B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
plus cancer registry
All included lesions underwent histology but
some were identified using a cancer-
registry-based follow-up of benign
diagnoses.
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not
reported): 42 in full sample; 31 in CAD vs
human observer interp and 20 in test set
'Benign' diagnoses: 435 melanocytic nevi;
103 in CAD-observer comp and 217 in test
set
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Were the reference standard results likely to correctly classify the target
condition (disease negative)? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Unclear
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Exclusions from analysis: None
Time interval to reference test: Not
reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? High risk
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Notes
Notes  
Terstappen 2013
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Not reported
Period of data collection: NR
Country: Sweden
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Study inclusion criteria Lesions
clinically suspicious for melanoma and showing
positive SIAscopic findings
Setting: Secondary (general dermatology) (details
from Authors' institution)
Prior testing: Clinical suspicion of malignancy
without dermatoscopic suspicion, showing positive
SIAscopic findings
Setting for prior testing: Secondary (general
dermatology)
Exclusion criteria: Poor quality index test image: 9
lesions excluded due to technical problems
Sample size (patients): No. eligible: 69; No.
included: 60
Sample size (lesions): No. eligible: 69; No. included:
60
Participant characteristics: ≤1mm thickness: 17/29
melanomas; 8/29 melanomas Breslow thickness
<0.76 mm (Clark II-III) and 9/29 Breslow thickness
0.76− ≤ 1.0 mm (Clark II-III) and 12 lesions Breslow
thickness ≥1.1 (Clark III-V).
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Was an adequate spectrum of cases used to train the algorithm?
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
Computer Assisted Diagnosis - Spectroscopy based
MSI-CAD system: SIAscope (Astron Clinica, UK) (classifier NR)
System details:
Spectrophotometric imaging system with hand–held skin probe (SIAscope V) and integrated software
(Dermetrics Version 2.0, Astron Clinica Ltd., Great Britain).
No derivation aspect (external validation study)
Lesion characteristics assessed: 
– Dermal melanin, blood displacement, collagen holes, erythematous blush
Additional predictors included: 
- No further information used
Method of diagnosis: 
- In person spectroscopic images (SIAgraphs)
- CAD-based diagnosis
Prior/other test data: 
- None reported
CAD output:
The instrument generates four images depicting the concentration of haemoglobin, melanin, collagen
and dermal melanin.
Diagnostic threshold: 
- "SIAscopic findings indicating melanoma were applied using the method described by Moncrieff
(2002)" Results described for: "the combined features (presence of blood displacement with
erythematous blush, collagen holes and presence of dermal melanin)" NB Moncrieff 2002 is a
derivation study for SIAscope and suggests a number of combinations of features indicative of
melanoma, the same features investigated here
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard: Histological diagnosis alone
Details: The excised specimens were routinely
processed and the histological sections, 4 μm thick,
were stained with haematoxylin and eosin. Before
cutting the specimen in slices, the lesion was oriented
and the positions of the SIAscopic areas of interest
were outlined by comparisons with the overview
clinical photo of the lesion
No. patients/lesions: 60
Disease positive: 29; Disease negative: 31
Target condition (Final diagnoses)
Melanoma: invasive 29, in situ 13 (included as D-)
BCC: 2
Benign diagnoses: 2 Sebhorrheic keratosis; 4
melanocytic lesions; 10 dysplastic naevi
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? No
Were the reference standard results likely to correctly classify the
target condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? High risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Exclusions from analysis: 9/69 lesions (2
invasive melanoma, two melanoma in situ,
and five benign lesions) had to be
excluded due to technical problems.
Time interval to reference test: Not
reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? High risk
Notes
Notes  
Tomatis 2003
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection: Jan 1995 to Mar 2000
(test set Apr 1999 to Mar 2000)
Country: Italy
Test set derived: Chronological; acquired in last
year of recruitment. Study population not
randomised (training set enriched with
melanomas)
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Cutaneous pigmented lesions that
required a surgical biopsy for diagnosis
Setting: Specialist unit (skin cancer/pigmented lesions
clinic) tumour institute of milan
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Unspecified
Exclusion criteria: "Difficult to diagnose" lesions, thick
and/or large melanomas and awkwardly situated lesions.
like those placed at the interdigital spaces, on ears,
nose, eyelids, etc.; lesions on the scalp due to hair
interference;
Sample size (patients): No. eligible NR; No. included:
534
Sample size (lesions): No. eligible NR; No. included: 573
Participant characteristics: Median age 36 y (range
10-95y); 59.7% Male; thickness ≤1mm: 91/132 MM
(68.9%); thickness 0.16 to 3.24 mm. Median Breslow
0.68mm; Mean diameter: 10mm (range 3 to 39mm)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Was an adequate spectrum of cases used to train the algorithm? Yes
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Computer Assisted Diagnosis - Spectroscopy based
MSI-CAD system: Telespectrophotometric system (ANN classifier; Linear discriminant classifier also
trained and reported, ANN selected at random for review)
System details:
Digital camera coupled with an illumination system with interference filters and computer for storage
and analysis of multispectral images. The Telespectrophotometric System consists of a CCD camera,
a set of 17 interference filters. a PC. and an illumination system composed by two halogen ( 2 X 100
W) and two lamps (2X 150 W) with emission in the infrared region .
Derivation study (internal validation)
The train set is required for the instruction of the classifiers whose diagnostic performances are
evaluated against an independent verify set. the considerable fraction of cases devoted to the
classifier training was selected to include an adequate number of positives
Derivation described in prior studies Marchesini 1995, Tomatis 1998, Furina 2000
Lesion characteristics assessed: 
– For each spectral image, five parameters (lesion descriptors) based on ABCD and related to colour
and shape of the imaged lesion were evaluated: mean reflectance, variegation index, roundness,
border irregularity.
Additional predictors included: 
- No further information used
Method of diagnosis: 
- Spectroscopic images
- CAD-based diagnosis
Prior/other test data: 
- None reported
CAD output:
- NR
Diagnostic threshold: 
- Threshold selected by authors using ROC analysis. No further information provided
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Was the CAD model evaluated in an independent study population? No
Was model overfitting accounted for during model development? Yes
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner?
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard 
- Histological diagnosis alone
Histology (not further described) 
- No. patients/lesions: 573 (210 in test set)
- Disease positive: 132 (37 in test set)
- Disease negative: 441 (136 in test set)
Target condition (Final diagnoses)
- Melanoma (in situ and invasive, or not reported): 37
(test set)
- 'Benign' diagnoses: 136 (test set)
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Yes
Were the reference standard results likely to correctly classify the
target condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Exclusions from analysis: None
Time interval to reference test: Appears
consecutive: 'images acquired in vivo before
surgey'. Interval not reported.
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Tomatis 2005
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: September 2002
to April 2004
Country: Italy
Test set derived: The study population was
split into three sets: train, verify and test.
The cases were randomly assigned to the
above sets among all the 1391 lesions with
histology.
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Study inclusion criteria Cutaneous
pigmented lesions with clinical and/or dermoscopicfeatures
that supported a suspicion for cutaneous melanoma and
therefore eligible for excision. A further of lesions all
diagnosed as clearly benign common nevi at both clinical and
dermoscopic evaluations that did not undergo excision, data
for these have not been included as >50% of benign group
must undergo histology or active follow-up.
Setting: Specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: Difficult to diagnose lesions, Poor quality
index test image incorrectly acquired or not correctly
segmented by the system
Sample size (patients): No. eligible: 1359 patients
Sample size (lesions): No. eligible: 1485; No. included: 1391
excised [94 excluded: lesions out of focus, 46 cases, 3%, or
system failure to correctly segment the lesion border (48
cases, 3%)].
Participant characteristics: Median age 36y (range 5 to 88y);
Male: 597 (43.9% of 1359); Pigmented (%): 100%; Located
on: Head/Neck: 2.9%, Trunk: 66.2%, Upper limbs/shoulder:
9.1%, Lower limbs/hip: 17%, Limbs: 4.8%
Thickness/depth: ≤1mm: 140/164 (85%) invasive MM;
median thickness 0.58 mm, (0.1 mm to 2.7 mm), for 164
invasive MM. Median size: 9 mm in maximum diameter; <=6
mm in 44 cases (24%).
Are the included patients and chosen study setting
appropriate? No
Did the study avoid including participants with multiple
lesions? No
Was an adequate spectrum of cases used to train the
algorithm? Yes
Are there concerns that the included patients and setting do
not match the review question? High
Index Test
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Index tests
Computer Assisted Diagnosis - Spectroscopy based
MSI-CAD system: SpectroShade (MHT, Verona, Italy) (ANN classifier)
System details:
Illumination assembly located inside a PC and an external detection device placed in a hand-held
probe, with integrated image analysis software
Derivation study (internal validation)
The train group (696 cases, including 90 melanomas) was used to optimize the inner fitting weights of
the neural network by means of a training algorithm. The verify set (348 cases, including 53
melanomas) was used to properly stop the training process preventing the so-called overlearning, i.e.,
a drop in the generalization capabilities of the classifier which would otherwise fit the noise pattern of
the data instead of defining a proper boundary between malignant and benign moles. The test set (347
cases, including 41 melanomas) was used to confirm, by independent data, the discrimination
performances of the system as obtained from the previous data sets.
Also described in prior studies Marchesini et al 1995, Tomatis et al 1998, 2003
Lesion characteristics assessed: 
– Features analysed: (i) reflectance (R); (ii) variegation (V); (iii) area (A); (iv) dark area ratio (DAR); (v)
dark island reflectance (DIR); (vi) dark distribution factor (DDF); (vii) dark permanence (D PER)
Additional predictors included: 
- No further information used
Method of diagnosis: 
- Spectroscopic images
- CAD-based diagnosis
Prior/other test data: 
- No further information used
CAD output:
- NR
Diagnostic threshold: 
- Threshold set to produce sensitivity of 80%
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development? Yes
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
#164a Computer assisted diagnosis techniques (dermoscopy and spectroscopy-based) for the diagnosis of skin cancer...
145 / 268
A. Risk of Bias
Target condition and reference standard(s)
Reference standard 
- Histological diagnosis alone Data provided for
subgroup (test set) that all underwent excision
Histology (not further described) 
- No. patients/lesions: 1391 (347 in test set)
- Disease positive: 184 (41 in test set)
- Disease negative: 1207 (306 in test set)
Target Condition (Final diagnoses)
Melanoma (invasive): 164 (full sample, number in test
set NR)
- Melanoma (in situ): 20 (full sample, number in test
set NR)
- Melanoma (in situ and invasive, or not reported): 41
(test set only)
- BCC: 7 (full sample, number in test set NR)
- Sebhorrheic keratosis: 27 (full sample, number in
test set NR)
- 'Benign' diagnoses: 280 dysplastic naevus, rest
various benign (893)
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Yes
Were the reference standard results likely to correctly classify the
target condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Time interval to reference test: Not
reported "Before surgery, images of the
1485 pigmented lesions were acquired in
vivo."
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Walter 2012
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Randomised controlled trial, only
experimental group included
Data collection: Prospective
Period of data collection March 2008 to May
2010
Country UK
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Adults with any suspicious
pigmented skin lesion, i.e. any lesion presented by a
patient, or opportunistically seen by a family doctor or
practice nurse, that could not immediately be
diagnosed as benign and about which the patient
could not be reassured.
Setting: Primary 15 general practices in eastern
England
Prior testing: Clinical suspicion of malignancy without
dermatoscopic suspicion
Setting for prior testing: Primary
Exclusion criteria: Those unable to give informed
consent or considered inappropriate to include by
their family doctor.
Sample size (patients): No. eligible: 1297; No.
included: 1293 in RCT, 643 in experimental group
Sample size (lesions): No. eligible: 1580; No.
included: 1583 in RCT, 788 in experimental group
Participant characteristics (whole population): Mean
age: 44.6y (SD 16.8). Male: 465 (36%). Ethnicity:
White 1214 (93.9%); Mixed 45 (3.5%); Missing: 34
(2.6%)
Lesion characteristics. Lesion thickness ≤1mm: in
'more than half' of MM
Are the included patients and chosen study setting appropriate? Yes
Did the study avoid including participants with multiple lesions? No
Was an adequate spectrum of cases used to train the algorithm?
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Computer Assisted Diagnosis - Spectroscopy based
MSI-CAD system: SIAscope + MoleMate (classifier NR)
System details:
SIAscopy with MoleMate (software image management system) viewing platform and integrated
primary care scoring algorithm
No derivation aspect (external validation study)
Lesion characteristics assessed: 
– Lesion characteristics not described
Additional predictors included: 
- None reported
Method of diagnosis: 
- In person diagnosis, spectroscopic images (SIAgraphs)
- CAD-aided diagnosis
Prior/other test data: 
- Clinical history and naked eye examination
Operators: 28 clinicians
Operator qualifications: 
- GP
- Other (describe) 2 nurse practitioners
Experience in practice: 
- Mixed experience (low and high experience combined) as previously recorded
Experience with index test: 
- Low experience / novice users
CAD output:
- SIAgraphs and Lesion score using Primary Care Scoring Algorithm
Diagnostic threshold:
Primary Care Scoring Algorithm (6 or more points regarded as suspicious)
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Low risk
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B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
plus FU and Epxert opinion
Histology (not further described) 215
(histology result missing in further 4)
Disease positive: 35; Disease negative: 180
Clinical FU plus histology of suspicious
lesions: 22 of the 411 referred patients were
monitored (not further described); 566 of the
1162 not referred underwent expert review
and were then re-assessed at 3-6 months
Disease positive: 1; Disease negative: 588
Expert opinion. Reviewed by two dermatology
experts using the recorded clinical history and
examination, a digital photograph, and
MoleMate image where available.
Disease positive: 0; Disease negative: 725
Target condition (Final diagnoses) 
Melanoma (invasive): 30; Melanoma (in situ):
6; BCC: 10
'Benign' diagnoses: 1306
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? No
Were the reference standard results likely to correctly classify the target
condition (disease negative)? No
Could the reference standard, its conduct, or its interpretation have
introduced bias? High risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? No
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? High
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: 417 withdrew from control
group after randomisation - 10 did not attend for
dermatology assessment; 19 excluded; 1 died; 4
missing histology (in referred group; included as
benign?); plus 12 with unknown outcome (in non-
referred group, assumed benign and included)
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? No
Could the patient flow have introduced bias? High risk
Notes
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Notes  
Wells 2012
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective - MelaFind
diagnoses from acquisition study were used
Retrospective image selection / Prospective
interpretation - Clinical and dermoscopic images
Period of data collection NR
Country US
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Pigmented lesions cases selected
from a repository of lesions amassed during an
acquisition study conducted by MELA Sciences Inc
for the US Food and Drug Administration
Setting: Company database (MELA Sciences Inc) of
lesion images amassed during an acquisition study
for the FDA
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): NR
Sample size (lesions): No. eligible NR; No. included:
47
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Was an adequate spectrum of cases used to train the algorithm?
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
1. Dermoscopy No algorithm
Method of diagnosis: Dermoscopic images
Prior test data: Clinical images and detailed clinical history
Diagnostic threshold: Not reported; Decision to biopsy the lesion / Melanoma or not
Diagnosis based on: Average (n=39)
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with index test: Not described
2. Computer Assisted Diagnosis - Spectroscopy based
MSI-CAD system: MelaFind (EO Sciences, USA) (classifier NR)
System details:
Multispectral imaging system with integrated image analysis software; device takes images in vivo
No derivation aspect (external validation study)
Described in prior study Monheit 2011
Lesion characteristics assessed: 
– NR
Additional predictors included: 
- None reported
Method of diagnosis: 
- In person diagnosis
- CAD-based diagnosis
Prior/other test data: 
- Unclear
CAD output:
- Binary output: (1) positive, (lesion should be considered for biopsy to rule out melanoma); and
(2) negative (lesion should be considered for later evaluation)
Diagnostic threshold: 
- Threshold not reported
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
Disease positive: 23 / Disease negative: 24
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not
reported): 23
'Benign' diagnoses: 24
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Were the reference standard results likely to correctly classify the target
condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Exclusions from analysis: None
Time interval to reference test: NR;
Images taken prior to biopsy
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Winkelmann 2016
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection not reported
Country Not reported
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Images of pigmented skin lesions
previously analysed by a digital classifier MSDSLA;
method of selection of the 12 not reported
Setting: Dermoscopy conference
Prior testing: Not reported
Setting for prior testing: Unspecified
Exclusion criteria: None reported
Sample size (patients): NR
Sample size (lesions): No. eligible No. included: 12
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Was an adequate spectrum of cases used to train the algorithm?
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
1. Visual inspection (VI) No algorithm
Method of diagnosis: Clinical photographs
Prior test data: Unclear
Diagnostic threshold: Not reported - biopsy decision
Diagnosis based on: Average (n=70)
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with index test: Not described
Other detail: Any other detail practitioners with a particular interest in skin cancer or technology may
have chosen to attend this conference and/or self-selected to take part in the study.
2. Dermoscopy No algorithm
Method of diagnosis: dermoscopic images
Prior test data: clinical images
Diagnostic threshold: Not reported - biopsy decision
Test observers as described for Visual Inspection (above)
3. Computer Assisted Diagnosis - Spectroscopy based
MSI-CAD system: MelaFind (EO Sciences, USA) (Logistic regression classifier)
System details:
Multispectral imaging system with integrated image analysis software; device takes images in vivo
No derivation aspect (reader study)
Lesion characteristics assessed: 
– NR
Additional predictors included: 
- None
Method of diagnosis: 
- Spectroscopic images
- CAD-aided diagnosis
Prior/other test data: 
- clinical and dermoscopic images
CAD output:
Binary output: (1) positive, (lesion should be considered for biopsy to rule out melanoma); and
(2) negative (lesion should be considered for later evaluation)
Diagnostic threshold: 
- Threshold not reported
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Unclear
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Visual inspection
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
Was the CAD model evaluated in an independent study population?
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study?
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Disease positive: 5 / Disease negative: 7
Target condition (Final diagnoses) 
Melanoma (invasive): 3 / Melanoma (in situ): 2
Mild/moderate dysplasia: 7 low grade dysplastic
nevi
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Were the reference standard results likely to correctly classify the target
condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Unclear
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Exclusions from analysis: None
Time interval to reference test: Not
reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Unclear
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Wollina 2007
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Not reported
Period of data collection: Jan 2003 to Oct
2004
Country: Germany (Dresden); Switzerland
(Locarno and Lugarno)
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Pigmented skin lesions
Setting: Secondary (general dermatology) Dept
Dermatology, Dresden; Primary (private clinic), Locarno
and Lugano
Prior testing: 
- No prior testing Lugano and Locarno (described as
representing 'a sort of first-screening check)
- Clinical and/or dermatoscopic suspicion Dresden
(described as having many patients referred for a
second level control)
Setting for prior testing: Unspecified
Exclusion criteria: None reported
Sample size (patients): No. eligible: 1308, No. included:
NR
Sample size (lesions): No. eligible: 3541, No. included:
466
Participant characteristics: Male: 566; 43.2% (full
sample)
Thickness/depth: ≤1mm: 38 (incl 8 in situ) Dresden: 22
(incl 4 in situ) Locarno: 7 (incl 2 in situ)Lugano 9 (incl 2
in situ)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Was an adequate spectrum of cases used to train the algorithm?
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Computer Assisted Diagnosis - Dermoscopy based
Derm-CAD system: DB-MIPs (Biomips Engineering, Italy) (Euclidian distances classifier)
System details:
Dermoscopy unit, internal steromicroscope, internal DB, pattern analysis system. DDA software
analysis – analyses 50 parameters subdivided into three categories, i.e. geometries, colours, and
textures and islands of colours (Burroni islands)
No derivation aspect (external validation study)
Lesion characteristics assessed: 
– characteristics included 35 variables including: variance of symmetry, maximum diameter, border’s
gradient, skin red average, red average, red tenth, unbalance, dark areas towards periphery,
dishomogeneity, blue dominant, transition, unbalance of transition
Additional predictors included: 
- No further information used
Method of diagnosis: 
- in person diagnosis
- CAD-aided diagnosis
Operator qualifications: 
- Not reported
Experience in practice: 
- Not described
Experience with index test: 
- Not described. States that test operators do not need a special training
Prior/other test data: 
- CAD used as part of clinical analysis
CAD output:
- Not specified
Diagnostic threshold: 
- The automated diagnosis was run at similprob=45 and similprob=75 thresholds, the latter being more
sensitive but less specific. Similprob=75 threshold selected at random for review.
Computer-assisted diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Was the CAD model evaluated in an independent study population? Yes
Was model overfitting accounted for during model development?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Was the diagnostic threshold to determine presence or absence of disease established in a previously published
study? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard 
- Histological diagnosis alone Unclear whether data
relate to compariaon with histology alone or to whoel
set of lesions, in which case the reference standard is
not reported for the majority of benign lesions
although the 'decision to follow-up' is mentioned
Histology (not further described) 
- No. patients/lesions: 466
- Disease positive: 52 (incl 8 in situ)
- Disease negative: Either 414 or 3489
Target condition (Final diagnoses)
- Melanoma (invasive): 44
- Melanoma (in situ): 8
- 'Benign' diagnoses: 414
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Unclear
Were the reference standard results likely to correctly classify the
target condition (disease negative)? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Was the use of expert opinion (with no histological confirmation) avoided as the reference standard? Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Exclusions from analysis: None
Time interval to reference test: CAD performed
during clinical diagnosis, before histopathology.
Interval to surgery not reported.
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Footnotes
Included studies: Two quality assessment items could not be evaluated for all studies, and so were left blank:
Patient Selection: Concerns regarding applicability: “Was an adequate spectrum of cases used to train the algorithm?
(training set)” (Could only be answered if the study included a derivation aspect)CAD Risk of Bias: "Was model overfitting
accounted for during model development?" (Could only be answered if the study included a derivation aspect)
Index test - CAD: Concerns regarding applicability: "Was the test interpretation carried out by an experienced examiner?
(Could only be answered if the study gave computer generated CAD results to clinicians to make a diagnosis [CAD–aided
diagnosis])"
Characteristics of excluded studies 
Abbas 2010
Reason for exclusion EXCLUDE on target condition
border detection not diagnosis
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Abbas 2011a
Reason for exclusion • EXCLUDE on index test
test used to determine border
• EXCLUDE if derivation study
 
Abbas 2011b
Reason for exclusion EXCLUDE on target condition
border detection not diagnosis
 
Abbas 2012
Reason for exclusion EXCLUDE if derivation study
Reports training on 20% and testing on 80% of images but results presented only for
whole dataset
• EXCLUDE but contact authors
Reports training on 20% and testing on 80% of images but results presented only for
whole dataset. Author responded - cannot help
 
Abbas 2013a
Reason for exclusion EXCLUDE on target condition
border detection not diagnosis
 
Abbas 2013b
Reason for exclusion EXCLUDE if individual lesion characteristics
seems to focus on border detection 
• EXCLUDE if derivation study
 
Abuzaghleh 2015
Reason for exclusion EXCLUDE if derivation study
• EXCLUDE but contact authors
In the experiments, 75% of the database images are used for training and 25% are
used for testing. No breakdown of D+/D- in the test set, cannot back calculate from the
sensitivity and specificity values given
 
Afonso 2012
Reason for exclusion • EXCLUDE on index test
Not used to differentiate malignant from benign lesions
 
Alfed 2015
Reason for exclusion • EXCLUDE if derivation study
no independent test set used 
 
Ali 2012
Reason for exclusion • EXCLUDE not a primary study
 
Altamura 2008
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Reason for exclusion EXCLUDE on index test
study of optimal surveillance/appropriate follow-up times not initial diagnosis
 
Andreassi 1999
Reason for exclusion EXCLUDE if derivation study
I think derivation? Uses jack knife validation
 
Armengol 2011
Reason for exclusion • EXCLUDE on index test
• EXCLUDE if derivation study
 
Arroyo 2011
Reason for exclusion EXCLUDE if individual lesion characteristics
• EXCLUDE if derivation study
 
Ballerini 2012
Reason for exclusion EXCLUDE on target condition
D+ includes AK
 
Barata 2012a
Reason for exclusion EXCLUDE if derivation study
 
Barata 2012b
Reason for exclusion EXCLUDE if derivation study
 
Barata 2013
Reason for exclusion EXCLUDE if derivation study
 
Barata 2015a
Reason for exclusion EXCLUDE if derivation study
USes LOO procedure
 
Barata 2015b
Reason for exclusion EXCLUDE if derivation study
uses 10-fold classification
 
Barata 2015c
Reason for exclusion EXCLUDE if derivation study
uses 10-fold classification
 
Binder 2000
Reason for exclusion • EXCLUDE if derivation study
no independent test set
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Bjerring 2001
Reason for exclusion • EXCLUDE not a primary study
leaflet
 
Blum 2004
Reason for exclusion EXCLUDE overlapping sudy population (Blum 2004b)
 
Boden 2013
Reason for exclusion EXCLUDE if derivation study
uses leave-one-out method; no independent test set 
 
Bono 1999
Reason for exclusion EXCLUDE if derivation study
• EXCLUDE on 2x2 data
LFR: not a test accuracy study
 
Borlu 2008
Reason for exclusion EXCLDUE not a primary study - not test accuracy; no patient data in this study
 
Brown 2000
Reason for exclusion EXCLUDE not a primary study
systematic review 
• systematic review
 
Carrara 2007
Reason for exclusion • EXCLUDE on reference standard
<50% benign lesions had histology or clinical follow-up
 
Celebi 2008
Reason for exclusion EXCLUDE if derivation study
this is a derivation study. From what I can deduce it seems like they used a sample of
100 images as a training set and test set. They then used the outcome of this to test
out the technique on all the 545 images from the study sample. Their outcome is
recorded as: "The performance of this decision tree on the entire image set (545
images) was a sensitivity of 69.35% and a specificity of 89.97%." 
 
Chen 2003
Reason for exclusion EXCLUDE if individual lesion characteristics
investigates colour only
• EXCLUDE if derivation study
• EXCLUDE on 2x2 data
 
Cheng 2012
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Reason for exclusion EXCLUDE if individual lesion characteristics
only telengiectasia used to evaluate whether a BCC or not. No other characteristics
are evaluated
• EXCLUDE if derivation study
 
Cheng 2013
Reason for exclusion EXCLUDE if derivation study
• EXCLUDE on 2x2 data
 
Christensen 2010
Reason for exclusion EXCLUDE if derivation study
 
Claridge 1992
Reason for exclusion EXCLUDE if individual lesion characteristics
appears to be looking at the shape of the lesion
 
Cukras 2013
Reason for exclusion EXCLUDE not a primary study
 
Day 2001
Reason for exclusion • EXCLUDE on reference standard
16/73 excised; 9 were melanoma
 
Debeir 1999
Reason for exclusion • EXCLUDE if derivation study
 
Di 2010
Reason for exclusion EXCLUDE if derivation study
primarily derivations study with small paragraph on a validation study; limited details
given 
• EXCLUDE on 2x2 data
se/sp given for validation study for individual characteristics but not for overall se/sp of
the system. [**could contact authors]
• EXCLUDE but contact authors
For the test database of 200 images do you have se/sp or 2x2 for the overall aability of
the classifier to detect melanoma? Table 2 provides data for indivudal lesoin
characteristcis only
 
Ding 2015
Reason for exclusion EXCLUDE if derivation study
uses leave one out technique
 
Dreiseitl 2005
Reason for exclusion EXCLUDE on index test
not test accuracy and the CDSS recommendations were simulated
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Durg 1993
Reason for exclusion EXCLUDE on target condition
detection of variegated colouring
 
Elbaum 2001
Reason for exclusion • EXCLUDE if derivation study
uses LOO procedure
 
Emery 2010
Reason for exclusion • EXCLUDE on reference standard
only 111/1211 lesions were excised and the others did not have any reported follow-
up. 
 
Engin 2016
Reason for exclusion • EXCLUDE on sample size
• EXCLUDE on reference standard
 
Ercal 1994
Reason for exclusion EXCLUDE if derivation study
 
Faal 2013
Reason for exclusion EXCLUDE if derivation study
The 436 images were split into 60% training and 40% test sets. They combined the
results of the training and tests sets as an average of the performace of the test, no
breakdown of the classifer rate according to the test and training images. 
 
Farina 2000
Reason for exclusion EXCLUDE if derivation study - no test set
 
Ferris 2016
Reason for exclusion EXCLUDE not a primary study
 
Fidalgo 2003
Reason for exclusion EXCLUDE on 2x2 data
• EXCLUDE duplicate or related publication
Appears to be superseded by Serrao 2006
• EXCLUDE but contact authors
Paper provides % of MM and of DN with DNAOS scores of >=5.5 and >7, is it possible
for you to provide the same information for the remaining 127 lesions in the study?
Also can you advise as to whether any of the 247 lesions included in this study overlap
with the 652 reported in Serrao 2006 (#1144)? 
 
Fikrle 2007
Reason for exclusion EXCLUDE on reference standard
follow up study need >=50% of participants to have their lesion excised. 
 
Fikrle 2013
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Reason for exclusion • EXCLUDE on reference standard
Follow up study <50% of study participants have their final diagnosis reached by
histopathology.
 
Fruhauf 2012
Reason for exclusion EXCLUDE on reference standard
35/219 underwent histology; 13 followed-up; 171 expert clinical Dx
 
Fueyo-Casado 2009
Reason for exclusion EXCLUDE on reference standard
<50% of the study population recieved histology as a test. No information given on
those who were followed up. 
 
Ganster 2001
Reason for exclusion EXCLUDE if derivation study
Use leave one out methods for cross validation Seem like they have a "test set" for the
automated diagnosis but it is not clear whether data given in table 1 incorporates data
from the training set as well. It is likely that there is some crossover. 
 
Garcia 2014
Reason for exclusion EXCLUDE on target condition
test aims to detect presence of pigment network, is not an evaluation of detection of
MM
 
Garcia-Uribe 2004
Reason for exclusion • EXCLUDE on index test
reflectance spectrometry/spectroscopy
• EXCLUDE if derivation study
*[very difficult to classify given mention of training/test sets of images, however all
images appear to have come from same sample of lesions, all of which were used to
develop the classifiers. Even though new images were obtained from same lesions, I
still think this is derivation] 
 
Garcia-Uribe 2010
Reason for exclusion • EXCLUDE on 2x2 data
only give the values for sensitivity and specificity but do not give a breakdown of D+/D-
numbers in the test set so not able to populate the 2x2 table. 
• EXCLUDE but contact authors
Paper provides sensitivity and specificity for the test set but does not give a
breakdown of numbers D+/D- to allow us to populate the 2x2 table.
 
Garnavi 2012
Reason for exclusion EXCLUDE on reference standard
not properly defined the reference standard, it could be the images were sampled from
a database of histopathologically diagnosed lesions but this is not very clear from the
paper
 
Gerger 2003
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Reason for exclusion EXCLUDE on reference standard
no reference standard in 133 nevi, unclear whether these were in the test set. Training
sets (n=2) and test set must overlap as total number of lesions (n=423) add up to more
than total included lesions (n=136).
 
Glotsos 2015
Reason for exclusion EXCLUDE if derivation study
uses LOO procedure
 
Gniadecka 2004
Reason for exclusion • EXCLUDE on index test
Raman spectroscopy
• EXCLUDE if derivation study
Seems like a derivation study; although methods do report use of a 'test set', this is not
further described 
• EXCLUDE on 2x2 data
 
Govindan 2007
Reason for exclusion • EXCLUDE on reference standard
"Six hundred and twenty seven (71%) lesions were diagnosed as benign and were
discharged from the PLC" "As the patients who were clinically diagnosed as having
benign lesions did not undergo biopsy of their lesions, the false negative rate for the
consultant could not be determined. None of the patients with benign lesions from this
study have reported back to the PLC with any concern about their lesions and none
have had excision biopsy of their lesions."
 
Green 1991
Reason for exclusion EXCLUDE if derivation study - no test set
 
Green 1994
Reason for exclusion EXCLUDE if derivation study
CAD - no independent test set
 
Guerra-Rosas 2015
Reason for exclusion EXCLUDE if derivation study
no test set
• EXCLUDE on 2x2 data
no se/sp presented
 
Guillod 1996
Reason for exclusion EXCLUDE if derivation study
 
Gutkowicz-Krusin 2000
Reason for exclusion EXCLUDE on sample size
2 melanoma
• EXCLUDE if derivation study
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Hacioglu 2013
Reason for exclusion Does not provide 2x2 data for an investigated outcome
 
Haenssle 2004
Reason for exclusion • EXCLUDE on target condition
this reads very much like a follow up paper- not sure it is really relevant to our reviews.
 
Haenssle 2010
Reason for exclusion EXCLUDE on 2x2 data
Does not report specificity
• EXCLUDE duplicate or related publication
same patients as Haenssle 2010 #191
 
Haniffa 2007
Reason for exclusion EXCLUDE on reference standard
looks like approximately 20% of patients recieved a final diagnosis by histology. 179
biopsies were performed. Total sample was 881 lesions 
 
Hintz-Madsen 2001
Reason for exclusion • EXCLUDE if derivation study
uses leave one out technique
 
Hoffmann 2003
Reason for exclusion EXCLUDE if derivation study
Uses LOO procedure
• EXCLUDE on 2x2 data
Only giving ROC values not able to extract a 2x2 table 
 
Horsch 1997
Reason for exclusion EXCLUDE if derivation study
 
Huang 1996
Reason for exclusion EXCLUDE if individual lesion characteristics
Border irregularity not overall dx
• EXCLUDE on 2x2 data
 
Ikuma 2013
Reason for exclusion EXCLUDE if derivation study
uses leave one out procedure
 
Isasi 2011
Reason for exclusion EXCLUDE if derivation study
 
Iyatomi 2006
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Reason for exclusion EXCLUDE if derivation study
uses LOO procedure and same lesions and tumour extraction method as Iyatomi 2006
• EXCLUDE on 2x2 data
 
Iyatomi 2008a
Reason for exclusion • EXCLUDE if derivation study
 
Iyatomi 2008b
Reason for exclusion • EXCLUDE if derivation study
 
Iyatomi 2008c
Reason for exclusion EXCLUDE if derivation study
the performance was evaluated by averaging both combinations (training and test
sets) they did not present the data separately; uses LOO procedure
• EXCLUDE on 2x2 data
Not test accuracy; compares automated with manual extraction of tumour area
 
Iyatomi 2010a
Reason for exclusion EXCLUDE if individual lesion characteristics
• EXCLUDE on 2x2 data
not a test accuracy study
 
Iyatomi 2010b
Reason for exclusion • EXCLUDE on target condition
differentiates melanocytic from non-melanocyitc lesinos and not malignant from benign
 
Iyatomi 2011
Reason for exclusion EXCLUDE on index test
colour calibration rather than MM detection
• EXCLUDE if individual lesion characteristics
• EXCLUDE on 2x2 data
not a test accuracy study
 
Jain 2015
Reason for exclusion • EXCLUDE not a primary study
 
Jakovels 2013
Reason for exclusion EXCLUDE on reference standard
reference standard test not reported
 
Jamora 2003
Reason for exclusion EXCLUDE on reference standard
no referene standard for index test negatives
 
Jaworek-Korjakowska 2016a
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Reason for exclusion • EXCLUDE if derivation study
no separate test set
 
Jaworek-Korjakowska 2016b
Reason for exclusion • EXCLUDE if derivation study
uses cross-validation with no separate test set
• EXCLUDE on 2x2 data
only gives accuracy, not se/sp
 
Jeddi 2016
Reason for exclusion • EXCLUDE on study population
unclear whether data for BCC inlcudes only those with lesions actually suspicious for
BCC
• EXCLUDE on index test
limited details
• EXCLUDE on reference standard
appears to be expert Dx
 
Kahofer 2002
Reason for exclusion • EXCLUDE if derivation study
Lesions not split into training/test
 
Kaur 2015
Reason for exclusion EXCLUDE on reference standard
% of benign with histology versus expert dx not reported
• EXCLUDE on 2x2 data
Only gives AUC and not se/sp
• EXCLUDE but contact authors
1. reference standard in benign group 2. se/sp for model using all four features needed
Dr WV Stoeker e-mail: wvs@mst.edu
 
Korotkov 2012
Reason for exclusion • EXCLUDE not a primary study
narrative review
 
Kuzmina 2011
Reason for exclusion EXCLUDE if derivation study
• EXCLUDE on reference standard
reference standard test not reported 
 
Landau 1999
Reason for exclusion • EXCLUDE if derivation study
No indication that system has previously been evaluated
 
LeAnder 2010
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Reason for exclusion • EXCLUDE if derivation study
no separate 2x2 data for training set and test set
 
Lefevre 2000
Reason for exclusion • EXCLUDE on index test
Limited test detail; cannot tell whether clinical or dermoscopic images used even
• EXCLUDE on reference standard
No details of reference standard
 
Lihacova 2013
Reason for exclusion EXCLUDE if derivation study
No test set
 
Liu 2012
Reason for exclusion EXCLUDE if derivation study
asymmetry detection; 10-fold cross validation
• EXCLUDE on 2x2 data
 
Machado 2015
Reason for exclusion EXCLUDE on target condition
detection of reticular pattern not MM 
 
Maglogiannis 2004
Reason for exclusion • EXCLUDE if derivation study
• EXCLUDE on 2x2 data
 
Maglogiannis 2006
Reason for exclusion EXCLUDE if derivation study
They incorporated the training set population together with the test set as shown below
"A training set of 500 cases was randomly selected from the dataset of the total cases.
The accuracy of the classification algorithm was examined using a test set consisted
of the full set of 1041 cases."
 
Manousaki 2006
Reason for exclusion EXCLUDE if derivation study - Training set only
 
Marchesini 1992
Reason for exclusion EXCLUDE if derivation study - no independent data set
 
Masood 2013
Reason for exclusion EXCLUDE if derivation study
 
Menzies 1999
Reason for exclusion • EXCLUDE not a primary study
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Mete 2011
Reason for exclusion • EXCLUDE if derivation study
• EXCLUDE on 2x2 data
Not test accuracy
 
Mhaske 2013
Reason for exclusion • EXCLUDE if derivation study
• EXCLUDE on 2x2 data
Not test accuracy
 
Moncrieff 2002
Reason for exclusion EXCLUDE if derivation study - no independent test set
 
Morrow 2010
Reason for exclusion • EXCLUDE not a primary study
narrative review
 
Nagaoka 2012
Reason for exclusion EXCLUDE on 2x2 data
they did not give the number of lesions in test set, they state The sensitivity of 90%
and specificity of 84% was obtained by applying this threshold value to the validation
set. Cannot see how to work out the 2x2 data from this information
• EXCLUDE but contact authors
Can you provide us with the number of lesions in the test set, with a breakdown of
number of melanoma vs other lesions? We can then use the sensitivity of 90% and
specificity of 84% provided to work out the 2x2. 
 
Nagaoka 2013
Reason for exclusion EXCLUDE if derivation study
index was developed on nonglabrous skin and is being applied to acral skin for first
time which makes it a derviation study?
• EXCLUDE on reference standard
No reference standard reported for D-
 
Nagaoka 2015
Reason for exclusion EXCLUDE on reference standard
• EXCLUDE but contact authors
reference standard not clearly reported - "Lesions that were clinically judged benign
were not biopsied because of ethical reasons." T. Nagaoka e-mail:
nagaoka@aoni.waseda.jp **Previous contact for prior studies was unsuccessful
 
Noroozi 2016
Reason for exclusion EXCLUDE on index test
 
Oka 2004
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Reason for exclusion • EXCLUDE not a primary study
letter
 
Oka 2004a
Reason for exclusion • EXCLUDE if derivation study
uses LOO procedure
 
Oka 2006
Reason for exclusion EXCLUDE not a primary study
letter
 
Pellacani 2004a
Reason for exclusion • EXCLUDE if individual lesion characteristics
 
Pellacani 2004b
Reason for exclusion EXCLUDE if individual lesion characteristics
this paper seems to be examing colours in melanocytic lesion (ML) images. which I
think means it is only looking at an individual lesion characteristic. However they do
have a test set so based on this it would be an include?
 
Pellacani 2006
Reason for exclusion EXCLUDE if derivation study
looks at detection of asymmetry between clinicians and computer
• EXCLUDE on 2x2 data
2x2 could be derived for overall asymmetry or border cut-off but not overall diagnosis
 
Perrinaud 2007
Reason for exclusion • EXCLUDE on sample size
CAD - fewer than 5 melanomas (not including 'typical' melanomas)
• EXCLUDE on index test
Does not provide data for visual inspection alone
 
Pompl 2000
Reason for exclusion EXCLUDE if derivation study
Train set (60 mel and 60 benign) reincluded for model evaluation
 
Rajpara 2009
Reason for exclusion EXCLUDE not a primary study
Systematic review
• systematic review
 
Rastgoo 2015
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Reason for exclusion • EXCLUDE if derivation study
Difficult one as it does describe splitting each set of 180 lesions into 70% for training,
15% for validation and 15% for testing (n=27?). But it's difficult to follow what the
results actually relate to, especially as the classifier is repeated 10 times with different
sets of dysplastic lesions but the same melanoma cases
 
Rigel 2012
Reason for exclusion EXCLUDE duplicate or related publication
CAD - all lesions included in Monheit 2011
 
Rosado 2003
Reason for exclusion • EXCLUDE not a primary study
Systematic Review
• systematic review
 
Rubegni 2001a
Reason for exclusion EXCLUDE not a primary study
letter
 
Rubegni 2001b
Reason for exclusion EXCLUDE if derivation study
paper states that the accuracy estimates (sensitivity, specificty) are given using the
leave one out method but they have not given a breakdown of the actually number. its
not possible to tell if they used the whole study sample. 
 
Rubegni 2002a
Reason for exclusion EXCLUDE if derivation study
the training and test data not given separately. 
 
Rubegni 2005
Reason for exclusion • EXCLUDE not a primary study
Editorial 
 
Rubegni 2010
Reason for exclusion EXCLUDE if derivation study
uses LOO procedure 
• EXCLUDE on 2x2 data
 
Rubegni 2013
Reason for exclusion • EXCLUDE if derivation study
 
Sadeghi 2013
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Reason for exclusion • EXCLUDE if individual lesion characteristics
irregular streaks
• EXCLUDE on 2x2 data
Only given the AUC values not possible to work out 2x2 from this. 
 
Safi 2011
Reason for exclusion EXCLUDE if derivation study
 
Salerni 2012
Reason for exclusion EXCLUDE on index test
test used for surveillance
 
Sboner 2001
Reason for exclusion EXCLUDE duplicate or related publication
same data as Sboner 2004
 
Sboner 2003
Reason for exclusion • EXCLUDE if derivation study
derivation? but describes 10-fold cross-validation rpocess for training/testing classifier.
Check w statistician Also could include dermatologists diagnosis (via dermoscopic
mages?) if read Se/Sp pairs from plot
 
Sboner 2004
Reason for exclusion EXCLUDE if derivation study
Uses LOO method with no independent test set for validation
[the whole set of cases is divided in 10 disjoint sets, which are used as test cases. For
each test set, the remaining nine sets are used to train the classifiers (training set).
The final results are the average values computed on the ten test sets.] 
 
Schindewolf 1993
Reason for exclusion EXCLUDE on 2x2 data
not given enough information to populate 2x2 data 
 
Schindewolf 1994
Reason for exclusion EXCLUDE on index test
evaluates CAD not VI
• EXCLUDE if derivation study
uses cross-validation
 
Schmid-Saugeon 2003
Reason for exclusion EXCLUDE if derivation study
no separate test set for validation
 
Schumacher 2016
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Reason for exclusion • EXCLUDE not a primary study
comment paper
 
Seidenari 1995
Reason for exclusion EXCLUDE on index test
comparing two ways of attaining videomicroscope images no accuracy data provided
• EXCLUDE on 2x2 data
 
Seidenari 2005
Reason for exclusion • EXCLUDE on reference standard
All D+ were excised (n=95) but only 45% of benign group were excised (76 AN plus
30% of BN (86/288)) and methods of estabishing final diagnosis was not reported for
the remainder. 
• EXCLUDE but contact authors
We would like to include test accuracy results from this study, however in order to do
so we would need some further information on how the final diagnosis was reached for
thos lesions that were not excised. We have noted that all D+ lesions were excised
(n=95) and 45% of benign lesions were excised (76 atypical naevi plus 30% of benign
(86/288)). Can you advise us as to how the final diagnosis was reached for the
remaining 126 benign lesions? 
 
Seidenari 2007
Reason for exclusion • EXCLUDE if individual lesion characteristics
CAD only - CAD system based on single characteristic 
 
Seidenari 2012
Reason for exclusion EXCLUDE on index test
CAD ONLY - does not evaluate a CAD system
• EXCLUDE if individual lesion characteristics
looks at indvdl lesion chars to distinguish Mel in situ, also gives mean ABCD and
seven point scores
• EXCLUDE on 2x2 data
• EXCLUDE but contact authors
Table 3 provides mean ABCD and seven point checklist scores, are you able to
provide us with a cross tabulation of results with each checklist at 'standard' thresholds
against final diagnosis? e.g. ABCD >4.75 and >5.45 for MIS and benoign groups 7-
point checklist: presence >=2 chars and >=3 chars?
 
Shakya 2012
Reason for exclusion EXCLUDE on target condition
SCC in situ is not inlcuded in target condition
 
She 2007
Reason for exclusion EXCLUDE if derivation study
 
She 2013
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Reason for exclusion • EXCLUDE if derivation study
no separate data for training and test set. used leave-one-out technique
 
Shimizu 2012
Reason for exclusion • EXCLUDE if derivation study
The performance was evaluated under the leave-one-out cross-validation test.
 
Skrovseth 2010
Reason for exclusion EXCLUDE not a primary study
Statistical paper for developing a new algorithm
 
Smith 2000
Reason for exclusion EXCLUDE if derivation study
 
Sober 1994
Reason for exclusion • EXCLUDE if individual lesion characteristics
Reports separately for shape, radii and border but not overall classification; note these
sare results for one centre taking part in a larger multi-centre study 
 
Stanganelli 1995
Reason for exclusion • EXCLUDE on index test
aim of study is to assess the intraobserver agreement 
 
Stanley 2007
Reason for exclusion EXCLUDE if individual lesion characteristics
• EXCLUDE if derivation study
 
Stanley 2008
Reason for exclusion EXCLUDE if derivation study
cross validation study (check eligibility); 
 
Stoecker 2005
Reason for exclusion EXCLUDE if individual lesion characteristics
• EXCLUDE if derivation study
 
Swanson 2010
Reason for exclusion EXCLUDE on index test
reflectance spectroscopy
• EXCLUDE if derivation study
This looks like an include as they mention a pilot study of 47 initial patients. There is
an additional 47 patients included, however it seems that they have combined the data
so for this reason it would be an excluded if derivation study-as the training data and
test data are combined. 
 
Tehrani 2006
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Reason for exclusion EXCLUDE if derivation study
*[Borderline exclude - 4 features of NMSC identifed in pilot study and re-examined in
larger sample here; diagnostic model then created based on signiicaince of
characteristics and se/sp data give. No test set presented]
 
Terstappen 2007
Reason for exclusion • EXCLUDE on study population
Includes only BCC - looking for BCC chars on Siascope
• EXCLUDE if derivation study
Derivation study; first application of Siascope to pigmented BCC; 21/25 lesions were
BCCs
 
Varol 2006
Reason for exclusion • EXCLUDE not a primary study
Link to study with correction "Error in Byline. In the the Study by Menzies et al titled
“The Performance of SolarScan: An Automated Dermoscopy Image Analysis
Instrument for the Diagnosis of Primary Melanoma,” published in the November 2005
issue of the ARCHIVES (2005;141:1388-1396), the name of the one of the authors
was misspelled. The author’s name is Alexandra Varol, B Med."
 
Vestergaard 2008
Reason for exclusion • EXCLUDE not a primary study
systematic review
• systematic review
 
Wallace 2000a
Reason for exclusion • EXCLUDE if derivation study
uses leave one out 
 
Wallace 2000b
Reason for exclusion EXCLUDE on 2x2 data
 
Wallace 2002
Reason for exclusion EXCLUDE if derivation study - Uses LOO cross-validation
 
Walter 2010
Reason for exclusion • EXCLUDE not a primary study
clinical trial protocol
 
Watson 2009
Reason for exclusion EXCLUDE on 2x2 data
Not test accuracy; training in MoleMate
 
Wazaefi 2012
Reason for exclusion • EXCLUDE if derivation study
no separate independent test set they used a 20 folds cross-validation 
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Wells 2011
Reason for exclusion • EXCLUDE not a primary study
see Wells 2012
• EXCLUDE duplicate or related publication
see Wells 2012
 
Wilson 2013
Reason for exclusion EXCLUDE on 2x2 data
this study is an economic evaluation of a SIAscopy, which itself was trialled in another
paper - not enough data to populate 2x2 table
 
Winkelmann 2015a
Reason for exclusion EXCLUDE duplicate or related publication
 
Winkelmann 2015b
Reason for exclusion EXCLUDE on target condition
D+ incldues 15 lesions with moderate dysplasia
• EXCLUDE on sample size
only 1 MM
 
Winkelmann 2015c
Reason for exclusion EXCLUDE on sample size
 
Winkelmann 2015d
Reason for exclusion • EXCLUDE duplicate or related publication
 
Winkelmann 2016a
Reason for exclusion EXCLUDE on index test
aim of the test to to investigate correlation with clinical histology features (development
of new CAD system?)
 
Wood 2008
Reason for exclusion EXCLUDE on 2x2 data
Not test accuracy - acceptability etc
 
Yoo 2015
Reason for exclusion EXCLUDE conference abstract
 
Zagrouba 2004
Reason for exclusion • EXCLUDE on reference standard
No reference standard details provided
• EXCLUDE but contact authors
Contacted re reference standard Author responded - can't help
 
Zhou 2010a
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Reason for exclusion • EXCLUDE if derivation study
 
Zhou 2010b
Reason for exclusion EXCLUDE if individual lesion characteristics
 
Zortea 2014
Reason for exclusion • EXCLUDE if derivation study
Although data are divided into training and test sets, the test set data is used more
than once over 20 realisations of each model, especailly th emalanomas, for which the
same 10 are used in each realisation
 
Zouridakis 2004
Reason for exclusion • EXCLUDE on study population
• EXCLUDE on sample size
• EXCLUDE if derivation study
 
Footnotes
Characteristics of studies awaiting classification 
Footnotes
Characteristics of ongoing studies 
Footnotes
Summary of results tables
1 Summary of findings table
Question: What is the diagnostic accuracy of computer-assisted diagnosis for the detection of: i) cutaneous invasivemelanoma and atypical intraepidermal melanocytic variants, ii) BCC, or iii) cSCC in adults?
Population:  
Adults with lesions suspicious for skin cancer, including:
Any lesion referred for specialist investigation due to suspicion of skin cancer, and
Any lesion excised due to suspicion of skin cancer
Index test: Computer-assisted diagnosis (CAD)
Comparator
test: Dermoscopy
Target
condition:
Cutaneous invasive melanoma and atypical intraepidermal melanocytic variants, or basal cell carcinoma
(BCC), or cutaneous squamous cell carcinoma (cSCC)
Reference
standard: Histology with or without long term follow-up
Action: If accurate, positive results of CAD will identify skin cancers that could otherwise be missed, while negativeresults will stop patients having unnecessary excision of skin lesions
Quantity of evidence
Number of
studies 42
a Total lesions
with test results 13,445
Total with
target condition 2452
Limitations 
Risk of bias: 
Patient selection methods were poorly reported with some concern (34/42) due to use of case-control
designs, exclusion of difficult to diagnose types of lesion, and inadequate reporting to assess risk of bias.
CAD was generally evaluated in independent populations (35/42). Some concern as it was not clear that the
reference standard was interpreted blind to the CAD results in 19/42 studies. Differential verification was
used in 6/42 studies, participants were excluded in 10/42, primarily due to technical difficulties with CAD.
Timing of tests was not mentioned in 28/42.
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Question: What is the diagnostic accuracy of computer-assisted diagnosis for the detection of: i) cutaneous invasivemelanoma and atypical intraepidermal melanocytic variants, ii) BCC, or iii) cSCC in adults?
Applicability
of evidence to
question:
High concern for poor clinical applicability of included studies. Almost all studies recruited narrowly defined
populations (41/42) and/or multiple lesions per patient (14/42) and may not be representative of populations
eligible for CAD. Studies provided little information regarding the thresholds used for presence of malignancy
(16/42) and often evaluated unestablished thresholds (23/42). Studies performing training of algorithms
provided scarce information on the range of conditions included in training sets. model derivation gave Little
information was given concerning the expertise of the histopathologist.
FINDINGS: All analyses are undertaken on subgroups of the studies
All included studies considered the detection of melanoma, three of which also looked at the detection of BCC and 1 at the
detection of cSCC. There is therefore not sufficient data to make summary statements regarding the accuracy of CAD for
the detection of BCC or cSCC. All results below consider the detection of the primary target condition: cutaneous invasive
melanoma and atypical intraepidermal melanocytic variants.
Test: Digital-dermoscopy based CAD (all systems)
Quantity of
evidence Number of studies 22
Total lesions with
test results 8992
Total with
melanoma 1063
Sensitivity
(95% CI):
Specificity
(95% CI):
90.1% (84.0, 94.0)
74.3% (63.6, 82.7)
  Numbers observed in a cohort of
1000 people being testedb
Consistency
Sensitivity estimates consistent.
Some heterogeneity in specificity
between studies.
Consequences
Prevalence
7% 20% 40%
True positives Receive necessaryexcision 63 180 360
False positives
Receive
unnecessary
excision
239 206 154
False negatives Do not receiverequired excision 7 20 40
True negatives Appropriately do notreceive excision 691 594 446
PPV   21% 46% 70%
NPV   99% 97% 92%
Test: Multispectral imaging based CAD (all systems)
Quantity of
evidence Number of studies 8
Total lesions with
test results 2401
Total with
melanoma 286
Sensitivity
(95% CI):
Specificity
(95% CI):
92.9% (83.7, 97.1)
43.6% (24.8, 64.5)
  Numbers observed in a cohort of
1000 people being tested
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Question: What is the diagnostic accuracy of computer-assisted diagnosis for the detection of: i) cutaneous invasivemelanoma and atypical intraepidermal melanocytic variants, ii) BCC, or iii) cSCC in adults?
Consistency
Sensitivity estimates consistent.
High heterogeneity in specificity
between studies.
Consequences 
Prevalence 
7% 20% 40%
True positives Receive necessaryexcision 65 186 372
False positives
Receive
unnecessary
excision
525 451 338
False negatives Do not receiverequired excision 5 14 28
True negatives Appropriately do notreceive excision 405 349 262
PPV   12% 29% 52%
NPV   99% 96% 90%
Footnotes
asix studies with overlapping lesions (Seidenari 1998 & Seidenari 1999; Tomatis 2003 & Bono 2002; Monheit 2011 &
Hauschild 2014)
bNumbers estimated at 25th, 50th (median) and 75% percentiles of invasive melanoma and atypical intraepidermal
melanocytic variants prevalence, observed across 42 studies reporting evaluations of CAD.
BCC - Basal cell carcinoma; CAD - computer-assisted diagnosis; CI - confidence interval; cSCC - cutaneous squamous cell
carcinoma; NPV - negative predictive value; PPV - positive predicitive value
Additional tables 
1 Glossary of terms
Term Definition
Artificial intelligence Computer systems undertaking tasks that normally require human intelligence, such asdecision–making or visual perception
Atypical intraepidermal
melanocytic variant
Unusual area of darker pigmentation contained within the epidermis that may progress to an
invasive melanoma; includes melanoma in situ and lentigo maligna
Atypical naevi Unusual looking but noncancerous mole or area of darker pigmentation of the skin
Basaloid cells Cells in the skin that look like those in epidermal basal layer
BRAF V600 mutation
BRAF is a human gene that makes a protein called B-Raf which is involved in the control of
cell growth. BRAF mutations (damaged DNA) occur in around 40% of melanomas, which
can then be treated with particular drugs.
BRAF inhibitors Therapeutic agents which inhibit the serine-threonine protein kinase BRAF mutatedmetastatic melanoma.
Breslow thickness A scale for measuring the thickness of melanomas by the pathologist using a microscope,measured in mm from the top layer of skin to the bottom of the tumour.
Congenital naevi A type of mole found on infants at birth
Dermoscopy Whereby a handheld microscope is used to allow more detailed, magnified, examination ofthe skin compared to examination by the naked eye alone
Dermo-epidermal junction The area where the lower part of the epidermis and top layer of the dermis meet
Dermis Layer of skin below the epidermis, composed of living tissue and containing bloodcapillaries, nerve endings, sweat glands, hair follicles and other structures
Desmoplastic subtypes of
SCC
An aggressive squamous cell carcinoma variant characterised by a proliferation of
fibroblasts and formation of fibrous connective tissue
Electrodesiccation The use of high frequency electric currents to cut, destroy or cauterise tissue. It is performedwith the use of a fine needle-shaped instrument
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Term Definition
Electrical impedance
spectroscopy
The measurement of electrical current properties as they pass through skin tissues, to
retrieve information on cellular structures
Epidermis Outer layer of the skin
False negative An individual who is truly positive for a disease, but whom a diagnostic test classifies themas disease-free.
False positive An individual who is truly disease-free, but whom a diagnostic test classifies them as havingthe disease.
Histopathology/Histology The study of tissue, usually obtained by biopsy or excision, for example under a microscope.
Incidence The number of new cases of a disease in a given time period.
Index test A diagnostic test under evaluation in a primary study
Interferometry The measurement of waves of light or sound after interference in order to extract information
Lentigo maligna Unusual area of darker pigmentation contained within the epidermis which includesmalignant cells but with no invasive growth. May progress to an invasive melanoma
Lymph node
Lymph nodes filter the lymphatic fluid (clear fluid containing white blood cells) that travels
around the body to help fight disease; they are located throughout the body often in clusters
(nodal basins).
Melanocytic naevus An area of skin with darker pigmentation (or melanocytes) also referred to as ‘moles’
Meta-analysis A form of statistical analysis used to synthesise results from a collection of individual studies.
Metastases/metastatic disease Spread of cancer away from the primary site to somewhere else through the bloodstream orthe lymphatic system.
Morbidity Detrimental effects on health.
Mortality
Either (1) the condition of being subject to death; or (2) the death rate, which reflects the
number of deaths per unit of population in relation to any specific region, age group,
disease, treatment or other classification, usually expressed as deaths per 100, 1000,
10,000 or 100,000 people.
Multidisciplinary team
A team with members from different healthcare professions and specialties (e.g. urology,
oncology, pathology, radiology, and nursing). Cancer care in the National Health Service
(NHS) uses this system to ensure that all relevant health professionals are engaged to
discuss the best possible care for that patient.
Naevus A mole or collection of pigment cells (plural: naevi or nevi)
Optical coherence tomography
(OCT)
Based on the same principle as ultrasound, OCT uses a handheld probe to measure the
optical scattering of near-infrared (1310 nm) light waves (rather than sound waves) from
under the surface of the skin
Prevalence The proportion of a population found to have a condition.
Prognostic factors/indicators Specific characteristics of a cancer or the person who has it which might affect the patient’sprognosis.
Receiver operating
characteristic (ROC) plot
A plot of the sensitivity and 1 minus the specificity of a test at the different possible
thresholds for test positivity; represents the diagnostic capability of a test with a range of
binary test results
Receiver operating
characteristic (ROC) analysis The analysis of a ROC plot of a test to select an optimal threshold for test positivity
Recurrence Recurrence is when new cancer cells are detected following treatment. This can occur eitherat the site of the original tumour or at other sites in the body.
Reference Standard A test or combination of tests used to establish the final or ‘true’ diagnosis of a patient in anevaluation of a diagnostic test
Reflectance confocal
microscopy (RCM)
A microscopic technique using infrared light (either in a handheld device or a static unit) that
can create images of the deeper layers of the skin
Resolution Resolution in an imaging system refers to its ability to distinguish two points in space asbeing separate points; resolution is measured in two directions: axial and lateral.
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Term Definition
Sensitivity In this context the term is used to mean the proportion of individuals with a disease whohave that disease correctly identified by the study test
Specificity The proportion of individuals without the disease of interest (in this case with benign skinlesions) who have that absence of disease correctly identified by the study test
Spectroscopy Study of the interaction between matter and electromagnetic radiation
Spindle subtypes of SCC A squamous cell carcinoma variant characterised by poorly differentiated spindle cellssurrounded by collagenous stroma
Staging Clinical description of the size and spread of a patient’s tumour, fitting into internationallyagreed categories.
Stratum corneum
The outermost layer of the epidermis. This layer is the most superficial layer of skin, which is
composed of flattened skin cells organised like a brick wall. In normal conditions cells are
not nucleated at this layer
Subclinical (disease) Disease that is usually asymptomatic and not easily observable, e.g. by clinical or physicalexamination.
Footnotes
2 A cross-tabulation of studies by CAD type, reported comparisons and target conditions
Study CAD type CAD system CAD diagnosis Comparison with
dermoscopy
Target
conditionsa
Bauer 2000 Derm–CADDB-MIPs CAD diagnostic
aid
in–person dermoscopy 1
Wollina 2007 Derm–CADDB-MIPs CAD diagnostic
aid
No 1
Burroni 2004 Derm–CADDB-MIPs CAD only No 1
Rubegni 2002 Derm–CADDB-MIPs CAD only No 1
Seidenari 1998 Derm–CADDB-MIPs CAD only image–based assessment 1
Seidenari 1999 Derm–CADDB-MIPs CAD only No 1
Stanganelli 2005 Derm–CADDB-MIPs CAD only No 1
Piccolo 2002 Derm–CADDEM-MIPS CAD only image–based assessment 1
Binder 1998 Derm–CADIBAS 2000 CAD only No 1
Barzegari 2005 Derm–CADMicroDERM CAD only No 1
Boldrick 2007 Derm–CADMicroDERM CAD only No 1
Serrao 2006 Derm–CADMicroDERM CAD only No 1
Dreiseitl 2009 Derm–CADImage J (MoleMax II) CAD only in–person dermoscopy 1
Maglogiannis 2015 Derm–CADSystem name NR (MoleMax
II)
CAD only No 1
Mollersen 2015 Derm–CADNevus Doctor
Mole Expert
CAD only No 1,5
Piccolo 2014 Derm–CADNevuscreen CAD diagnostic
aid
image–based assessment 1
Cascinelli 1992 Derm–CADSkin View CAD only No 1,5
Cristofolini 1997 Derm–CADSkin View CAD only No 1
Menzies 2005 Derm–CADSolarScan CAD only Excluded (different sample
sizes)
1,4
Binder 1994 Derm–CADSystem name NR CAD only image–based assessment 1
Blum 2004b Derm–CADSystem name NR CAD only Excluded (different sample
sizes)
1
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Study CAD type CAD system CAD diagnosis Comparison with
dermoscopy
Target
conditionsa
Ferris 2015 Derm–CADSystem name NR CAD only Excluded (different sample
sizes)
1,2,5
Gilmore 2010 Derm–CADSystem name NR CAD only image–based assessment 1
Menzies 1996 Derm–CADSystem name NR CAD only image–based assessment 4
Hauschild 2014 MSI–CAD MelaFind CAD diagnostic
aid
image–based assessment 1,4
Winkelmann 2016 MSI–CAD MelaFind CAD diagnostic
aid
image–based assessment 1
Friedman 2008 MSI–CAD MelaFind CAD only image–based assessment 1,4
Monheit 2011 MSI–CAD MelaFind CAD only No 1
Wells 2012 MSI–CAD MelaFind CAD only image–based assessment 1
Sgouros 2014 MSI–CAD Siascope (version NR) CAD only No 5
Glud 2009 MSI–CAD Siascope II CAD only image–based assessment 1
Terstappen 2013 MSI–CAD Siascope V CAD only No 4
Walter 2012 MSI–CAD Siascope V (MoleMate) CAD diagnostic
aid
No 1,4,5
Tomatis 2005 MSI–CAD Spectroshade CAD only No 1
Ascierto 2010 MSI–CAD Spectroshade CAD only in–person dermoscopy 4
Gutkowicz Krusin
1997
MSI–CAD System name NR CAD only No 1
Tomatis 2003 MSI–CAD Telespectrophotometric
system
CAD only No 1
Bono 1996 MSI–CAD Telespectrophotometric
System
CAD only No 4
Bono 2002 MSI–CAD Telespectrophotometric
System
CAD only in–person dermoscopy 1
Garcia Uribe 2012 DRS–CAD OIDRS CAD only No 1,5
Malvehy 2014 EIS–CAD Nevisense CAD only Excluded (different sample
sizes)
1,2,3,4,5
Mohr 2013 EIS–CAD Nevisense CAD only No 1,2,4,5
Footnotes
Key: Derm-CAD – Dermoscopy based computer–assisted diagnosis; DRS–CAD – diffuse reflectance spectroscopy
computer–assisted diagnosis; EIS-CAD - Electrical impedance based computer assisted diagnosis; MSI-CAD - Multispectral
imaging based computer–assisted diagnosis; NR – Not reported; OIDRS - oblique incidence reflectance spectroscopy.
a1 – Invasive melanoma and atypical intraepidermal melanocytic variants, 2 – Basal cell carcinoma, 3 – cutaneous
Squamous cell carcinoma, 4 – Invasive melanoma alone, 5 – Any skin cancer or lesion requiring excision
3 Characteristics of included digital dermoscopy-based CAD (Derm–CAD) systems
Derm-CAD
processing
machine
Role of machine Image analysis Classifier CAD output Studies
MicroDERM
(Visiomed AG,
Germany)
dermoscopy unit with
internal camera
containing analysis
system
DANAOS software
combines analytical system
based on ABCD with
database of 21,000 PSLs.
ANN DANAOS score indicating
risk of malignancy
Barzegari
2005
Serrao 2006
Boldrick
2007
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Derm-CAD
processing
machine
Role of machine Image analysis Classifier CAD output Studies
DB–Dermo
MIPS (Biomips
Engineering,
Italy)
dermoscopy unit,
internal
stereomicroscope,
internal DB, pattern
analysis system
DB–MIPS pattern analysis
system – integrated
database stores the
patient's data and the
description of the lesion
along with the image icons.
38 features analysed
(grouped into geometries,
colours and
Burroni's islands of colours).
ANN Diagnosis suggested
(e.g. melanoma, benign
melanocytic nevus)
Bauer 2000
Rubegni
2002
Automatic Data Analysis for
Melanoma early detection
(ADAM) software which
analyses boundary shape,
texture and colour
distribution
SVM Low risk, intermediate
risk or high risk of
melanoma
Stanganelli
2005
DB–MIPS pattern analysis
system
Multivariate
discriminant
analysis
Graphical output and
numerical output of
features provided.
Diagnosis suggested
(e.g. melanoma, benign
melanocytic nevus)
Seidenari
1998
Seidenari
1999
DB–MIPS pattern analysis
system
KNN Diagnosis suggested
(e.g. melanoma, benign
melanocytic nevus)
Burroni 2004
DB–MIPS pattern analysis
system
Linear
discrimination
Diagnosis suggested
(e.g. melanoma, benign
melanocytic nevus)
Burroni 2004
DDA software analysis –
analyses 50 parameters
subdivided into three
categories, i.e. geometries,
colours, and textures and
islands of colours (Burroni
islands)
Euclidian
distances
Not specified Wollina 2007
DEM–MIPS
(Biomips SRL,
Siena, Italy)
Commercially available
software coupled to
stereomicroscope Wild
M-650 (Leica), video
camera, computer,
colour monitor.
DEM-MIPS software (Digital
Epi Microscopy Melanoma
Image Processing Software;
Biomips SRL, Siena, Italy).
Evaluates colorimetric and
geometric features (not
reported).
ANN Not specified Piccolo 2002
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Derm-CAD
processing
machine
Role of machine Image analysis Classifier CAD output Studies
Skin View Computerised image
analysis system, digital
television, videocamera.
Connection with the
computer is through a
digitising board able to
process colour images
Features of ABCD system
plus clinical data (anatomic
site, months of growth, size,
shape, colour, ulceration or
regression)
NR ≥2 of 8 binary (on/off)
indicators indicates
malignancy: 1 shape
(asymmetry); 2 clinical
data (changes through
time, regression,
ulceration); 3 size (mm);
4 colour (distribution of
hue); 5 darkness (percent
of black mixed with the
hue); 6 saturation
(percent of white mixed
with the hue); 7 border
(sharpness of transition
between lesion and
healthy skin; 8 texture.
Cascinelli
1992
Cristofolini
1997
Nevus Doctor Computerised image
analysis system coupled
to digital dermatoscope
ND takes a dermoscopic
image from the
Canon/DermLite device as
input and classifies the
lesion.
Features not reported
NR Probability of malignancy Mollersen
2015
MoleExpert
(DermoScan
GmbH,
Germany)
(micro Version
3.3.30.156).
Computerised image
analysis with output
giving probability of
malignancy
Features of ABCD system
plus other features (not
listed), e.g. colour variation
and grey veil.
NR Number between −5.00
and 5.00, where high
values indicate suspicion
of melanoma
Mollersen
2015
Image J (NIH,
Bethesda,
USA)
Image segmentation,
feature extraction,
image analysis coupled
with dermatoscope
MoleMax II
29 Features analysed from
38 extracted features
describing shape, form and
colour.
ANN 2 outputs: 1) Visual
rendering of analysis
showing coloured areas.
2) Excision vs. no
excision decision (system
considers the green zone
of the scale as benign (0
to 0.1), the yellow zone
suspicious (0.1 to 0.4),
and the red zone
malignant (0.4 to 1)).
Dreiseitl
2009
IBAS 2000
workstation
(Zeiss,
Oberkochen,
Germany)
Digital image analysis
workstation attached to
Wild binocular
stereomicroscope M
650 (Wild Heerbrugg
AG, Switzerland)
Analysis of 16
morphometric parameters
from the lesion and the
border image: lesion area
and perimeter: minimum
polar distance, maximum
polar distance, aspect ratio,
circularity shape factor,
variances of grey, number
different colours, range
different colours. Border
features and area:
maximum and minimum
border width, ratio of border
area to lesion area, ratio of
border perimeter to lesion
perimeter.
ANN Dichotomous decision:
MM vs. Benign (CN or
DN).
The network was trained
to yield a value from 0 to
1 in the output nodes.
The node yielding the
greatest numerical output
was then used as the
classification result.
Binder 1998
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Derm-CAD
processing
machine
Role of machine Image analysis Classifier CAD output Studies
Nevuscreen ®
(Arkè s.a.s.,
Avezzano,
Italy)
Digital database
containing image
analysis software,
coupled to digital
dermatoscope
Nevuscreen software
automatically analyses
ABCD features
 
NR
TDS score: <4.75 benign,
4.75–5.45 suspicious,
>5.45 highly suggestive
of melanoma
Piccolo 2014
SolarScan
(Polartechnics
Lts, Australia)
dermoscopy video unit
with internal algorithm
for image analysis
103 automated image
analysis variables extracted:
consisting of various
properties of colour, pattern,
and geometry. Number
analysed not reported.
linear
discriminant
analysis
Probability of melanoma,
with cut–off (not provided)
for benign vs. melanoma
Menzies
2005
Name not
reported
Computer analysis of
stored images captured
using different
dermoscopy/camera
combinations
54 features analysed, such
as border irregularity,
eccentricity, length of major
and minor axes, and colour
histogram properties
Digital forest
classifier
Severity score (the
fraction of decision trees
(n = 1000) in which the
path ends in ‘‘malignant’’.
Lesion classified as
malignant if its image
traced a path to a
malignant node in at least
40% of the trees)
Ferris 2015
Name not
reported
Computer analysis of
stored images captured
using digital
stereomicroscope
Features analysed as
present or absent (pattern
analysis): Pigment network,
brown globules, radial
streaming, pseudopods,
black dots, margin,
pigmentation,
depigmentation
ANN NR Binder 1994
Name not
reported
Computer analysis of
digital dermoscopy
images (Molemax II)
features corresponding to
the number, size and
asymmetry of dots:
(a)Number of dots, (b) Total
Number of pixels in dots, (c)
mean number of pixels in
dots, (d) variance of num.
pixels in dots ,(e) fraction of
lesion area occupied by
dark dots. Asymmetry:
radial, angular, primary axis.
Comparison
of 5
classifiers:
Multilayer
perceptron
kNN
Random
forest
SVM
polykernel
c=5*
SVM PUK
kernel
NR Maglogiannis
2015
Name not
reported
Computer analysis of
stored images captured
using digital microscope
14 features investigated: 4
asymmetry features, colour
variance (red, green, blue),
mean colour (red, green,
blue, intensity), range colour
(red, green, blue).
SVM
(principal
components
analysis)
NR Gilmore
2010
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Derm-CAD
processing
machine
Role of machine Image analysis Classifier CAD output Studies
Name not
reported
Computer analysis of
stored images captured
using digital microscope
Negative Features: Point
and axial symmetry of
pigmentation
Presence of only a single
colour.
Positive Features: Blue-
white, veil, Multiple brown
dots, Pseudopods, Radial
streaming, Scarlike
depigmentation, Peripheral
black dots/globules, Multiple
(5-6) colours, Multiple
blue/grey dots, Broadened
network
Classification
and
regression
tree
Presence of indicative
features (Melanoma = 0/2
morphologically negative
features AND at least 1/9
positive morphological
features)
Menzies
1996
Name not
reported
Computer analysis of
stored images captured
using digital microscope
Analysis of 64 analytical
parameters including: a
large number of
morphological parameters
such as
margin, geometric
parameters (surface area,
extent, largest diameter and
largest orthogonal
diameter), invariant
moments, symmetry,
colours (red, green, blue
and grey value), texture
(energy, entropy,
correlation, inverse
difference moment and
inertia), number of regions,
focus and difference of the
lesion and its convex cover.
Vision algebra
methods
NR Blum 2004b
Footnotes
*(classifier selected at random for inclusion in review)
Key: ANN – artificial neural network; CN – common naevus; DN – dysplastic naevus; KNN – K–nearest neighbour; NR – not
reported; MM – malignant melanoma; SVM – support vector machine; TDS – total dermoscopic score
4 Characteristics of included Spectroscopy-based CAD (Spectro-CAD) systems
Spectro–CAD system
[spectroscopy type]
Role of machine Image analysis Classifier CAD Output Studies
SpectroShade (MHT,
Verona Italy)
[MSI–CAD]
Illumination assembly
located inside a PC and
an external detection
device placed in a
hand-held probe, with
integrated image
analysis software
Features analysed:
(i) reflectance (R);
(ii) variegation (V);
(iii) area (A); (iv)
dark area ratio
(DAR); (v) dark
island reflectance
(DIR); (vi) dark
distribution factor
(DDF); (vii) dark
permanence (D
PER)
ANN (multilayer
perceptron)
NR Tomatis
2005
SpectroShade coupled
with a MoleMax II
dermatoscope
NR Diagnostic category: 1
no melanoma, 2
doubtful melanoma, 3
suspected melanoma,
4 probable melanoma
Ascierto
2010
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Spectro–CAD system
[spectroscopy type]
Role of machine Image analysis Classifier CAD Output Studies
MelaFind (early
predecessor)
[MSI-CAD]
Digital camera and
illumination assembly
coupled to a computer,
with separate image
analysis
Features analysed:
Lesion asymmetry,
border, gradient,
centroid, texture,
colour
Multiparametric
linear classifier
NR Gutkowicz
Krusin 1997
MelaFind (STRATA Skin
Sciences [formerly Mela
Sciences Inc], Horsham,
PA, USA)
[MSI-CAD]
Multispectral imaging
system with integrated
image analysis
software; device takes
images in vivo
MelaFind image
analysis
NR Binary output: (1)
positive, (lesion should
be considered for
biopsy to rule out
melanoma); and
(2) negative (lesion
should be considered
for later evaluation)
Monheit
2011
6 constrained
linear classifiers
Binary output: excise
or follow–up
Friedman
2008
NR Monheit 2011 Wells 2012
Logistic
regression
Monheit 2011 Winkelmann
2016
NR Monheit 2011 Hauschild
2014
Telespectrophotometric
system [MSI–CAD]
Digital camera coupled
with an illumination
system with
interference filters and
computer for storage
and analysis of
multispectral images
From each spectral
image, three
parameters, i.e.
mean reflectance,
variegation index
and lesion area;
were derived at the
corresponding
wavelength.
Linear
discriminant
NR Bono 1996
For each spectral
image, five
parameters (lesion
descriptors) based
on ABCD and
related to colour
and shape of the
imaged lesion were
evaluated: mean
reflectance,
variegation index,
roundness, border
irregularity.
Linear
discriminant
vs. ANN*
NR
Tomatis
2003
Linear
discriminant
NR Bono 2002
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Spectro–CAD system
[spectroscopy type]
Role of machine Image analysis Classifier CAD Output Studies
SIAscopy ™ (Astron
Clinica, UK) [MSI–CAD]
Spectrophotometric
imaging system with
hand–held skin probe
(SIAscope II) and
integrated software
Analysis of dermal
melanin,
erythematous blush,
lesion asymmetry,
collagen 'holes',
blood commas, or
irregularities in the
collagen
NR SIAgraphs and Binary
output (based on
Australian Scoring
System): ‘strong
chance of melanoma'
or 'low risk of
melanoma'
Glud 2009
Spectrophotometric
imaging system with
hand–held skin probe
(SIAscope V) and
integrated software
(software Dermetrics
Version 2.0, Astron
Clinica Ltd., Great
Britain)
NR SIAgraphs (no further
information)
Terstappen
2013
SIAscope (MedX Health
Corp, Canada)
[MSI–CAD]
Spectrophotometric
imaging system with
hand–held skin probe
(SIAscope, version NR)
and integrated software
NR SIAgraphs and lesion
score using Primary
Care Scoring Algorithm
(6 or more points
regarded as
suspicious)
Sgouros
2014
SIAscope (MedX Health
Corp, Canada)
[MSI–CAD]
SIAscopy with
MoleMate (software
image management
system) viewing
platform and integrated
primary care scoring
algorithm
NR SIAgraphs and lesion
score using Primary
Care Scoring Algorithm
(6 or more points
regarded as
suspicious)
Walter 2012
Oblique Incidence
Diffuse Reflectance
Spectroscopy
[DRS–CAD]
Light probe coupled to
imaging spectrograph,
camera, and computer
to store images.
NR ANN Diagnostic category
(e.g. CN, MM, DN,
BCC, cSCC)
Garcia Uribe
2012
Nevisense (SciBase III,
Sweden)
[EIS–CAD]
Electrical Impedance
spectroscopy imaging
system with integrated
image analysis software
The system
measures the
overall electrical
resistance and
reactance at 35
different frequencies
SVM (non-
probabilistic
binary linear
classifier)
The system computes
both a score (0–10)
and a dichotomous
output (EIS
negative/positive) at a
fixed cut-off. The fixed
threshold is set at 4,
i.e. scores < 4 are EIS
negative and scores of
≥ 4 are EIS positive.
Mohr 2013
Malvehy
2014
Footnotes
* Classifier excluded at random
Key: ANN – artificial neural network; BCC – basal cell carcinoma; cSCC – cutaneous squamous cell carcinoma; CAD -
computer-assisted diagnosis; CN – common naevus; DN – dysplastic naevus; EIS - electrical impedance spectroscopy; KNN
– K–nearest neighbour; NR – not reported; MM – malignant melanoma; MSI – multispectral imaging; SVM – support vector
machine.
5 Summary estimates of sensitivity and specificity for CAD according to target condition
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Index test, target
condition
StudiesCases/Number of
participants
Summary sensitivity (95% CI)
%
Summary specificity (95% CI)
%
Main analyses: Invasive melanoma and atypical intraepidermal melanocytic variants
Derm–CAD 22 1063/8992 90.1 (84.0, 94.0) 74.3 (63.6, 82.7)
MSI–CAD 8 286/2401 92.9 (83.7, 97.1) 43.6 (24.8, 64.5)
EIS–CAD (Nevisense*) 2 368/2389 97.0 (94.7, 98.3) 33.6 (31.6, 35.7)
Individual CAD systems: Invasive melanoma and atypical intraepidermal melanocytic variants
DB–MIPS (Derm–CAD) 6 502/1903 95.2 (89.5, 97.9) 89.1 (78.7, 94.8)
Skin View (Derm–CAD) 2 45/220 80.0 (65.8, 89.3) 47.4 (40.1, 54.8)
MelaFind (MSI–CAD) 5 196/1798 97.1 (91.9, 98.9) 29.8 (12.3, 56.3)
Main analyses: Basal cell carcinoma
EIS–CAD (Nevisense*) 2 69/2389 100 (94.7, 100) 26.3 (24.5, 28.1)
Secondary target condition: invasive melanoma alone
Derm–CAD 2 120/950 90.8 (84.2, 94.9) 63.5 (60.2, 66.7)
MSI–CAD 5 116/386 76.5 (43.0, 93.3) 60.7 (38.5, 79.2)
EIS–CAD (Nevisense*) 2 226/2389 98.2 (95.4, 99.3) 38.0 (36.0, 40.1)
Secondary target condition: any skin cancer or lesions requiring excision
EIS–CAD (Nevisense*) 2 644/2389 93.5 (91.3, 95.1) 32.6 (30.4, 34.8)
Footnotes
* For EIS-CAD the only evidence available was for one system
Key: CAD - computer-assisted diagnosis; CI - confidence interval; Derm-CAD - digital dermoscopy based computer-assisted
diagnosis; EIS-CAD - electrical impedance spectroscopy based computer-assisted diagnosis; MSI-CAD - multispectral
imaging based computer-assisted diagnosis.
6 Comparisons of CAD with dermoscopy for detection of the primary target condition: invasive melanoma and
atypical intraepidermal melanocytic variants
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Test Number of
studies
Number of
cases
Number of
patients
Pooled sensitivity (95%
CI)
Pooled specificity (95%
CI)
Derm–CAD versus image–based dermoscopy – indirect comparison
Derm–CAD 22 1063 8992 90.1 (84.0, 94.0) 74.3 (63.6, 82.7)
Image-based
dermoscopy
5 153 765 93.3 (83.4, 97.5) 88.5 (57.3, 97.8)
Difference (95% CI), P
value
  -3.21 (-11.2, 4.79), P =
0.43
-14.1 (-34.4, 6.06), P =
0.17
Derm–CAD versus image–based dermoscopy – direct comparison
Derm–CAD 5 153 765 94.1 (89.1, 96.9) 80.8 (68.2, 89.3)
Image-based
dermoscopy
5 153 765 93.9 (85.1, 97.7) 88.3 (56.5, 97.8)
Difference (95% CI), P
value
  0.17 (-6.61, 6.95), P =
0.96
-7.44 (-28.4, 13.6), P =
0.49
MSI–CAD versus image-based dermoscopy – indirect comparison
MSI–CAD 8 286 2401 92.9 (83.7, 97.1) 43.6 (24.8, 64.5)
Image-based
dermoscopy
5 154 371 74.0 (66.5, 80.3) 58.7 (43.5, 72.4)
Difference (95% CI), P
value
  18.9 (9.58, 28.2), P =
0.003
-15.0 (-40.7, 10.6), P =
0.26
MSI–CAD versus image-based dermoscopy – direct comparison
MSI–CAD 5 154 371 96.8 (92.4, 98.6) 29.8 (12.4, 56.1)
Image-based
dermoscopy
5 154 371 74.0 (66.5, 80.3) 58.7 (43.5, 72.4)
Difference (95% CI), P
value
  22.7 (15.2, 30.2), P <
0.001
-28.9 (-56.3, -1.48), P =
0.039
Melafind (MSI–CAD) versus Image–based dermoscopy – indirect comparison
MelaFind 5 196 1798 97.4 (94.0, 98.9) 29.3 (12.1, 55.6)
Image-based
dermoscopy
4 142 288 72.5 (64.6, 79.2) 50.7 (42.6, 58.7)
Difference (95% CI), P
value
  24.5 (16.5, 32.4), P <
0.001
-20.9 (-45.5, 3.75), P =
0.10
Melafind (MSI–CAD) versus Image–based dermoscopy – direct comparison
MelaFind 4 142 288 96.5 (91.8, 98.5) 22.8 (8.38, 48.9)
Image-based
dermoscopy
4 142 288 72.5 (64.6, 79.2) 50.7 (42.6, 58.7)
Difference (95% CI), P
value
  23.9 (16.0, 31.9), P <
0.001
-27.9 (-50.1, -5.66), P =
0.014
Derm–CAD versus MSI–CAD - indirect comparison
Derm–CAD 22 1063 8992 90.1 (84.0, 94.0) 74.3 (63.6, 82.7)
MSI–CAD 8 286 2401 92.9 (83.7, 97.1) 43.6 (24.8, 64.5)
Difference (95% CI), P
value
  2.83 (-5.04, 10.7),
P = 0.48
-30.7 (-53.8, -7.64), P =
0.009
Footnotes
Key: CAD - computer-assisted diagnosis; CI - confidence interval; Derm-CAD - digital dermoscopy based computer-assisted
diagnosis; MSI-CAD - multispectral imaging based computer-assisted diagnosis; P - probability.
7 Sensitivity and Specificity of CAD systems in Unreferred Populations
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Derm-CAD
CAD System Study Target condition TPFP FNTP Sensitivity (95% CI)Specificity (95% CI)
DB-MIPS Wollina 2007 MM+Mis 31 16 2 60 0.89 [0.67, 0.99] 0.84 [0.80, 0.88]
MSI-CAD
CAD System Study Target condition TPFP FNTP Sensitivity (95% CI)Specificity (95% CI)
MoleMate SIAscopeWalter 2012 MM+Mis 18 209 0 539 1.00 [0.81, 1.00] 0.72 [0.69, 0.75]
MoleMate SIAscopeWalter 2012 MM 14 213 0 539 1.00 [0.77, 1.00] 0.72 [0.68, 0.75]
MoleMate SIAscopeWalter 2012 Any* 23 204 2 537 0.92 [0.74, 0.99] 0.72 [0.69, 0.76]
SIAscope Sgouros 2014 Any* 26 7 5 6 0.84 [0.66, 0.96] 0.46 [0.19, 0.75]
Footnotes
Any - any skin cancer or lesion requring excision (secondary objective); CI - confidence interval; Derm-CAD - digital
dermoscopy based computer-assisted diagnosis; FN - false negative; FP - false positive; MSI-CAD - multispectral imaging
based computer-assisted diagnosis; MM - invasive melanoma only (secondary objective); MM+Mis - invasive melanoma and
atypical intraepidermal melanocytic variants (primary objective); TN - true negative; TP - true positive.
8 Direct comparisons of single CAD studies with dermoscopy for diagnosis of melanoma and other types of
skin cancer
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Study Sensitivity (true positives/cases) % Difference (95%
CI) 
Specificity (true negatives/non cases)
%
Difference (95%
CI)
MSI–CAD study comparisons: invasive melanoma and atypical intraepidermal melanocytic variants
  MSI–CAD In–persondermoscopy
  MSI–CAD In–persondermoscopy
 
Bono 2002 80.3 (53/66) 90.9 (60/66) -10.6 (-22.8,
1.58)
49.0 (121/247) 74.5 (184/247) -25.5 (-33.5,
-17.0)
MSI–CAD study comparisons: Invasive melanoma
  MSI–CAD In–persondermoscopy   MSI–CAD
In–person
dermoscopy
 
Ascierto
2010
66.7 (8/12) 100 (12/12) -33.3 (-60.9,
-2.20)
76.2 (32/42) 45.2 (19/42) 31.0 (10.1,
48.4)
  MelaFind 
(MSI–CAD)
Image-based
dermoscopy  
Melafind
(MSI–CAD)
Image-based
dermoscopy
 
Friedman
2008
100 (21/21) 81.0 (17/21) 19.1 (-0.15,
40.0)
29.5 (23/78) 44.9 (35/78) -15.4 (-29.6,
-0.23)
Derm–CAD comparisons: invasive melanoma and atypical intraepidermal melanocytic variants
  Derm–CAD In–persondermoscopy   Derm–CAD
In–person
dermoscopy
 
Bauer 2000 92.9 (39/42) 78.6 (33/42) 14.3 (-1.06,
29.5)
97.8 (267/273) 96.3 (263/273) 1.47 (-1.55,
4.64)
Dreiseitl
2009 *
88.9 (24/27) 96.3 (26/27) -7.41 (-24.6,
8.88)
48.0 (207/431) 71.9 (310/431) -23.9 (-30.1,
-17.4)
  Unnamed
system
Derm–CAD 
Image-based
dermoscopy  
Unnamed
system
Derm–CAD
Image-based
dermoscopy
 
Menzies
1996
88.9 (40/45) 91.1 (41/45) -2.22 (-15.7,
11.2)
75.6 (90/119) 70.6 (84/119) 5.04 (-6.21,
16.1)
  DB-MIPS 
(Derm–CAD)
In–person
dermoscopy  
DB-MIPS 
(Derm–CAD)
In–person
dermoscopy
 
Bauer 2000 92.9 (39/42) 78.6 (33/42) 14.3 (-1.06,
29.5)
97.8 (267/273) 96.3 (263/273) 1.47 (-1.55,
4.64)
  DB-MIPS 
(Derm–CAD)
Image-based
dermoscopy  
DB-MIPS 
(Derm–CAD)
Image-based
dermoscopy
 
Seidenari
1998
93.5 (29/31) 80.6 (25/31) 12.9 (-4.62,
30.5)
94.9 (56/59) 94.9 (56/59) 0.00 (-9.44,
9.44)
CAD–based diagnosis vs. CAD–aided diagnosis: invasive melanoma and atypical intraepidermal melanocytic variants
  CAD–based 
diagnosis CAD–aided diagnosis  
CAD–based 
diagnosis
CAD–aided 
diagnosis
 
Dreiseitl
2009 *
88.9 (24/27) 74.1 (20/27) 14.8 (-6.4, 34.9) 48.0 (207/431) 81.9 (353/431) -33.9 (39.6,
-27.7)
Hauschild
2014
96.9 (63/65) 78.5 (51/65) 18.5 (7.3, 30.1) 9.2 (6/65) 46.2 (30/65) -36.9 (-49.9,
-22.0)
Footnotes
* Patient-based analysis unlike other studies in the table which were lesion-based.
Key: CAD - computer-assisted diagnosis; CI - confidence interval; Derm-CAD - digital dermoscopy based computer-assisted
diagnosis; MSI-CAD - multispectral imaging based computer-assisted diagnosis.
9 Sensitivity and Specificity of Oblique Incidence Diffuse Reflectance Spectrometry CAD (OIDRS–CAD)
studies for primary target condition: invasive melanoma and atypical intraepidermal melanocytic variants
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Index test, target
condition
True
positives
False
positives
False
negatives
True
negatives
Sensitivity (95% CI)
%
Specificity (95% CI)
%
Garcia Uribe 2012 9 13 1 113 90.0 (59.6, 98.2) 89.7 (83.2, 93.9)
Footnotes
10 Sensitivity and Specificity of Electrical Impedance Spectroscopy CAD (EIS–CAD) studies for each primary
target condition
Index test, target
condition
True
positives
False
positives
False
negatives
True
negatives
Sensitivity (95% CI)
%
Specificity (95% CI)
%
Invasive melanoma and atypical intraepidermal melanocytic variants
Mohr 2013 101 246 2 97 98.1 (93.2, 99.5) 28.3 (23.8, 33.3)
Malvehy 2014 256 1095 9 583 96.6 (93.7, 98.2) 34.7 (32.5, 37.1)
Basal cell carcinoma
Mohr 2013 21 351 0 74 100 (84.5, 100) 17.4 (14.1, 21.3)
Malvehy 2014 48 1359 0 536 100 (92.6, 100) 28.3 (26.3, 30.4)
Cutaneous Squamous cell carcinoma
Malvehy 2014 7 1095 0 841 100 (59.0, 100) 43.3 (41.3, 45.7)
Footnotes
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Classification pending references
Data and analyses 
Data tables by test
Test StudiesParticipants
1 Derm-CAD Microderm (MM+MiS) 3 793
2 Derm-CAD DBMIPS (MM+MiS) 6 1903
3 Derm-CAD DBMIPS vs Dermoscopy (MM+MiS) 2 405
4 Derm-CAD DEMMIPS (MM+MiS) 1 341
5 Derm-CAD SkinView (MM) 0 0
6 Derm-CAD SkinView (MM+MiS) 2 220
7 Derm-CAD SkinView (Any) 1 44
8 Derm-CAD NevusDr (MM+MiS) 1 870
9 Derm-CAD NevusDr (Any) 1 870
10 Derm-CAD ImageJ (MM+MiS) 1 3021
11 Derm-CAD IBAS2000 (MM+MiS) 1 29
12 Derm-CAD Nevuscreen (MM+MiS) 1 165
13 Derm-CAD SolarScan (MM) 1 786
14 Derm-CAD SolarScan (MM+MiS) 1 786
15 Derm-CAD No name (MM) 1 164
16 Derm-CAD No name (MM+MiS) 5 864
17 Derm-CAD No name (Any) 1 173
18 Derm-CAD No name (BCC) 1 173
19 Derm-CAD DBMIPS_UNREF (MM+MiS) 1 357
20 MSI-CAD SIAscope_UNREF (MM) 1 766
21 MSI-CAD SIAscope_UNREF (MM+MiS) 1 766
22 MSI-CAD SIAscope_UNREF (Any) 1 766
23 MSI-CAD SpectroShade (MM) 1 54
24 MSI-CAD SpectroShade (MM+MiS) 1 347
25 EIS-CAD-Nevisense (MM) 2 2389
26 EIS-CAD-Nevisense (MM+MiS) 2 2389
27 EIS-CAD-Nevisense (Any) 2 2389
28 EIS-CAD-Nevisense (BCC) 2 2389
29 EIS-CAD-Nevisense (cSCC) 1 1943
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Test StudiesParticipants
30 MSI-CAD Melafind (MM) 2 229
31 MSI-CAD Melafind (MM+MiS) 5 1798
32 MSI-CAD Melafind_vs Dermoscopy (MM+MiS) 4 288
33 MSI-CAD Melafind (Any) 0 0
34 MSI-CAD SIAscopy (MM) 1 60
35 MSI-CAD SIAscopy (MM+MiS) 1 83
36 MSI-CAD SIAscope Only_UNREF (Any) 1 44
37 DRS-CAD OIDRS (MM+Mis) 1 136
38 DRS-CAD OIDRS (Any + dysplastic) 1 136
39 DRS-CAD OIDRS (Any) 1 89
40 MSI-CAD TS (MM) 1 43
41 MSI-CAD TS (MM+MiS) 1 173
42 CAD–DRS–TS vs Dermoscopy (MM+MiS) 1 313
43 MSI-CAD OTHER (MM+MiS) 0 0
44 MSI-CAD NR_ML (MM+MiS) 0 0
45 Derm-CAD OTHER (MM) 0 0
46 PersonDERM-DigidermDBMIPS (MM+MiS) 1 315
47 ImageDERM-DigidermDBMIPS (MM+MiS) 1 90
48 ImageDERM-DigidermDEMMIPS (MM+MiS) 1 341
49 PersonDerm-DigidermImageJ (MM+MiS) 1 458
50 ImageDerm-DigidermNevuscreen (MM+MiS) 1 165
51 ImageDerm-DigidermNR (MM) 1 164
52 ImageDerm-DigidermNR (MM+MiS) 2 169
53 PersonDERM-DRS-SpectroShade (MM) 1 54
54 ImageDERM-DRSMelafind (MM) 1 99
55 ImageDERM-DRSMelafind (MM+MiS) 4 288
56 ImageDERM-DRSSIA (MM+MiS) 1 83
57 PersonDERM-DRSTS (MM+MiS) 1 313
58 Derm-CAD (direct comparison only) (MM+MiS) 10 2233
59 Image-based Dermoscopy (for Derm-CAD comparison) (MM+MiS) 5 765
60 In-person based Dermoscopy - Derm-CAD studies (MM+MiS) 2 773
61 MSI-CAD (direct comparison only) (MM+MiS) 8 1059
62 Image-based Dermoscopy (for MSI-CAD comparison) (MM+MiS) 5 371
63 MSI-CAD All systems (MM+MiS) 8 2401
64 Derm-CAD All systems (MM+MiS) 22 8992
65 Derm-CAD MoleExpert (Any) 1 870
66 Derm-CAD All systems (MM) 2 950
67 Image-based Dermoscopy - Derm-CAD studies (MM) 1 164
68 MSI-CAD All (Melafind) (MM+MiS), CAD + Clinician (diagnostic aid) only 2 142
69 MSI-CAD All (MM+MiS), CAD only 6 777
70 MSI-CAD Melafind (MM+MiS), CAD only 3 174
71 Derm-CAD All (MM+MiS), CAD + Clinician (diagnostic aid) only 3 589
72 Derm-CAD All (MM+MiS), CAD only 19 8403
Figures
Figure 1
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Caption
Sample photographs of superficial spreading melanoma (left) and nodular melanoma (right)
Figure 2
Caption
Sample photographs of BCC (left) and cSCC (right)
Figure 3
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Caption
Examples of commercially available CAD systems using digital dermoscopy (A), electrical impedance spectroscopy (B) and
multispectral imaging (C and D). Reproduced with permission of the manufacturers. Copyright © [2018] [MedX Corp,
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Canada; DermoScanGmbH, Germany; SciBase III, Sweden]: reproduced with permission.
Figure 4
Caption
Current clinical pathway for people with skin lesions
Figure 5
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Caption
PRISMA flow diagram.
Figure 6
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Caption
Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages
across included studies
Figure 7
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Caption
Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study
Figure 8 (Analysis 11) 
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Caption
Forest plot of different types of digital dermoscopy CAD systems (DermCAD) for the detection of invasive melanoma or
intraepidermal melanocytic variants (MM+MiS)
Figure 9 (Analysis 10) 
#164a Computer assisted diagnosis techniques (dermoscopy and spectroscopy-based) for the diagnosis of skin cancer...
225 / 268
Caption
Summary plot of digital dermoscopy CAD systems (Derm-CAD) for the detection of invasive melanoma or intraepidermal
melanocytic variants (MM+MiS)
Figure 10 (Analysis 38) 
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Caption
Forest plot of data for image-based dermoscopy diagnosis and digital dermoscopy CAD systems (Derm-CAD) for the
detection of invasive melanoma or intraepidermal melanocytic variants (MM+MiS)
Figure 11 (Analysis 38) 
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Caption
Summary plot of image-based dermoscopy diagnosis versus digital dermoscopy CAD systems (Derm-CAD) for the detection
of invasive melanoma or intraepidermal melanocytic variants (MM+MiS)
Figure 12 (Analysis 15) 
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Caption
Summary plot of direct comparisons between image-based dermoscopy diagnosis versus digital dermoscopy CAD systems
(Derm-CAD) for the detection of invasive melanoma or intraepidermal melanocytic variants (MM+MiS)
Figure 13 (Analysis 1) 
Caption
Forest plot of different types of multi-spectral imaging CAD (MSI-CAD) for the detection of invasive melanoma or
#164a Computer assisted diagnosis techniques (dermoscopy and spectroscopy-based) for the diagnosis of skin cancer...
229 / 268
intraepidermal melanocytic variants (MM+MiS)
Figure 14 (Analysis 4) 
Caption
Summary plot of multi-spectral imaging CAD (MSI-CAD) for the detection of invasive melanoma or intraepidermal
melanocytic variants (MM+MiS)
Figure 15 (Analysis 37) 
Caption
Forest plot of data for image-based dermoscopy diagnosis and multi-spectral imaging CAD systems (MSI-CAD) for the
detection of invasive melanoma or intraepidermal melanocytic variants (MM+MiS)
Figure 16 (Analysis 37) 
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Caption
Summary plot of image-based dermoscopy diagnosis versus multi-spectral imaging CAD systems (MSI-CAD) for the
detection of invasive melanoma or intraepidermal melanocytic variants (MM+MiS)
Figure 17 (Analysis 8) 
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Caption
Summary plot of direct comparisons between image-based dermoscopy diagnosis versus multi-spectral imaging CAD
systems (MSI-CAD) for the detection of invasive melanoma or intraepidermal melanocytic variants (MM+MiS)
Figure 18 (Analysis 18) 
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Caption
Summary plot for the multi-spectral imaging CAD system (MSI-CAD) DBMIPS for the detection of invasive melanoma or
intraepidermal melanocytic variants (MM+MiS)
Figure 19 (Analysis 21) 
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Caption
Summary plot for the multi-spectral imaging CAD system (MSI-CAD) MelaFind for the detection of invasive melanoma or
intraepidermal melanocytic variants (MM+MiS)
Figure 20 (Analysis 32) 
Caption
Forest plot of different types of multi-spectral imaging CAD system(MSI-CAD) for the detection of invasive melanoma alone
(MM)
Figure 21 (Analysis 32) 
#164a Computer assisted diagnosis techniques (dermoscopy and spectroscopy-based) for the diagnosis of skin cancer...
234 / 268
Caption
Summary plot of different types of multi-spectral imaging CAD (MSI-CAD) for the detection of invasive melanoma alone (MM)
Figure 22 (Analysis 8) 
Caption
Forest plot of direct comparisons between image-based dermoscopy diagnosis versus multispectral imaging CAD systems
(MSI-CAD) for the detection of invasive melanoma or intraepidermal melanocytic variants (MM+MiS)
Figure 23 (Analysis 15) 
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Caption
Forest plot of direct comparisons between image-based dermoscopy diagnosis versus digital dermoscopy CAD systems
(Derm-CAD) for the detection of invasive melanoma or intraepidermal melanocytic variants (MM+MiS)
Sources of support 
Internal sources
No sources of support provided
External sources
NIHR Systematic Review Programme, UK
The National Institute for Health Research (NIHR), UK
The NIHR, UK, is the largest single funder of the Cochrane Skin Group
Feedback 
Appendices 
1 Current content and structure of the Programme Grant
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List of reviews  
Estimated number of
studies Diagnosis of melanoma 
1. Visual inspection versus visual inspection plus dermoscopy 120
2. Teledermatology 12
3. Mobile phone applications 2
4. Computer-aided diagnosis: dermoscopy based and spectroscopy based techniques 37
5. Reflectance confocal microscopy 19
6. High frequency ultrasound 3
7. Overview: comparing the accuracy of tests for which sufficient evidence was identified either
alone or in combination –
Diagnosis of keratinocyte skin cancer (basal cell carcinoma and cutaneous squamous cell
carcinoma)
 
8. Visual inspection ± dermoscopy 22
9. Computer aided diagnosis: dermoscopy based and spectroscopy based techniques 3
10. Optical coherence tomography 6
11. Reflectance confocal microscopy 9
12. High frequency ultrasound 1
13. Exfoliative cytology 5
14. Overview: comparing the accuracy of tests for which sufficient evidence was identified either
alone or in combination –
Staging of melanoma  
15. Ultrasound 25 to 30
16. Computer tomography 5 to 10
17. Positron emission tomography or positron emission tomography-computer tomography 20 to 25
18. Magnetic resonance imaging 5
19. Sentinel lymph node biopsy ± high frequency ultrasound 70
20. Overview: comparing the accuracy of tests for which sufficient evidence was identified either
alone or in combination –
Staging of cutaneous squamous cell carcinoma  
21. Imaging tests review 10 to 15
22. Sentinel lymph node biopsy ± high frequency ultrasound 15 to 20
2 Acronyms
Acronym Definition
μm micrometre
AK actinic keratosis
ANN artificial neural network
BCC basal cell carcinoma
BD Bowen’s disease
BPC between person comparison (of tests)
CAD computer assisted diagnosis
CCS case control study
CS case series
cSCC cutaneous squamous cell carcinoma
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Acronym Definition
D- disease negative
D+ disease positive
Derm–CAD Digital dermoscopy based computer assisted diagnosis
DF dermatofibroma
DRS diffuse reflectance spectroscopy
DRSi diffuse reflectance spectroscopy imaging
Dx diagnosis
EIS electrical impedance spectroscopy
FN false negative
FP false positive
FU Follow- up
GP general practitioner
H&E haematoxylin and eosin stain
HFUS high frequency ultrasound
Hz hertz
KHz kilohertz
K–NN k nearest neighbour
MHz megahertz
MiS melanoma in situ (or lentigo maligna)
MM malignant melanoma
mm millimetre
MSI multispectral imaging
N/A not applicable
NC non comparative
nm nanometre
NPV negative predictive value
NR not reported
P prospective
PPV positive predictive value
PSL pigmented skin lesion
R retrospective
RCM reflectance confocal microscopy
RCT randomised controlled trial
SCC squamous cell carcinoma
SD standard deviation
se sensitivity
sp specificity
spectro–CADspectroscopy based computer–assisted diagnosis
SK seborrhoeic keratosis
SSM superficial spreading melanoma
SVM Support vector machine
TN true negative
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Acronym Definition
TS Telespectrophotometry System
VI visual inspection
UNREF Unreferred population
WPC within person comparison (of tests)
WPC-algs within person comparison (of algorithms)
3 Proposed sources of heterogeneity
i. Population characteristics
general versus higher risk populations
patient population: Primary /secondary / specialist unit
lesion suspicion: general suspicion/atypical/equivocal/NR
lesion type: any pigmented; melanocytic
inclusion of multiple lesions per participant
ethnicity
ii. Index test characteristics
the nature of and definition of criteria for test positivity
observer experience with the index test
approaches to lesion preparation (e.g., the use of oil or antiseptic gel for dermoscopy)
iii. Reference standard characteristics
reference standard used
whether histology-reporting meets pathology-reporting guidelines
use of excisional versus diagnostic biopsy
whether two independent dermatopathologists reviewed histological diagnosis
iv. Study quality
consecutive or random sample of participants recruited
index test interpreted blinded to the reference standard result
index test interpreted blinded to the result of any other index test
presence of partial or differential verification bias (whereby only a sample of those subject to the index test are verified by
the reference test or by the same reference test with selection dependent on the index test result)
use of an adequate reference standard
overall risk of bias
4 Final search strategies
Melanoma search strategies to August 2016
Database: Ovid MEDLINE(R) 1946 to August week 3 2016
Search strategy:
1 exp melanoma/
2 exp skin cancer/
3 exp basal cell carcinoma/
4 basalioma$1.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or
adenoma$1 or epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or
keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1
or epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or CSCC or NMSC).ti,ab.
11 keratinocy$.ti,ab.
12 Keratinocytes/
13 or/1-12
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14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 exp epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 exp diagnosis, computer-assisted/
38 MoleMax.ti,ab.
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 Aura.ti,ab.
44 (optical adj2 scan$).ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 (high adj3 ultraso$).ti,ab.
51 (canine adj2 detect$).ti,ab.
52 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
53 smartphone$.ti,ab.
54 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
55 Mole Detective.ti,ab.
56 Spot Check.ti,ab.
57 (mole$1 adj2 map$).ti,ab.
58 (total adj2 body).ti,ab.
59 exfoliative cytolog$.ti,ab.
60 digital analys$.ti,ab.
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61 (image$1 adj3 software).ti,ab.
62 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or
teledermatoscop$ or tele-dermatoscop$).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (computer adj2 diagnos$).ti,ab.
65 exp sentinel lymph node biopsy/
66 (sentinel adj2 node).ti,ab.
67 nevisense.mp. or HFUS.ti,ab.
68 electrical impedance spectroscopy.ti,ab.
69 history taking.ti,ab.
70 patient history.ti,ab.
71 (naked eye adj (exam$ or assess$)).ti,ab.
72 (skin adj exam$).ti,ab.
73 physical examination/
74 ugly duckling.mp. or UD.ti,ab.
75 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
76 ABCDE.mp. or VOC.ti,ab.
77 clinical accuracy.ti,ab.
78 Family Practice/ or Physicians, Family/ or clinical competence/
79 (confocal adj2 microscop$).ti,ab.
80 diagnostic algorithm$1.ti,ab.
81 checklist$.ti,ab.
82 virtual imag$1.ti,ab.
83 volatile organic compound$1.ti,ab.
84 dog$1.ti,ab.
85 gene expression analy$.ti,ab.
86 reflex transmission imag$.ti,ab.
87 thermal imaging.ti,ab.
88 elastography.ti,ab.
89 or/14-88
90 (CT or PET).ti,ab.
91 PET-CT.ti,ab.
92 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
93 exp Deoxyglucose/
94 deoxy-glucose.ti,ab.
95 deoxyglucose.ti,ab.
96 CATSCAN.ti,ab.
97 exp Tomography, Emission-Computed/
98 exp Tomography, X-ray computed/
99 positron emission tomograph$.ti,ab.
100 exp magnetic resonance imaging/
101 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
102 exp echography/
103 Doppler echography.ti,ab.
104 sonograph$.ti,ab.
105 ultraso$.ti,ab.
106 doppler.ti,ab.
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107 magnetic resonance imag$.ti,ab.
108 or/90-107
109 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
110 "Sensitivity and Specificity"/
111 exp cancer staging/
112 or/109-111
113 108 and 112
114 89 or 113
115 13 and 114
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations 29 August 2016
Search strategy:
1 basalioma$1.ti,ab.
2 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or
adenoma$1 or epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
3 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
4 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or
keratinocyt$).ti,ab.
5 nmsc.ti,ab.
6 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1
or epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
7 (BCC or CSCC or NMSC).ti,ab.
8 keratinocy$.ti,ab.
9 or/1-8
10 dermoscop$.ti,ab.
11 dermatoscop$.ti,ab.
12 photomicrograph$.ti,ab.
13 (epiluminescence adj2 microscop$).ti,ab.
14 (confocal adj2 microscop$).ti,ab.
15 (incident light adj2 microscop$).ti,ab.
16 (surface adj2 microscop$).ti,ab.
17 (visual adj (inspect$ or examin$)).ti,ab.
18 ((clinical or physical) adj examin$).ti,ab.
19 3 point.ti,ab.
20 three point.ti,ab.
21 pattern analys$.ti,ab.
22 ABCD$.ti,ab.
23 menzies.ti,ab.
24 7 point.ti,ab.
25 seven point.ti,ab.
26 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
27 artificial intelligence.ti,ab.
28 AI.ti,ab.
29 computer assisted.ti,ab.
30 computer aided.ti,ab.
31 neural network$.ti,ab.
32 MoleMax.ti,ab.
33 image process$.ti,ab.
34 automatic classif$.ti,ab.
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35 image analysis.ti,ab.
36 SIAscop$.ti,ab.
37 Aura.ti,ab.
38 (optical adj2 scan$).ti,ab.
39 MelaFind.ti,ab.
40 SIMSYS.ti,ab.
41 MoleMate.ti,ab.
42 SolarScan.ti,ab.
43 VivaScope.ti,ab.
44 (high adj3 ultraso$).ti,ab.
45 (canine adj2 detect$).ti,ab.
46 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
47 smartphone$.ti,ab.
48 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
49 Mole Detective.ti,ab.
50 Spot Check.ti,ab.
51 (mole$1 adj2 map$).ti,ab.
52 (total adj2 body).ti,ab.
53 exfoliative cytolog$.ti,ab.
54 digital analys$.ti,ab.
55 (image$1 adj3 software).ti,ab.
56 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or
teledermatoscop$ or tele-dermatoscop$).ti,ab.
57 (optical coherence adj (technolog$ or tomog$)).ti,ab.
58 (computer adj2 diagnos$).ti,ab.
59 (sentinel adj2 node).ti,ab.
60 nevisense.mp. or HFUS.ti,ab.
61 electrical impedance spectroscopy.ti,ab.
62 history taking.ti,ab.
63 patient history.ti,ab.
64 (naked eye adj (exam$ or assess$)).ti,ab.
65 (skin adj exam$).ti,ab.
66 ugly duckling.mp. or UD.ti,ab.
67 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
68 ABCDE.mp. or VOC.ti,ab.
69 clinical accuracy.ti,ab.
70 (Family adj (Practice or Physicians)).ti,ab.
71 (confocal adj2 microscop$).ti,ab.
72 clinical competence.ti,ab.
73 diagnostic algorithm$1.ti,ab.
74 checklist$.ti,ab.
75 virtual imag$1.ti,ab.
76 volatile organic compound$1.ti,ab.
77 dog$1.ti,ab.
78 gene expression analy$.ti,ab.
79 reflex transmission imag$.ti,ab.
80 thermal imaging.ti,ab.
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81 elastography.ti,ab.
82 or/10-81
83 (CT or PET).ti,ab.
84 PET-CT.ti,ab.
85 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
86 deoxy-glucose.ti,ab.
87 deoxyglucose.ti,ab.
88 CATSCAN.ti,ab.
89 positron emission tomograph$.ti,ab.
90 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
91 Doppler echography.ti,ab.
92 sonograph$.ti,ab.
93 ultraso$.ti,ab.
94 doppler.ti,ab.
95 magnetic resonance imag$.ti,ab.
96 or/83-95
97 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
98 96 and 97
99 82 or 98
100 9 and 99
Database: Embase 1974 to 29 August 2016
Search strategy:
1 *melanoma/
2 *skin cancer/
3 *basal cell carcinoma/
4 basalioma$.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$ or adenoma$
or epithelioma$ or lesion$ or malignan$ or nodule$)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or
keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or cscc).mp. or NMSC.ti,ab.
11 keratinocyte.ti,ab.
12 keratinocy$.ti,ab.
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 *epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
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24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 MoleMax.ti,ab.
38 exp diagnosis, computer-assisted/
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 (optical adj2 scan$).ti,ab.
44 Aura.ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 confocal microscop$.ti,ab.
51 (high adj3 ultraso$).ti,ab.
52 (canine adj2 detect$).ti,ab.
53 ((mobile or cell$ or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
54 smartphone$.ti,ab.
55 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
56 Spot Check.ti,ab.
57 Mole Detective.ti,ab.
58 (mole$1 adj2 map$).ti,ab.
59 (total adj2 body).ti,ab.
60 exfoliative cytolog$.ti,ab.
61 digital analys$.ti,ab.
62 (image$1 adj3 software).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or
teledermatoscop$).mp. or tele-dermatoscop$.ti,ab.
65 (computer adj2 diagnos$).ti,ab.
66 *sentinel lymph node biopsy/
67 (sentinel adj2 node).ti,ab.
68 nevisense.ti,ab.
69 HFUS.ti,ab.
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70 electrical impedance spectroscopy.ti,ab.
71 history taking.ti,ab.
72 patient history.ti,ab.
73 (naked eye adj (exam$ or assess$)).ti,ab.
74 (skin adj exam$).ti,ab.
75 *physical examination/
76 ugly duckling.ti,ab.
77 UD sign$.ti,ab.
78 ((physician$ or clinical or physical) adj (exam$ or recog$ or triage)).ti,ab.
79 ABCDE.ti,ab.
80 clinical accuracy.ti,ab.
81 *general practice/
82 (confocal adj2 microscop$).ti,ab.
83 clinical competence/
84 diagnostic algorithm$.ti,ab.
85 checklist$1.ti,ab.
86 virtual image$1.ti,ab.
87 volatile organic compound$1.ti,ab.
88 VOC.ti,ab.
89 dog$1.ti,ab.
90 gene expression analys$.ti,ab.
91 reflex transmission imaging.ti,ab.
92 thermal imaging.ti,ab.
93 elastography.ti,ab.
94 dog$1.ti,ab.
95 gene expression analys$.ti,ab.
96 reflex transmission imaging.ti,ab.
97 thermal imaging.ti,ab.
98 elastography.ti,ab.
99 or/14-93
100 PET-CT.ti,ab.
101 (CT or PET).ti,ab.
102 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
103 exp Deoxyglucose/
104 CATSCAN.ti,ab.
105 deoxyglucose.ti,ab.
106 deoxy-glucose.ti,ab.
107 *positron emission tomography/
108 *computer assisted tomography/
109 positron emission tomograph$.ti,ab.
110 *nuclear magnetic resonance imaging/
111 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
112 *echography/
113 Doppler.ti,ab.
114 sonograph$.ti,ab.
115 ultraso$.ti,ab.
116 magnetic resonance imag$.ti,ab.
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117 or/100-116
118 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
119 "Sensitivity and Specificity"/
120 *cancer staging/
121 or/118-120
122 117 and 121
123 99 or 122
124 13 and 123
Database: Cochrane Library (Wiley) 2016 searched 30 August 2016 CDSR Issue 8 of 12 2016 CENTRAL Issue 7 of 12 2016
HTA Issue 3 of 4 July 2016 DARE Issue 3 of 4 2015
Search strategy:
#1 melanoma* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyte*
#2 MeSH descriptor: [Melanoma] explode all trees
#3 "skin cancer*"
#4 MeSH descriptor: [Skin Neoplasms] explode all trees
#5 skin near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
#6 nmsc
#7 "squamous cell" near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*) near/2 (skin or epiderm* or cutaneous)
#8 "basal cell" near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*)
#9 pigmented near/2 (lesion* or nevus or mole* or naevi or naevus or nevi or skin)
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 dermoscop*
#12 dermatoscop*
#13 Photomicrograph*
#14 MeSH descriptor: [Dermoscopy] explode all trees
#15 confocal near/2 microscop*
#16 epiluminescence near/2 microscop*
#17 incident next light near/2 microscop*
#18 surface near/2 microscop*
#19 "visual inspect*"
#20 "visual exam*"
#21 (clinical or physical) next (exam*)
#22 "3 point"
#23 "three point"
#24 "pattern analys*"
#25 ABDC
#26 menzies
#27 "7 point"
#28 "seven point"
#29 digital near/2 (dermoscop* or dermatoscop*)
#30 "artificial intelligence"
#31 "AI"
#32 "computer assisted"
#33 "computer aided"
#34 AI
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#35 "neural network*"
#36 MoleMax
#37 "computer diagnosis"
#38 "image process*"
#39 "automatic classif*"
#40 SIAscope
#41 "image analysis"
#42 "optical near/2 scan*"
#43 Aura
#44 MelaFind
#45 SIMSYS
#46 MoleMate
#47 SolarScan
#48 Vivascope
#49 "confocal microscopy"
#50 high near/3 ultraso*
#51 canine near/2 detect*
#52 Mole* near/2 map*
#53 total near/2 body
#54 mobile* or smart near/2 phone*
#55 cell next phone*
#56 smartphone*
#57 "mitotic index"
#58 DermoScan or SkinVision or DermLink or SpotCheck
#59 "Mole Detective"
#60 "Spot Check"
#61 mole* near/2 map*
#62 total near/2 body
#63 "exfoliative cytolog*"
#64 "digital analys*"
#65 image near/3 software
#66 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop*
or tele-dermatolog*
#67 "optical coherence" next (technolog* or tomog*)
#68 computer near/2 diagnos*
#69 sentinel near/2 node*
#70 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or
#28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45
or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or
#63 or #64 or #65 or #66 or #67 or #68 or #69
#71 ultraso*
#72 sonograph*
#73 MeSH descriptor: [Ultrasonography] explode all trees
#74 Doppler
#75 CT or PET or PET-CT
#76 "CAT SCAN" or "CATSCAN"
#77 MeSH descriptor: [Positron-Emission Tomography] explode all trees
#78 MeSH descriptor: [Tomography, X-Ray Computed] explode all trees
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#79 MRI
#80 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees
#81 MRI or fMRI or NMRI or scintigraph*
#82 "magnetic resonance imag*"
#83 MeSH descriptor: [Deoxyglucose] explode all trees
#84 deoxyglucose or deoxy-glucose
#85 "positron emission tomograph*"
#86 #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84 or #85
#87 stage* or staging or metasta* or recurrence or sensitivity or specificity or "false negative*" or thickness*
#88 MeSH descriptor: [Neoplasm Staging] explode all trees
#89 #87 or #88
#90 #89 and #86
#91 #70 or #90
#92 #10 and #91
#93 BCC or CSCC or NMCS
#94 keratinocy*
#95 #93 or #94
#96 #10 or #95
#97 nevisense
#98 HFUS
#99 "electrical impedance spectroscopy"
#100 "history taking"
#101 "patient history"
#102 naked next eye near/1 (exam* or assess*)
#103 skin next exam*
#104 "ugly duckling" or (UD sign*)
#105 MeSH descriptor: [Physical Examination] explode all trees
#106 (physician* or clinical or physical) near/1 (exam* or recog* or triage*)
#107 ABCDE
#108 "clinical accuracy"
#109 MeSH descriptor: [General Practice] explode all trees
#110 confocal near microscop*
#111 "diagnostic algorithm*"
#112 MeSH descriptor: [Clinical Competence] explode all trees
#113 checklist*
#114 "virtual image*"
#115 "volatile organic compound*"
#116 dog or dogs
#117 VOC
#118 "gene expression analys*"
#119 "reflex transmission imaging"
#120 "thermal imaging"
#121 elastography
#122 #97 or #98 or #99 or #100 or #101 or #102 or #103 or #104 or #105 or #106 or #107 or #108 or #109 or #110 or #111
or #112 or #113 or #114 or #115 or #116 or #117 or #118 or #119 or #120 or #121
#123 #70 or #122
#124 #96 and #123
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#125 #96 and #90
#126 #125 or #124
#127 #10 and #126
Database : CINAHL Plus (EBSCO) 1937 to 30 August 2016
Search strategy:
S1 (MH "Melanoma") OR (MH "Nevi and Melanomas+")
S2 (MH "Skin Neoplasms+")
S3 (MH "Carcinoma, Basal Cell+")
S4 basalioma*
S5 (basal cell) N2 (cancer* or carcinoma* or mass or masses or tumor* or tumour* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*)
S6 (pigmented) N2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin)
S7 melanom* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt*
S8 nmsc
S9 TX BCC or cscc or NMSC
S10 (MH "Keratinocytes")
S11 keratinocyt*
S12 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11
S13 dermoscop* or dermatoscop* or photomicrograph* or (3 point) or (three point) or ABCD* or menzies or (7 point) or
(seven point) or AI or Molemax or SIASCOP* or Aura or MelaFind or SIMSYS or MoleMate or SolarScan or smartphone* or
DermoScan or SkinVision or DermLink or SpotCheck
S14 (epiluminescence or confocal or incident or surface) N2 (microscop*)
S15 visual N1 (inspect* or examin*)
S16 (clinical or physical) N1 (examin*)
S17 pattern analys*
S18 (digital) N2 (dermoscop* or dermatoscop*)
S19 (artificial intelligence)
S20 (computer) N2 (assisted or aided)
S21 (neural network*)
S22 (MH "Diagnosis, Computer Assisted+")
S23 (image process*)
S24 (automatic classif*)
S25 (image analysis)
S26 SIAScop*
S27 (optical) N2 (scan*)
S28 (high) N3 (ultraso*)
S29 elastography
S30 (mobile or cell or cellular or smart) N2 (phone*) N2 (app or application*)
S31 (mole*) N2 (map*)
S32 total N2 body
S33 exfoliative cytolog*
S34 digital analys*
S35 image N3 software
S36 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop*
or tele-dermatoscop* teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop*
S37 (optical coherence) N1 (technolog* or tomog*)
S38 computer N2 diagnos*
S39 sentinel N2 node
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S40 (MH "Sentinel Lymph Node Biopsy")
S41 nevisense or HFUS or checklist* or VOC or dog*
S42 electrical impedance spectroscopy
S43 history taking
S44 "Patient history"
S45 naked eye
S46 skin exam*
S47 physical exam*
S48 ugly duckling
S49 UD sign*
S50 (physician* or clinical or physical) N1 (exam*)
S51 clinical accuracy
S52 general practice
S53 (physician* or clinical or physical) N1 (recog* or triage)
S54 confocal microscop*
S55 clinical competence
S56 diagnostic algorithm*
S57 checklist*
S58 virtual image*
S59 volatile organic compound*
S60 gene expression analys*
S61 reflex transmission imag*
S62 thermal imaging
S63 S13 or S14 or S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR
S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR
S41 OR S42 OR S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR
S55 OR S56 OR S57 OR S58 OR S59 OR S60 OR S61 OR S62
S64 CT or PET
S65 PET-CT
S66 FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical*
S67 (MH "Deoxyglucose+")
S68 deoxy-glucose or deoxyglucose
S69 CATSCAN
S70 CAT-SCAN
S71 (MH "Deoxyglucose+")
S72 (MH "Tomography, Emission-Computed+")
S73 (MH "Tomography, X-Ray Computed")
S74 positron emission tomograph*
S75 (MH "Magnetic Resonance Imaging+")
S76 MRI or fMRI or NMRI or scintigraph*
S77 echography
S78 doppler
S79 sonograph*
S80 ultraso*
S81 magnetic resonance imag*
S82 S64 OR S65 OR S66 OR S67 OR S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR S77
OR S78 OR S79 OR S80 OR S81
S83 stage* or staging or metasta* or recurrence or sensitivity or specificity or (false negative*) or thickness
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S84 (MH "Neoplasm Staging")
S85 S83 OR S84
S86 S82 AND S85
S87 S63 OR S86
S88 S12 AND S87
Database: Science Citation Index SCI Expanded (Web of Science) 1900 to 30 August 2016
Conference Proceedings Citation Index (Web of Science) 1900 to 1 September 2016
Search strategy:
#1 (melanom* or nonmelanom* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyt*)
#2 (basalioma*)
#3 ((skin) near/2 (cancer* or carcinoma or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma*
or lesion* or malignan* or nodule*))
#4 ((basal) near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*))
#5 ((pigmented) near/2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin))
#6 (nmsc or BCC or NMSC or keratinocy*)
#7 ((squamous cell (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*))
#8 (skin or epiderm* or cutaneous)
#9 #8 AND #7
#10 #9 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#11 ((dermoscop* or dermatoscop* or photomicrograph* or epiluminescence or confocal or "incident light" or "surface
microscop*" or "visual inspect*" or "physical exam*" or 3 point or three point or pattern analy* or ABCDE or menzies or 7
point or seven point or dermoscop* or dermatoscop* or AI or artificial or computer aided or computer assisted or neural
network* or Molemax or image process* or automatic classif* or image analysis or siascope or optical scan* or Aura or
melafind or simsys or molemate or solarscan or vivascope or confocal microscop* or high ultraso* or canine detect* or
cellphone* or mobile* or phone* or smartphone or dermoscan or skinvision or dermlink or spotcheck or spot check or mole
detective or mole map* or total body or exfoliative psychology or digital or image software or optical coherence or
teledermatology or telederm* or teledermoscop* or teledermatoscop* or computer diagnos* or sentinel))
#12 ((nevisense or HFUS or impedance spectroscopy or history taking or patient history or naked eye or skin exam* or
physical exam* or ugly duckling or UD sign* or physician* exam* or physical exam* or ABCDE or clinical accuracy or general
practice or confocal microscop* or clinical competence or diagnostic algorithm* or checklist* or virtual image* or volatile
organic or VOC or dog* or gene expression or reflex transmission or thermal imag* or elastography))
#13 #11 or #12
#14 ((PET or CT or FDG or deoxyglucose or deoxy-glucose or fluorodeoxy* or radiopharma* or CATSCAN or positron
emission or computer assisted or nuclear magnetic or MRI or FMRI or NMRI or scintigraph* or echograph* or Doppler or
sonograph* or ultraso* or magnetic reson*))
#15 ((stage* or staging or metast* or recurrence or sensitivity or specificity or false negative* or thickness*))
#16 #14 AND #15
#17 #16 OR #13
#18 #10 AND #17
Refined by: DOCUMENT TYPES: (MEETING ABSTRACT OR PROCEEDINGS PAPER)
5 Full text inclusion criteria
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Criterion Inclusion Exclusion
 
Study design
 
For diagnostic and staging reviews
Any study for which a 2×2 contingency table can be
extracted, e.g.
diagnostic case control studies
'cross-sectional' test accuracy study with
retrospective or prospective data collection
studies where estimation of test accuracy was not the
primary objective but test results for both index and
reference standard were available
RCTs of tests or testing strategies where participants
were randomised between index tests and all
undergo a reference standard (i.e. accuracy RCTs)
 
< 5 melanoma cases (diagnosis reviews)
< 10 participants (staging reviews)
Studies developing new criteria for diagnosis
unless a separate 'test set' of images were
used to evaluate the criteria (mainly digital
dermoscopy)
Studies using 'normal' skin as controls
Letters, editorials, comment papers, narrative
reviews
Insufficient data to construct a 2×2 table
Target
condition
 
Melanoma
Keratinocyte skin cancer (or non-melanoma skin
cancer)
BCC or epithelioma
cSCC
 
Studies exclusively conducted in children
Studies of non-cutaneous melanoma or SCC
Population For diagnostic reviews
Adults with a skin lesion suspicious for melanoma, BCC,
or cSCC (other terms include pigmented skin
lesion/nevi, melanocytic, keratinocyte, etc.)
Adults at high risk of developing melanoma skin cancer,
BCC, or cSCC
For staging reviews
Adults with a diagnosis of melanoma or cSCC
undergoing tests for staging of lymph nodes or distant
metastases or both
 
People suspected of other forms of skin cancer
Studies conducted exclusively in children
Index tests For diagnosis
Visual inspection/clinical examination
Dermoscopy/dermatoscopy
Teledermoscpoy
Smartphone/mobile phone applications
Digital dermoscopy/artificial intelligence
Confocal microscopy
Ocular coherence tomography
Exfoliative cytology
High frequency ultrasound
Canine odour detection
DNA expression analysis/gene chip analysis
Other
For staging
CT
PET
PET-CT
MRI
Ultrasound +/fine needle aspiration cytology FNAC
SLNB +/high frequency ultrasound
Other
Any test combination and in any order
Any test positivity threshold
Any variation in testing procedure (e.g. radioisotope used)
 
Sentinel lymph biopsy for therapeutic rather
than staging purposes
Tests to determine melanoma thickness
Tests to determine surgical margins/lesion
borders
Tests to improve histopathology diagnose
LND
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Criterion Inclusion Exclusion
Reference
standard
 
For diagnostic studies
Histopathology of the excised lesion
Clinical follow-up of non-excised/benign appearing
lesions with later histopathology if suspicious
Expert diagnosis (studies should not be included if
expert diagnosis is the sole reference standard)
For studies of imaging tests for staging
Histopathology (via LND or SLMB)
Clinical/radiological follow-up
A combination of the above
For studies of SLNB accuracy for staging
LND of both SLN+ and SLn participants to identify all
diseased nodes
LND of SLN+ participants and follow-up of SLN
participants to identify a subsequent nodal recurrence in
a previously investigated nodal basin
 
For diagnostic studies
Exclude if any disease positive participants
have diagnosis unconfirmed by histology
Exclude if > 50% of disease negative
participants have diagnosis confirmed by expert
opinion with no histology or follow-up
Exclude studies of referral accuracy, i.e.
comparing referral decision with expert
diagnosis, unless evaluations of
teledermatology or mobile phone applications
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma; CT: computed tomography; FNAC: fine needle
aspiration cytology; LND: lymph node dissection; MRI: magnetic resonance imaging; PET: positron emission tomography;
PET-CT: positron emission tomography computed tomography; RCT: randomised controlled trial; SCC: squamous cell
carcinoma; SLN+: positive sentinel lymph node; SLn: negative sentinel lymph node; SLNB: sentinel lymph node biopsy.
6 Quality assessment (based on QUADAS-2)
The following tables use text that was originally published in the QUADAS-2 tool by Whiting and colleagues ( Whiting 2011 ).
Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
1) Was a consecutive or random sample of participants or
images enrolled?
Yes – if paper states consecutive or random
No – if paper describes other method of sampling
Unclear – if participant sampling not described
2) Was a case-control design avoided? Yes – if consecutive or random or case-control design
clearly not used
No – if study described as case-control or describes
sampling specific numbers of participants with particular
diagnoses
Unclear – if not described
 
3) Did the study avoid inappropriate exclusions, e.g.,
'difficult to diagnose' lesions not excluded
lesions not excluded on basis of disagreement between
evaluators
Yes - if inappropriate exclusions were avoided
No – if lesions were excluded that might affect test
accuracy, e.g., 'difficult to diagnose' lesions, or where
disagreement between evaluators was observed
Unclear – if not clearly reported but there is suspicion that
difficult to diagnose lesions may have been excluded
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Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
 
4) For between-person comparative studies only (i.e.,
allocating different tests to different study participants):
A) were the same participant selection criteria used for
those allocated to each test?
B) was the potential for biased allocation between tests
avoided through adequate generation of a randomised
sequence?
C) was the potential for biased allocation between tests
avoided through concealment of allocation prior to
assignment?
For A)
Yes – if same selection criteria were used for each index
test, No – if different selection criteria were used for each
index test, Unclear – if selection criteria per test were not
described, N/A – if only 1 index test was evaluated or all
participants received all tests
For B)
Yes – if adequate randomisation procedures are
described, No – if inadequate randomisation procedures
are described, Unclear – if the method of allocation to
groups is not described (a description of 'random' or
'randomised' is insufficient), N/A – if only 1 index test was
evaluated or all participants received all tests
For C)
Yes – if appropriate methods of allocation concealment
are described, No – if appropriate methods of allocation
concealment are not described, Unclear – if the method
of allocation concealment is not described (sufficient
detail to allow a definite judgement is required), N/A – if
only 1 index test was evaluated
 
Could the selection of participants have introduced bias?
For non-comparative and within person-comparative studies
If answers to all of questions 1), 2), and 3) 'Yes':1.
If answers to any 1 of questions 1), 2), or 3) 'No':2.
If answers to any 1 of questions 1), 2), or 3) 'Unclear':3.
For between-person comparative studies
If answers to all of questions 1), 2), 3), and 4) 'Yes':1.
If answers to any 1 of questions 1), 2), 3), or 4) 'No':2.
If answers to any 1 of questions 1), 2), 3), or 4) 'Unclear':3.
 
For non-comparative and within person-comparative studies
Risk is low1.
Risk is high2.
Risk unclear3.
For between-person comparative studies
Risk is low1.
Risk is high2.
Risk unclear3.
PARTICIPANT SELECTION (1) - CONCERNS REGARDING APPLICABILITY
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Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
 
1) Are the included participants and chosen study setting
generalisable to the patient population who will receive the test
in practice? (Test set)
This item is not asking whether exclusion of certain
participant groups might bias the study's results (as in Risk
of Bias above), but is asking whether the chosen study
participants and setting are appropriate to answer our
review question. Because we are looking to establish test
accuracy in both primary presentation and referred
participants, a study could be appropriate for 1 setting and
not for the other, or it could be unclear as to whether the
study can appropriately answer either question
For each study assessed, please consider whether it is
more relevant for A) participants with a primary presentation
of a skin lesion or B) referred participants, and respond to
the questions in either A) or B) accordingly. If the study
gives insufficient details, please respond Unclear to both
parts of the question
 
A) For studies that will contribute to the analysis of
participants with a primary presentation of a skin lesion (i.e.,
test naive)
Yes – if participants included in the study appear to be
generally representative of those who might present in a
usual practice setting
No – if study participants appear to be unrepresentative of
usual practice, e.g., in terms of severity of disease,
demographic features, presence of differential diagnosis or
comorbidity, setting of the study, and previous testing
protocols
Unclear – if insufficient details are provided to determine the
generalisability of study participants
B) For studies that will contribute to the analysis of referred
participants (i.e., who have already undergone some form of
testing)
Yes – if study participants appear to be representative of
those who might be referred for further investigation. If the
study focuses only on those with equivocal lesions, for
example, we would suggest that this is not representative of
the wider referred population
No – if study participants appear to be unrepresentative of
usual practice, e.g., if a particularly high proportion of
participants have been self-referred or referred for cosmetic
reasons. Other factors to consider include severity of
disease, demographic features, presence of differential
diagnosis or comorbidity, setting of the study, and previous
testing protocols
Unclear – if insufficient details are provided to determine the
generalisability of study participants
2) Did the study avoid including participants with multiple
lesions?
Yes – if the difference between the number of included
lesions and number of included participants is less than 5%
No – if the difference between the number of included
lesions and number of included participants is greater than
5%
Unclear – if it is not possible to assess
3) Was an adequate spectrum of cases used to train the
algorithm? (training set)
For melanoma studies:
Yes – if all PSLs, main types of melanoma all present
(nodular, SSM, Mis), main types of dysplasia present, and a
range of benign diagnoses included.
For keratinocyte cancer studies:
Yes - if the main malignant diagnoses are included (BCC,
cSCC), as well as main types of atypia/dysplasia and a
range of benign differential diagnoses (AK, SK, BD).
No - if study participants appear to be unrepresentative of
usual practice, for example with a specific focus on certain
lesions groups, e.g. melanoma and common nevus only
Unclear – insufficient details to determine generalisability of
study participants
N/A - algorithm trained in a previous study
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Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
 
Is there concern that the included participants do not match the
review question?
If the answer to question 1) and 2) and 3) 'Yes':1.
If the answer to question 1) or 2) or 3) 'No':2.
If the answer to question 1) or 2) or 3) 'Unclear'3.
 
Concern is low1.
Concern is high2.
Concern is unclear3.
INDEX TEST (2) - RISK OF BIAS (to be completed per test evaluated)
1) Was the index test or testing strategy result interpreted
without knowledge of the results of the reference standard?
Yes – if index test described as interpreted without
knowledge of reference standard result or, for prospective
studies, if index test is always conducted and interpreted
prior to the reference standard
No – if index test described as interpreted in knowledge of
reference standard result
Unclear – if index test blinding is not described
2) Was the diagnostic threshold at which the test was
considered positive (i.e., melanoma present) prespecified?
Yes – if threshold was prespecified (i.e., prior to analysing
study results)
No – if threshold was not prespecified
Unclear – if not possible to tell whether or not diagnostic
threshold was prespecified
 
3) Was the CAD classification algorithm evaluated in an
independent patient population?
Yes – Test set only study (validated in previous study) OR
validated within–study in a test set using in a different group
of participants recruited from a different source (external
validation) OR validated within–study in a test set
comprising a randomised subset of one larger participant
population also used for model training
No – Algorithm developed and evaluated within the same
study (internal validation) where training and test sets use
the same population which is not divided randomly
Unclear – The relationship between training and tests sets is
not reported clearly
4) Was model overfitting accounted for? Yes – a shrinkage method was applied, e.g. bootstrapping
for calibration in the large, calibration in the small,
overoptimisation, optimisation, use of a verify set to optimise
stopping.
No – study clearly reports that no method was applied
Unclear – overfitting not discussed or corrected
N/A - study does not contain a derivation element
 
Could the conduct or interpretation of the index test have
introduced bias?
If answers to questions 1) and 2) and 3) and 4) 'Yes' or1.
'N/A':
If answers to any of questions 1) or 2) or 3) or 4) 'No':2.
If answers to any of questions 1) or 2) or 3) or 4) 'Unclear':3.
 
Risk is low1.
Risk is high2.
Risk is unclear3.
INDEX TEST (2) - CONCERN ABOUT APPLICABILITY
 
1) Were thresholds or criteria for diagnosis reported in
sufficient detail to allow replication?
Study results can only be reproduced if the diagnostic
threshold is described in sufficient detail. This item applies
equally to studies using pattern recognition and those using
checklists or algorithms to aid test interpretation
Yes – If the criteria for diagnosis of melanoma were reported
in sufficient detail to allow replication
No – if the criteria for diagnosis of melanoma were not
reported in sufficient detail to allow replication
Unclear – If some but not sufficient information on criteria for
diagnosis to allow replication were provided
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Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
2) Was the test interpretation carried out by an experienced
examiner?
Yes – if the test was interpreted by 1 or more speciality-
accredited dermatologists, or by examiners of any clinical
background with special interest in dermatology and with
any formal training in the use of the test
No – if the test was not interpreted by an experienced
examiner (see above)
Unclear – if the experience of the examiner(s) was not
reported in sufficient detail to judge or if examiners were
described as 'Expert' with no further detail given
N/A – if system-based diagnosis, i.e., no observer
interpretation
 
3) Was the diagnostic threshold to determine presence or
absence of disease established in a previously published
study?
E.g., previously evaluated/established
algorithm/checklist used
lesion characteristics indicative of melanoma used
objective (usually numerical) threshold used
Yes – if a previously evaluated/established tool to aid
diagnosis of melanoma was used or if the diagnostic
threshold used was established in a previously published
study
No – if an unfamiliar/new tool to aid diagnosis of melanoma
was used, if no particular algorithm was used, or if the
objective threshold reported was chosen based on results in
the current study
Unclear – if insufficient information was reported
 
Is there concern that the index test, its conduct, or
interpretation differ from the review question?
If answers to questions 1), 2), and 3) 'Yes':1.
If answers to questions 1), 2), or 3) 'No':2.
If answers to questions 1), 2), or 3) 'Unclear':3.
 
Concern is low1.
Concern is high2.
Concern is unclear3.
REFERENCE STANDARD (3) - RISK OF BIAS
 
1) Is the reference standard likely to correctly classify the
target condition?
A) Disease-positive – 1 or more of the following:
histological confirmation of melanoma following biopsy or
lesion excision
clinical follow-up of benign-appearing lesions for at least 3
months following the application of the index test, leading to
a histological diagnosis of melanoma
B) Disease-negative – 1 or more of the following:
histological confirmation of absence of melanoma following
biopsy or lesion excision in at least 80% of disease-negative
participants
clinical follow-up of benign-appearing lesions for a minimum
of 3 months following the index test in up to 20% of disease-
negative participants
 
A) Disease-positive
Yes – if all participants with a final diagnosis of melanoma
underwent 1 of the listed reference standards
No – If a final diagnosis of melanoma for any participant was
reached without histopathology
Unclear – if the method of final diagnosis was not reported
for any participant with a final diagnosis of melanoma or if
the length of clinical follow-up used was not clear or if a
clinical follow-up reference standard was reported in
combination with a participant-based analysis and it was not
possible to determine whether the detection of a malignant
lesion during follow-up is the same lesion that originally
tested negative on the index test
B) Disease-negative
Yes – If at least 80% of benign diagnoses were reached by
histology and up to 20% were reached by clinical follow-up
for a minimum of 3 months following the index test
No – if more than 20% of benign diagnoses were reached
by clinical follow-up for a minimum of 3 months following the
index test or if clinical follow-up period was less than 3
months
Unclear – if the method of final diagnosis was not reported
for any participant with benign or non-melanoma diagnosis
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Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
 
2) Were the reference standard results interpreted without
knowledge of the results of the index test?
Please score this item for all studies even though
histopathology interpretation is usually conducted with
knowledge of the clinical diagnosis (from visual inspection or
dermoscopy or both). We will deal with this by not including the
response to this item in the 'Risk of bias' assessment for these
tests. For reviews of all other tests, this item will be retained
Yes – if the reference standard diagnosis was reached
blinded to the index test result
No – if the reference standard diagnosis was reached with
knowledge of the index test result
Unclear – if blinded reference test interpretation was not
clearly reported
 
Could the reference standard, its conduct, or its interpretation
have introduced bias?
If answers to questions 1) and 2) 'Yes':1.
If answers to questions 1) or 2) 'No':2.
If answers to questions 1) or 2) 'Unclear':3.
 
Risk is low1.
Risk is high2.
Risk is unclear3.
REFERENCE STANDARD (3) - CONCERN ABOUT APPLICABILITY
 
1) Expert opinion (with no histological confirmation) was not
used as a reference standard
'Expert opinion' means diagnosis based on the standard
clinical examination, with no histology or lesion follow-up
Yes – if expert opinion was not used as a reference
standard for any participant
No – if expert opinion was used as a reference standard for
any participant
Unclear – if not clearly reported
2) Was histology interpretation carried out by an experienced
histopathologist or by a dermatopathologist?
Yes – if histology interpretation was reported to be carried
out by an experienced histopathologist or
dermatopathologist
No – if histology interpretation was reported to be carried out
by a less experienced histopathologist
Unclear – if the experience/qualifications of the pathologist
were not reported
 
Is there concern that the target condition as defined by the
reference standard does not match the review question?
If answers to all questions 1) and 2), 'Yes':1.
If answers to any 1 of questions 1) or 2) 'No':2.
If answers to any 1 of questions 1) or 2) 'Unclear':3.
 
Concern is low1.
Concern is high2.
Concern is unclear3.
FLOW AND TIMING (4): RISK OF BIAS
 
1) Was there an appropriate interval between index test and
reference standard?
A) For histopathological reference standard, was the interval
between index test and reference standard ≤ 1 month?
B) If the reference standard includes clinical follow-up of
borderline/benign-appearing lesions, was there at least 3
months' follow-up following application of index test(s)?
 
A)
Yes – if study reports ≤ 1 month between index and
reference standard
No – if study reports > 1 month between index and
reference standard
Unclear – if study does not report interval between index
and reference standard
B)
Yes – if study reports ≥ 3 months' follow-up
No – if study reports < 3 months' follow-up
Unclear – if study does not report the length of clinical
follow-up
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Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
2) Did all participants receive the same reference standard? Yes – if all participants underwent the same reference
standard
No – if more than 1 reference standard was used
Unclear – if not clearly reported
3) Were all participants included in the analysis? Yes – if all participants were included in the analysis
No – if some participants were excluded from the analysis
Unclear– if not clearly reported
 
Could the participant flow have introduced bias?
If answers to questions 1), 2), and 3) 'Yes':1.
If answers to any 1 of questions 1), 2), or 3) 'No':2.
If answers to any 1 of questions 1), 2), or 3) 'Unclear':3.
 
Risk is low1.
Risk is high2.
Risk is unclear3.
BCC = basal cell carcinoma; cSCC = cutaneous squamous cell carcinoma.
7 Forest plots for the direct comparison of CAD systems vs. image-based dermoscopy
Figure 22; Figure 23
8 Results of sensitivity analysis for CAD systems (excludes diagnostic aid studies)
Index test StudiesCases/Number of participants Summary sensitivity (95% CI) %Summary specificity (95% CI) %
Primary target condition: Invasive melanoma and atypical intraepidermal melanocytic variants
MSI-CAD 7 281/2389 93.7 (83.9, 97.7) 41.7 (22.0, 64.6)
Derm-CAD19 955/8403 88.5 (81.3, 93.1) 71.3 (60.0, 80.4)
DB–MIPS 4 427/1479 96.4 (84.9, 99.2) 85.5 (75.7, 91.7)
MelaFind 4 191/1786 97.9 (94.6, 99.2) 24.8 (8.82, 52.9)
Secondary target condition: Invasive melanoma alone 
MSI-CAD 4 80/256 83.1 (26.5, 98.5) 66.9 (41.6, 85.1)
9 Forest plots for diagnosis of MM+Mis and MM in unreferred populations
Graphs
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